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ABSTRACT 
ROLE OF T LYMPHOCYTE TRAFFICKING IN DIABETIC CARDIOMYOPATHY 
CHOWDHURY SAYEF ABDULLAH 
2016 
Diabetic cardiomyopathy is a distinct pathological condition characterized by 
myocardial fibrosis and cardiac dysfunction in diabetic patients. The resolution of 
myocardial fibrosis to improve cardiac function in diabetes is an active area of research. 
Notably, increased T lymphocyte infiltration into myocardium has been attributed to 
increased cardiac fibrosis and dysfunction in diabetes. However, the experimental data on 
the role of T lymphocyte modulation in diabetic myocardial fibrosis is scarce. To this 
end, sphingosine 1-phosphate receptor 1 (S1P1) regulates the egress of mature T 
lymphocytes from lymphoid organs to blood and peripheral organs. Thus, the inhibition 
of T cells trafficking through S1P1 receptor modulation is a potential translational 
approach to protect the heart in diabetes. We hypothesized that inhibition of T 
lymphocyte trafficking by modulating S1P1 receptor protects diabetic heart and 
ameliorates fibrosis. To accomplish this overarching objective, we conducted three 
related studies: (1) assess the effects of fingolimod (S1P1 receptor modulator) treatment 
in diabetes-induced myocardial fibrosis in mice; (2) study cardiac fibrosis and 
dysfunction in diabetes using conditional T-cell S1P1 knockout (TS1P1KO) mice; (3) 
evaluate the effects of CD4+ T cells transfer to TS1P1KO mice in diabetes-induced 
myocardial fibrosis and dysfunction. 
xix 
 
We have demonstrated that FTY720 treatment induces sustained CD4+ and CD8+ 
T cells deficiency in the blood with reduced CD3+ T cells infiltration into myocardium of 
diabetic wild-type (WT) mice. Notably, FTY720 treatment reduced cardiac fibrosis area 
and improved cardiac contractility in diabetic WT mice. Our results in Rag1 knock-out 
(KO) mice lacking mature lymphocytes, further, confirmed that systemic T lymphocytes 
depletion is associated with cardioprotection. However, FTY720 treatment exacerbated 
fibrosis and attenuated contractility in diabetic KO mice. Therefore, we utilized Cre-loxP 
genetic approach to generate conditional T cell specific S1P1 receptor knock-out 
(TS1P1KO) mice to study S1P1 receptor mediated T cells trafficking effects in diabetes-
induced cardiac fibrogenesis. 
One of the unique findings of our study is reduced cardiac fibrosis area in 
TS1P1KO mice in chronic diabetes. TS1P1KO mice showed profound CD4
+ and CD8+ T 
cells deficiency in circulation and reduced CD3+ T cells infiltration into myocardium in 
diabetes. We also found that diabetic TS1P1KO mice myocardium had reduced 
profibrotic molecular and cellular milieu. However, normoglycemic TS1P1KO buffer 
treated mice exhibited increased fibrosis area and reduced cardiac contractility. This 
result indicates the potential role of different types of lymphocytes, and lymphocyte ratio 
in the blood in maintaining cardiac collagen homeostasis. Although TS1P1KO mice have 
reduced T lymphocytes in the blood, the mice had higher circulatory B lymphocytes, 
which also has been implicated in myocardial fibrosis. Thus, to establish the involvement 
of S1P1 mediated T lymphocytes trafficking in cardiac fibrosis, we conducted adoptive 
transfer of littermate T cells to TS1P1KO mice.  
xx 
 
Among CD4+ and CD8+ T cells, all four subsets of CD4+ T cells have been shown 
to be involved in cardiac fibrosis. Therefore, our aim was to investigate the effects of 
littermate CD4+ T cells transfer on cardiac fibrosis and myocardial contractile force in 
TS1P1KO mice in both normoglycemic and hyperglycemic conditions. Our flow 
cytometry analysis revealed increased CD4+ and CD4+Foxp3+ T cells in the blood of 
TS1P1KO mice after CD4
+ T cells transfer. Strikingly, we found that CD4+ T cells 
transfer reversed cardioprotection in hyperglycemic TS1P1KO mice, while it protected 
normoglycemic TS1P1KO mice heart. In both conditions, TS1P1KO mice showed 
increased CD3+ T cells infiltration after CD4+ T cell transfer. These results underpin S1P1 
mediated T cells trafficking in maintaining cardiac collagen homeostasis in both 
normoglycemic and hyperglycemic conditions. 
Overall, through pharmacological and genetic approaches we have demonstrated 
that S1P1 mediated T cells trafficking is involved in cardiac fibrogensis in chronic 
diabetes. Our studies provide strong evidence of T lymphocytes S1P1 receptor signaling 
as a translational target to protect diabetic heart and ameliorate fibrosis.
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CHAPTER 1: INTRODUCTION 
1.1. Diabetes and cardiovascular diseases 
Diabetes mellitus is characterized by hyperglycemia (increased glucose in plasma) 
due to defects in insulin secretion, insulin action or both.1 There are two major prevalent 
form of diabetes, namely, type 1 and type 2 diabetes.2,3 Type 1 diabetes is characterized 
by early onset due to autoimmune destruction of the insulin producing pancreatic beta 
cells.2,3 Thus, type 1 diabetic patients require exogenous insulin administration to 
maintain their blood glucose level.3 Etiological risk factors of Type 2 diabetes include 
obesity, aging, high calorie intake, lack of exercise and sedentary lifestyle.2,3 Due to these 
risk factors, the tissues and cells exhibit reduced insulin sensitivity (insulin resistance) 
and glucose uptake in type 2 diabetes leading to increased glucose level in the blood.2,3 
According to the American Diabetes Association guidelines, normal fasting blood 
glucose level is below 100 mg/dl, while a fasting blood glucose level ≥126 mg/dl is 
indicative of diabetes.1 According to the current estimates from World Health 
Organization (WHO), there are more than 300 million people affected by diabetes and is 
estimated to increase to more than 347 million people worldwide by 2030.4,5 In the 
United States, 29.1 million Americans are affected by diabetes with 1.4 million newly 
diagnosed diabetes each year.6 Type 1 diabetes accounts for approximately 5% of all 
diagnosed diabetes, while type 2 diabetes accounts for the other 90-95% of diagnosed 
diabetes cases.6,7 Although there are many oral drugs available to maintain blood glucose 
level in diabetic patients, half of the type 2 diabetic patients ultimately rely on insulin 
administration to maintain the normal blood glucose level.3 Thus, chronic hyperglycemia 
2 
 
is a hallmark of both type of diabetes and is a pivotal factor in the development of 
diabetic complications in patients.3  
Hyperglycemia causes injury, dysfunction and failure in vital organs including heart, 
kidney, eye, nerves and blood vessels in diabetic patients.1,3 WHO reports nearly 50% of 
diabetic patient’s death occurs from cardiovascular disease, such as heart failure and 
atherosclerosis.8 Epidemiological studies have reported strong association between 
diabetes and heart failure.7,8,9 Framingham heart study conducted by the National Heart, 
Lung and Blood Institute of US to identify cardiovascular disease (CVD) risk factors 
reported two-fold and five-fold higher heart failure risk in diabetic men and women, 
respectively, than age matched non-diabetic control subjects.10 Chronic hyperglycemia 
has been shown to affect cardiac function independent of other diabetes-associated CVD 
risk factors, such as atherosclerosis, cerebrovascular disease and hypertension.3,9,10 The 
distinct pathologic alterations in the myocardium induced by diabetes are defined as 
“diabetic cardiomyopathy”.9 Diabetic cardiomyopathy can occur in the absence of other 
CVD risk factors and can contribute to heart failure development in diabetic patients.3,9 
Different pathological mechanisms have been shown to be involved in the development 
of diabetic cardiomyopathy. Nonetheless, different cellular effectors and their 
mechanisms of involvement in diabetic cardiomyopathy need further investigation. 
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1.2. Diabetic cardiomyopathy 
The European Society of Cardiology defines cardiomyopathy as a myocardial 
disorder characterized by abnormal heart muscle structure and function, in absence of 
coronary artery disease, hypertension, congenital heart disease and heart valve disease.11 
Based on etiology, cardiomyopathy can be divided into two types, primary 
cardiomyopathy and secondary cardiomyopathy.11 Primary cardiomyopathy occurs from 
disease of the heart muscle cells due to genetic mutation including hypertrophic 
cardiomyopathy and dilated cardiomyopathy.11 Secondary cardiomyopathy occurs due to 
systemic syndromes such as diabetes, myocarditis and alcohol overuse that negatively 
affect cardiac function.11 Thus, diabetic cardiomyopathy is a secondary cardiomyopathy 
that occurs in diabetes associated chronic hyperglycemia leading to the development of 
the heart failure in diabetic patients.12,13 
Rubler et al. first described diabetic cardiomyopathy as a distinct clinical 
pathophysiology prevalent in diabetic patients.9 In this study, the authors reported left 
ventricular hypertrophy with myocardial fibrosis in diabetic patient hearts who deceased 
from heart failure without having coronary artery disease, hypertension or other 
etiological conditions underlying for observed heart failure.9 Regan et al. confirmed these 
findings in a later study.14 In line with these observations, recent larger population based 
studies revealed a 1.5-fold higher risk of heart failure in patients with diabetes after 
adjusting for multiple variables including age, sex, obesity, antihypertensive medications, 
atrial fibrillation, smoking habit, alcohol use, plasma cholesterol, educational level and 
physical activity.15 Therefore, epidemiological studies further confirmed that diabetes can 
by itself cause development of cardiomyopathy, termed as diabetic cardiomyopathy. 
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Diabetic cardiomyopathy is considered as an important contributing factor for increased 
prevalence of heart failure in diabetic patients.12,13 
The pathophysiology of diabetic cardiomyopathy development involves various 
pathological changes in heart under diabetes including endothelial dysfunction, myocyte 
apoptosis, interstitial inflammation, myocardial fibrosis and diastolic dysfunction 
followed by systolic dysfunction, if unresolved.13,16-18 Myocardial fibrosis is a pivotal 
etiological factor in diabetic cardiomyopathy that underlies diastolic dysfunction 
development in diabetes patient heart.19-23 Hyperglycemia activates and affects a diverse 
set of molecular and cellular pathways present in mammalian heart that ultimately leads 
to increased myocardial fibrosis in diabetes.24 During the early stages of diabetes, the 
heart exhibits reduced antioxidant capacity and increased generation of reactive oxygen 
species (ROS) resulting in oxidative stress.25 Increased ROS accumulation occurs 
through different metabolic pathways including increased flux of glucose into electron 
transport chain promoting superoxide generation by electron transfer to molecular oxygen 
in mitochondria, increased formation of non-enzymatic advanced glycation end products 
(AGEs) and activation of their receptors. Further, activation of other signaling pathways 
including activation of protein kinase C isoforms, and reduction of intracellular 
antioxidants including nicotinamide adenine dinucleotide phosphate (NADPH) and 
glutathione (GSH) induce overproduction of superoxide radicals.25,26 Intracellular ROS, 
in turn, can activate redox sensitive transcription factor NF-κB, which is the central 
modulator of transcription of numerous genes including proinflammatory cytokines and 
adhesion molecules in the diabetic myocardium.27,28 Thus, oxidative stress leads to an 
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ongoing inflammation in diabetic heart that is further potentiated by activation of 
proinflammatory pathways. 
Presence of inflammation in diabetic myocardium is manifested as enhanced 
expression of proinflammatory cytokines including tumor necrosis factor-α (TNF-α), 
interleukin-6 (IL-6), interleukin-1β (IL-1β) and profibrotic growth factors, such as 
transforming growth factor-β1 (TGF-β1). Inflammation further enhances chemokines 
expression, such as chemokine C-C motif ligand-2 and 5 (CCL2, CCL5) and adhesion 
molecules expression including intercellular adhesion molecule-1 (ICAM-1), vascular 
adhesion molecule-1 (VCAM-1) and monocyte chemoattractant protein-1 (MCP-1).3,28-35 
Increased expression of adhesion molecules under chronic inflammation further enhances 
recruitment of blood derived immunocompetent cells including lymphocytes, monocytes, 
macrophages, reparative mesenchymal cells and fibrocytes into the diabetic 
myocardium.36,37 The recruited immune cells, in turn, secrete cytokines and growth 
factors which potentiate, the profibrotic microenvironment development in the 
myocardium. Proinflammatory and profibrotic microenvironments, in turn, activate 
resident and recruited collagen producing fibroblasts and fibroblast progenitor cells that 
results in increased collagen synthesis by these cells. Increased collagen deposition in 
myocardium ultimately leads to fibrosis development in diabetes (Table 1-1).16,38  
Increased cardiac fibrosis in diabetic myocardium underlies diastolic and systolic 
dysfunction in diabetes patients (Table 1-1).13,17 Enhanced fibrosis reduces myocardial 
ventricular wall compliance and stiffens the ventricular walls that impair cardiac 
ventricles relaxation during diastole. Impaired cardiac ventricular relaxation, in turn, 
leads to diastolic dysfunction. Diastolic dysfunction further, if unresolved, leads to 
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systolic dysfunction underlying development of heart failure.13,17-19,39-42 Prevalence of 
diastolic dysfunction is estimated to be as high as 40% to 60% patients with type 1 and 
type 2 diabetes without overt coronary artery disease.21-23 Other epidemiological studies 
also show association between enhanced myocardial fibrosis with impaired ventricular 
function in diabetic patients.17 Increased myocardial collagen content has been detected 
in insulin dependent diabetic normotensive patients as compared to age- and sex-matched 
control subjects, assessed by ultrasound echoreflectivity.18 Similar results with increased 
myocardial collagen in diabetic patients have been confirmed in larger studies by Fang et 
al.19 Thus, epidemiological studies confirmed the presence of myocardial fibrosis with 
cardiac dysfunction in diabetic patients. To this end, resolution of myocardial fibrosis to 
improve cardiac function in diabetes is an active area of research. As discussed above, the 
recruited effector immune cells facilitate and potentiate myocardial fibrosis. Thus, the 
modulation of immune cells function is a potential approach to ameliorate myocardial 
fibrosis in diabetes. 
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Table 1-1: Summary of diabetic cardiomyopathy associated notable pathophysiological, 
structural and functional changes in myocardium.  
Diabetic Cardiomyopathy 
Pathophysiological Changes 
 Increased ROS 
generation 
 Increased AGEs 
 Decreased antioxidants 
 Oxidative stress 
 Increased inflammation 
 Activation of immune 
system 
 Increased cell death 
 Myocardial fibrosis 
Structural Changes 
 Maladaptive cardiac 
remodeling 
 Increased LV wall 
thickness 
 Increased LV mass 
Functional Changes 
 Impaired 
diastolic function 
 Impaired systolic 
function 
 
ROS: reactive oxygen species, AGEs: advanced glycation end products, LV: left 
ventricle. 
1.3. Myocardial fibrosis in diabetic cardiomyopathy 
As discussed earlier (see section 1.2.), myocardial fibrosis is one of the hallmark 
pathological features in diabetic patient heart as detected by echocardiography and 
autopsy studies.9,11,18-23 The mechanism of fibrosis induced cardiac dysfunction involves 
impairment of heart diastolic relaxation. Human heart works through consecutive systole 
(contraction) and diastole (relaxation) phases. During systole, the heart pumps the blood 
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throughout the body, whereas during diastole heart ventricles relax to fill blood that is 
pumped at the next systole. Increased cardiac fibrosis reduces ventricular wall 
compliance and increases stiffness that impairs normal relaxation of ventricles during 
diastole leading to diastolic dysfunction.42-44 Excess collagen deposition in myocardium, 
further impedes proper contraction of the heart as electrical impulse conduction gets 
impaired due to collagen deposition in between cardiomyocytes.42-46 Thus, enhanced 
myocardial fibrosis underlies the development of diastolic dysfunction preceding systolic 
dysfunction in diabetic patient that ultimately leads to heart failure development.47,48 
Myocardial fibrosis is a complex, multifactorial process that occurs at the site of 
tissue injury and inflammation.36,40,46 It is a natural tissue repair process that results from 
increased deposition of non-contractile collagen in cardiac interstitium leading to cardiac 
functional impairment.46 Two types of cardiac fibrosis has been described reparative 
(replacement) fibrosis and reactive fibrosis.46 Reparative fibrosis occurs after sudden cell 
death of a large number of cardiomyocytes resulting from myocardial infarction upon 
coronary artery block. On the other hand, reactive fibrosis develops in chronic 
inflammatory conditions, such as diabetes and hypertension. Reactive fibrosis, if 
unresolved, can turn into reparative fibrosis (Figure 1-1).44-46 The increased synthesis of 
collagen during fibrogenesis involves molecular stimuli to cellular functions as discussed 
below. 
Myocardial fibrosis is characterized by increased collagen deposition in the heart 
tissue.40 The extracellular matrix protein (ECM) components provide support for cellular 
function in the heart including distribution of mechanical forces, signal transduction as 
well as play important role in maintaining functional cardiac shape and size.41 
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Myocardial ECM components consist of fibril collagen, proteoglycans and 
glycosaminoglycans.42 The most abundant fibrillary collagen in the heart is collagen type 
I and type III including less abundant types of IV, V, and VI, elastin and laminin.41-43 In 
diabetic heart, as was discussed earlier (see section 1.2), increased ROS, inflammation 
and growth factor stimuli result in enhanced synthesis of the ECM proteins leading to the 
development of cardiac fibrosis.43,44 During cardiac fibrogeneis, cardiomyocytes and non-
cardiomyocytes including resident cardiac fibroblasts, immune cells, vascular endothelial 
cells and the immunocompetent cells, closely interact with each other in fibrotic 
remodeling of the heart (Figure 1-1).46 The fibroblasts upon stimulation by inflammatory 
signals produce and secrete collagen matrix proteins in excess, while other cells, such as 
macrophages, mast cells, lymphocytes, cardiomyocytes and vascular cells secrete 
profibrogenic cytokines that stimulate fibroblasts’ collagen synthesizing activity.36,49 
Diabetes associated hyperglycemic conditions can activate, among others, fibrogenic 
transforming growth factor beta-1 (TGF-β1) signaling.50,51 TGF-β1 is a well reported 
mediator in cardiac fibrosis and the most predominant isoform present in cardiovascular 
system among three isoforms.52-54 TGF-β1 mediates its effects by directly inducing 
matrix protein synthesis by stimulating collagen producing cells, decreasing production 
of matrix degrading proteolytic enzymes, and modulating the expression of integrins, 
which increases cellular adhesions to the matrix.55,56 TGF-β1 is present in both 
cardiomyocytes and cardiac fibroblasts and has been found to take part in cardiomyocyte 
growth, fibrosis and re-expression of fetal isoforms of myofibrillar protein genes, that are 
salient characteristics of pathological cardiac remodeling.57-60  Further, the recruited 
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blood derived immune cells also participate in fibrosis by secreting cytokines, growth 
factors, and can transdifferentiate in collagen synthesizing fibroblasts.36,48,61  
 
 
 
 
 
 
 
 
 
 
Figure 1-1: Cellular composition of myocardium and fibrosis type. Cardiac interstitium 
comprises of cardiomyocytes and non-cardiomyocytes including macrophages, 
lymphocytes, mast cells, myofibroblasts, endothelial cells (upper panel). Under chronic 
inflammation (diabetes, hypertension) or due to sudden loss of cardiomyocytes 
(myocardial infarction) non-contractile collagen deposited in cardiac interstitium as a 
natural tissue repair process results in reactive and replacement fibrosis, respectively. All 
cellular components in cardiac tissue participate in cardiac fibrogenesis. Adapted and 
modified from Mewton et al.46 
Reactive Fibrosis Reparative Fibrosis 
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Among other recruited cell types, fibrocytes are mesenchymal origin monocyte 
precursor cells that are recruited at the site of injury. Fibrocytes have both inflammatory 
properties like innate immune cells (i.e., macrophages) and tissue remodeling properties 
(i.e., fibroblasts).62,63 Chronic inflammatory conditions promote accumulation, 
differentiation and trafficking of fibrocytes to the inflamed tissue. Cluster of 
differentiation antigen 34 (CD34) is one of the biomarkers to distinguish fibrocytes from 
other cells in tissues.64,65 These cells are spindle shaped, adherent cells in cell culture 
studies. Chronic proinflammatory conditions and profibrotic microenvironment can 
stimulate fibrocytes to secrete collagen. Fibrocytes can also transdifferentiate into 
collagen synthesizing fibroblasts.61-63 Altogether, fibrocytes have been reported to be 
important components in fibrosis generation under chronic inflammatory conditions, 
although a therapeutic intervention strategy to modulate fibrocytes function is yet to be 
established. 
No specific treatment strategy to ameliorate myocardial fibrosis in diabetes has been 
yet determined. Inhibition of renin-angiotensin-aldosterone system by angiotensin 
converting enzyme (ACE)  inhibitors and aldosterone antagonists have shown beneficial 
effect in hypertensive diabetic patient heart in the context of cardiac remodeling.66,67 
However, cardiac remodeling has also been observed in normotensive diabetic patients.20 
This indicates that further research is required to understand the mechanism of cardiac 
fibrosis generation to devise effective therapeutic approach to ameliorate maladaptive 
cardiac remodeling under diabetes. 
 
 
12 
 
1.4. T lymphocytes involvement in myocardial fibrosis 
T lymphocytes are lymphoid lineage adaptive immune cells. T lymphocytes can 
be divided mainly into two types, helper T cells (CD4+, TH) and cytotoxic T cells (CD8
+, 
TC).
68 Based on their cytokine expression pattern and functions, CD4+ T cells can be 
further divided into TH1, TH2, TH17 and regulatory T cells (Tregs). TH1 cells secrete 
mainly interferon-γ (IFN-γ), TH2 cells secrete interleukin-4 (IL-4), TH17 cells secret IL-
17 and Treg cells secrete TGF-β.
68 In C57BL/6 mice, induction of TH1 lymphocytes 
through TCR-Vβ peptide increases collagen content and cross-linking of collagen fibers 
with reduced collagen degrading MMP enzyme activity.69 In the same report, TH2 
induction resulted in decreased collagen content with increased collagen degrading 
matrix metalloproteinase (MMP) enzyme activity.69 Co-culture experiments with 
untreated fibroblasts revealed that both TH1 and TH2 lymphocytes can affect fibroblast 
function, whereas TH1 decreases MMP-9 gene expression and TH2 increases MMP-9 
activity.69 In another study, overexpression of TH1 lymphocytes increased left ventricular 
interstitial fibrosis with diastolic dysfunction as detected by transthoracic 
echocardiography in mice.70 TH1 cytokine IFN-γ has been shown to induce interferon 
regulatory factor 1 (IRF1) which is a positive regulatory factor of collagen cross-linking 
enzyme lysyl oxidase (LOX).71 Notably, chronic hypertensive BALB/c mice with 
predominant TH2 cytokine expression exhibited increased ventricular collagen and cross-
linking.72 Thus, depending on the physiological conditions both TH1 and TH2 cytokines 
can participate in cardiac fibrogenesis, whereas TH1 cytokines play a role in initiation 
phase of fibrosis and TH2 cytokines potentiate fibrosis in chronic conditions.
72,73 
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More recently, in experimental heart failure model including left coronary artery 
occlusion induced myocardial infarction model and chronic pressure overload transverse 
aortic constriction model, T lymphocytes proliferation has been detected in heart draining 
secondary lymphoid organs i.e., lymph nodes (LNs) by flow cytometry analysis of 
proliferation marker Ki67 expression in T cells.74-76 Increased proliferation of T cells in 
heart draining lymph nodes corresponds to an increased presence of lymphocytes in the 
heart tissue in these models.74-76 Thus, it is proposed that after myocardial injury, 
activation of antigen presenting cells (APCs) by cardiac derived neoantigens occurs.77 
Activated APCs, in turn, activate T lymphocytes in heart draining lymph nodes (Figure 1-
2). Activated effector T cells then migrate to injured myocardium and participate in 
fibrogenesis.77 Increased T lymphocytes infiltration and presence in cardiac tissue has 
been shown to increase in collagen content and fibrosis in heart.75,76 Thus, T lymphocytes 
has been detected as an important participant in myocardial fibrosis after cardiac injury 
(Figure 1-2).74-77 To this end, it is intriguing to note that the modulation of T cells 
trafficking from lymphoid organs to blood/heart could be a potential therapeutic approach 
to protect heart under cardiac injury/inflammation. 
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Figure 1-2: Proposed role of T lymphocytes trafficking to heart in steady state and post-
myocardial infarction. In steady state, tolerogenic antigen presenting cells (APCs) 
prevent T cell activation, whereas after myocardial injury activation of APCs result in 
activation of T lymphocytes in heart draining lymph nodes. Adapted and modified from 
Hofmann et al.77 
Proinflammatory cytokines have been shown to negatively affect cardiac 
contractility leading to heart failure.78-80 Several epidemiological studies have reported 
that expansion of proinflammatory T lymphocytes expressing TH1 cytokine IFN-γ in 
diabetic patients positively correlated with cardiac diseases including acute coronary 
syndrome and coronary atherosclerotic heart disease.81,82 Thus, the modulation of T 
lymphocytes to attenuate cardiac fibrosis is a potential therapeutic avenue that needs to 
be further investigated. 
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1.5. Role of Sphingosine 1-phosphate receptor 1 in T lymphocytes trafficking 
T lymphocytes upon maturation increase cell surface expression of sphingosine 1-
phosphate receptor 1 (S1P1) in thymus.
83 Sphingosine 1-phosphate receptor 1 (S1P1) is a 
G-protein coupled receptor that signals through Gαi/o subunit.
84,85 Upon activation, Gαi/o 
activates phosphatidylinositol 3-kinase (PI3K) effector pathway that activates Rac 
pathway.84,85 Rac pathway controls cell polarization, lamellipodium formation and 
expansion and organization of focal complexes at the frontal edge of the cell and 
adhesion. The endogenous natural ligand for S1P1 is the bioactive lipid molecule 
sphingosine 1-phosphate (S1P).86,87 S1P is synthesized by phosphorylation from 
membrane lipid sphingosine. Two isoforms of sphingosine kinase enzyme catalyzed the 
conversion of sphingosine to sphingosine 1-phosphate. Notably, S1P is degraded by S1P 
lyase enzyme in tissues due to the high expression of this enzyme. Thus, S1P 
concentration in tissues (e.g. thymus, lymph nodes) is low (5-20 nM) as compared to high 
concentration in plasma (200-900 nM).85,88 This creates a concentration gradient of S1P 
from lymphoid tissues to systemic circulation. Thus, the increased expression of S1P1 
receptor on cell surface enables T lymphocytes to sense the increased chemotactic 
gradient of S1P in systemic circulation leading to egress from the lymphoid organs to the 
blood (Figure 1-3C).83-89  
Under normal physiological conditions, T lymphocytes continually recirculate 
between secondary lymphoid organs and blood, which increases the likelihood of T cell 
interaction with antigen presenting cells (APCs) e.g. macrophages, dendritic cells, B 
lymphocytes.90 T cells encounter antigen bearing APCs in secondary lymphoid organs, 
such as lymph nodes and spleen. Presentation of foreign antigen to T cells by APCs 
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activate the T cells followed by proliferation in respective secondary lymphoid organs. 
Activated effector T cells then migrate to target tissue to generate appropriate immune 
response by secreting cytokines, activating B cells through cell-cell contact (CD4+ T 
cells) or direct cell killing (CD8+ T cells).77,90  
T lymphocytes trafficking through S1P-S1P1 signaling axis has been utilized for 
therapeutic purposes. Fingolimod (FTY720) is a novel immunomodulatory drug that acts 
on S1P1 receptor (Figure 1-3A and 1-3B).
91,92 It is a structural analogue of sphingosine 
and phosphorylated by sphingosine kinase 2 enzyme in vivo.93 Phosphorylated FTY720 
binds to S1P1 as an agonist that later induces β-arrestin mediated internalization from cell 
surface. S1P1-FTY720 complex in cell cytosol stays longer due to metabolic stability of 
FTY720 against S1P lyase and promotes proteasomal degradation of the receptor.94 Thus, 
FTY720 reduces mature single positive CD4+ and CD8+ T cells in blood (Figure 1-3C).95 
FTY720 administration in murine experimental autoimmune encephalomyelitis (EAE) 
model and in multiple sclerosis patients reduces autoimmune TH17 cells in blood and 
CNS that protects the central nervous system from autoimmune T cell mediated 
destruction of neural tissues.88-89,92  
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Figure 1-3: Sphingosine 1-phosphate receptor 1 in T lymphocytes trafficking. (A) 
Chemical structure of sphingosine 1-phosphate and phosphorylated (S)-FTY720. (B) 
Biosynthesis of sphingosine 1-phosphate from sphingomyelin. (C) Simplified 
representation of S1P-S1P1 mediated egress of T lymphocytes from lymph nodes and 
inhibition of their egress by FTY720 to systemic circulation. Images are adapted and 
modified from Brinkmann et al.92 (Figure 1-3A and 1-3B) and Camm et al. (Figure 1-
3C).88 
 
 
 
A 
B 
C 
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As discussed earlier, T lymphocytes are involved in myocardial fibrosis and 
dysfunction; however, therapeutic strategies to modulate T cell function in the setting of 
cardiac disease need to be further explored. Experimental data of modulation of T cells’ 
role in diabetic cardiomyopathy are also lacking. Thus, in current dissertation work, we 
studied T cell trafficking modulation effect in myocardial fibrosis and contractility in a 
murine diabetic cardiomyopathy model. 
1.6. Streptozotocin induced type 1 diabetic cardiomyopathy model 
 Streptozotocin (STZ) is a glucosamine-nitorosourea that is structurally similar to 
glucose and is taken up by insulin producing beta cells of islets of Langerhans through 
cell membrane glucose transporter 2 (GLUT2) (Figure 1-4A and 1-4B).96 STZ is a DNA 
alkylating agent that methylates guanine at O6 position. This transfer of methyl group 
from STZ to DNA molecule results in DNA fragmentation that increases the activation of 
DNA repair enzyme poly (ADP-ribose) polymerase (PARP)97. Overactivation of PARP 
results in diminished cellular NAD+ and ATP stores. The cellular energy store depletion 
results in beta cell necrosis.97,98 Thus, STZ induced DNA methylation of pancreatic beta 
cells ultimately ensues destruction of insulin producing beta cells (Figure 1-4B).96-99 
 Streptozotocin induced mice model is a widely used type 1 diabetic mice model 
as these mice lack insulin producing beta cells upon STZ treatment.100 STZ recipient 
mice promptly develop hyperglycemia (450 to 540 mg/dl) within 7 to 14 days after the 
first administration with marked reduction in plasma insulin levels (<20 pmol/L).14,15,100 
Both high dose (single dose of up to 200 mg/kg) and low dose with consecutive regimens 
have been reported in the literature to induce diabetes in rodents.100 Animal Models of 
Diabetic Complications Consortium (AMDCC) recommends low dose protocol with five 
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consecutive injections of 50 mg/kg STZ to induce type 1 diabetes in rodents.100 In the 
present dissertation work, a similar protocol was used to induce type 1 diabetes in mice 
according to AMDCC guidelines.  
 
 
  
 
 
 
 
Figure 1-4: Mechanism of action of streptozotocin-induced type 1 diabetes. (A) 
Chemical structure of streptozotocin. (B) Simplified schematic diagram of mechanism of 
action of streptozotocin to induce type 1 diabetes in mice. Adapted and modified from 
Lenzen.96 
Streptozotocin (STZ) induced type 1 diabetic mouse model represents salient 
cellular and functional features of diabetic cardiomyopathy under hyperglycemia that 
makes it suitable to study molecular mechanisms and effects of therapeutic 
interventions.13 STZ induced mice myocardium show reduced contractile protein α-actin 
and myosin ATPase activity, altered calcium handling, impaired diastolic function and 
progressive systolic dysfunction corresponding to the magnitude and duration of 
hyperglycemia progression.12,13 STZ murine myocardium has been reported to show 
A Streptozotocin 
Selective pancreatic beta cell uptake 
through the GLUT2 transporter  
Beta cell toxicity through DNA 
alkylation  
Beta cell death through necrosis  
Insulin-dependent diabetes mellitus 
(chronic hyperglycemia)  
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increased cellular ROS levels with enhanced superoxide production, increased NADPH 
oxidase expression and decreased GSSG/GSH ratio indicating presence of oxidative 
stress.12,13,32,33 Increased expression of adhesion molecules, such as ICAM-1, VCAM-1 
and MCP-1 in STZ rodent myocardium has been detected.32,33 Impaired calcium 
homeostasis by myocytes has been also observed in STZ murine hearts, including 
attenuated expression and activity of sarcoendoplasmic reticulum Ca2+-ATPase 2a 
enzyme with impaired calcium release and reuptake.100 These molecular consequences 
coupled with structural abnormalities in STZ murine hearts including increased cardiac 
fibrosis with decline in cardiac function.13,100,101  
 In the present dissertation, we assessed T lymphocytes trafficking modulation 
effect on the extent of myocardial fibrosis and contractility by utilizing validated STZ-
induced murine diabetic cardiomyopathy model. 
1.7. Cre-loxP recombination approach to generate T cell specific S1P1 
receptor knock out mice 
Sphingosine 1-phsophate receptor 1 (S1P1)  is a widely distributed G protein-
coupled receptor in central nervous system, cardiovascular system, endothelial cells, 
hepatocytes and kidney tubular cells in human and rodents.85 S1P1 expression and 
activation in vascular endothelial cells are essential for new blood vessel formation and 
endothelial junction integrity maintenance.84,88 Global knockout of S1P1 receptor is lethal 
as mice die at early embryonic stage from hemorrhage due to leaky blood vessel 
formation.84,102 Lack of S1P1 receptor results in deformity in endothelial junction 
formation leading to hemorrhage.84,102 Thus, cell- and tissue- specific S1P1 receptor gene 
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knock out approach has been utilized for experimental studies. In this regard, Cre-loxP 
site specific genetic recombination approach is one of the successful approach. 
Cre-loxP recombination system is a conditional gene inactivation approach that 
allows investigators to study single gene function in tissue- or cell-specific manner. It is a 
binary genetic system includes complementary activator and responder cassettes bearing 
two separate lines of transgenic mice.103,104 Activator and responder cassette containing 
mice are then crossed to generate progeny containing both activator and responder 
cassettes.104 The activator cassette contains Cre recombinase gene under the control of 
tissue specific promoter gene. The responder cassette contains flanked gene of interest by 
loxP sequences, usually coding region of a protein. After crossing activator and responder 
cassettes containing mouse strains, tissue specific Cre recombinase expression in 
offspring mice leads to excision of the flanked gene by loxP sites as Cre recombination 
action is specific at loxP sites (Figure 1-5).105,106  
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Figure 1-5: Simplified scheme of conditional gene knock-out approach by using Cre-
loxP site specific recombination system. Mouse (A) bearing flanked specific genomic 
DNA sequence ‘A’ by two loxP sites is responder cassette containing mouse line. Mouse 
(B) bearing Cre transgene with a tissue-or cell-specific promoter ‘P’ is activator cassette 
containing mouse line. Cre mediated recombination under the tissue promoter ‘ P’ occurs 
at two loxP sites of the particular cells of the tissue, resulting in deletion of gene ‘A’ 
specifically of the tissue- or cells- targeted offspring mice (C) . Adapted and modified 
from Strachan et al.106 
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In our investigation, we generated conditional T cell specific S1P1 knock out mice 
by crossing S1P1
loxP/loxP mice containing flanked exon 2 of S1P1 gene with lymphocyte 
tyrosine kinase (Lck)-Cre promoter containing mice.83 Offspring mice from the crossing 
that contain both a floxed target sequence and a Cre transgene were identified by 
genotyping PCR. T cell specific S1P1 knock out mice were utilized to study effects of 
S1P1 genetic depletion of T lymphocytes in myocardial fibrosis in STZ-induced type 1 
diabetic cardiomyopathy model. 
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1.8. Rationale and objectives 
As we discussed in previous sections (see section 1.4. and 1.5.), T lymphocytes 
are involved in myocardial fibrosis in cardiac diseases including hypertension, chronic 
heart failure and myocardial infarction. However, the experimental data in modulating T 
lymphocytes role in long term hyperglycemic condition to ameliorate cardiac fibrosis and 
improve cardiac contractility is scarce. In addition, the effects of T lymphocytes 
inhibition in fibrotic microenvironment have not been investigated in chronic diabetes. 
To this end, we hypothesized that modulation of T lymphocytic S1P1 receptor protects 
diabetic myocardium by reducing profibrotic milieu in chronic diabetic conditions. Our 
studies encompass broadly three areas including diabetes, immune system and 
cardiovascular diseases (Figure 1-6). More specifically, we studied the effects of T 
lymphocytes trafficking modulation in diabetic cardiomyopathy associated myocardial 
fibrosis (Figure 1-6). 
 
Figure 1-6: Simplistic representation of physiological fields of study in this dissertation. 
 
Three areas of study (broadly) Specific areas studied  
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The objectives of this dissertation are as follows: 
I. To determine the effects of pharmacological inhibition of T lymphocytes trafficking 
in myocardial fibrogenesis in chronic streptozotocin (STZ)-induced type 1 diabetes in 
mice (chapter 2).  
a. to assess the effects of S1P1 modulator-fingolimod (FTY720) administration 
in T lymphocytes number in the blood and extent of cardiac fibrosis in wild-
type (WT) C57BL/6 mice in chronic diabetes; 
b. to assess myocardial fibrosis and cardiac function in recombination activating 
gene 1 knock-out (Rag1 KO) mice as complementary to WT C57Bl/6 mice 
under chronic diabetes; 
c. to determine the effects of T lymphocytes trafficking modulation in 
profibrotic cellular and molecular milieu in diabetic myocardium of WT and 
KO mice. 
II. To investigate the effects of T cell specific S1P1 receptor genetic depletion in T 
lymphocytes trafficking in the blood and cardiac fibrosis in STZ-induced diabetic 
cardiomyopathy model (chapter 3). 
a. to generate T cell specific S1P1 receptor knockout (TS1P1KO) mice and study 
T lymphocytes number in the blood and secondary lymphoid organs of 
TS1P1KO mice; 
b. to study fibrotic remodeling in TS1P1KO mice under STZ-induced diabetic 
cardiomyopathy model; 
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c. to assess profibrotic cellular and molecular expression in TS1P1KO mice 
myocardium under chronic diabetes; 
III. To evaluate the effects of CD4+ T cells transfer to TS1P1KO mice in myocardial 
fibrosis under chronic diabetes (chapter 4). 
a. to isolate CD4+ T cells from littermate mice spleen and adoptive transfer of 
isolated CD4+ T cells to TS1P1KO mice; 
b. to study the effects of CD4+ T cells transfer in T cells number in the blood and 
myocardium in TS1P1KO mice; 
c. to assess myocardial fibrosis in TS1P1KO mice after CD4+ T cells transfer in 
STZ-induced diabetic cardiomyopathy model. 
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CHAPTER 2: EFFECTS OF S1P RECEPTOR 1 MODULATOR FINGOLIMOD ON 
CARDIAC FIBROSIS IN DIABETIC CARDIOMYOPATHY 
2.1. Introduction 
As discussed in chapter 1, cardiovascular dysfunction resulting in heart failure is a 
prevalent cause of morbidity and mortality in diabetic patients.2,10 Diabetic 
cardiomyopathy, first reported by Rubler et al., refers to structural and functional 
abnormalities in diabetic heart as characterized by myocyte apoptosis, interstitial 
inflammation, myocardial fibrosis and ventricular dysfunction independent of other 
cardiovascular disease risk factors e.g., age, gender, hypertension, coronary artery 
disease, congenital heart disease and valvular heart disease.9,15,16,24,31,32,107,108 Myocardial 
fibrosis, one of the cardinal features of diabetic cardiomyopathy, contributes to increased 
ventricular stiffness which leads to contractile dysfunction in failing diabetic hearts.46,109 
Epidemiological studies have shown increased proinflammatory T cell subsets expansion 
in diabetic patient blood that correlates with adverse cardiac events including acute 
coronary syndrome.79,110 Recent investigations in murine pressure-overload-induced heart 
failure model have shown the presence of T lymphocytes in injured cardiac tissue 
associated with exacerbated fibrosis.76 Increased T lymphocytes infiltration in diabetic 
myocardium has been detected that correlates with enhanced collagen deposition in 
myocardium with increased ventricular stiffness.111 T lymphocytes secrete 
proinflammatory cytokines, growth factors that activate profibrotic cells.73 Stimulated 
profibrotic cells, such as fibroblasts and fibrocytes, secrete excess collagen that facilitates 
fibrosis development in heart.73,163 Although different approaches including antibody-
induced neutralization or genetic knockout of signaling protein of T cells have 
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demonstrated reduced fibrosis in murine heart failure models, therapeutic interventions to 
protect hearts in T cell mediated injury need to be explored. Modulation of T cell 
trafficking and its effect in long term diabetic fibrogenesis are not known yet. Further, the 
crosstalk between T cells and other cellular components in myocardial fibrosis is not 
completely understood. Therefore, we hypothesized that the modulation of T cell 
trafficking could protect heart from diabetes-associated fibrosis and cardiac dysfunction. 
In this chapter, we investigated T cell trafficking modulation by using novel 
immunomodulator drug fingolimod (FTY720) in wild-type C57BL/6 mice through 
streptozotocin-induced type 1 diabetic cardiomyopathy model. Rag1 knock-out mice that 
lacks mature lymphocytes were used as a complementary genetic approach of wild-type 
C57BL/6 mice.113  
Sphingosine 1-phosphate receptor 1 (S1P1) is a cell membrane resident G protein-
coupled receptor. Sphingosine 1-phosphate (S1P) is the endogenous ligand for S1P 
receptor 1. Mature T lymphocytes upregulate the expression of sphingosine 1-phosphate 
receptor for egress from lymphoid organs to circulation.114 Interaction of S1P and S1P1 is 
crucial for egress of mature T lymphocytes from lymphoid organs to circulation. FTY720 
is a S1P analogue which binds to S1P1 as an agonist. The binding of FTY720 to S1P1 
down-modulates cell surface S1P1 receptor on T cells and disables the T cells to sense the 
chemotactic gradient of endogenous ligand S1P in circulation. Thus, FTY720 induces 
lymphopenia by sequestering lymphocytes in secondary lymphoid organs.91,95,115 
Additionally, S1P and S1P1 signaling have been implicated in inflammation mediation in 
myocardial injury.116 Notably, S1P1 expression status in diabetic myocardium has not yet 
been reported. Thus, chronic FTY720 administration effects in long term experimental 
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diabetes settings in the context of myocardial fibrotic remodeling and cardiac function 
needs to be explored.  
In this dissertation, we evaluated the effects of chronic administration of FTY720 
on cardiac fibrosis and cardiac function in streptozotocin-induced diabetic wild-type and 
Rag1 knockout mice at the end of 11-week experimental period. In this study, we 
assessed outcomes of FTY720 treatment in murine diabetic cardiomyopathy model. We 
determined T lymphocytes number in heart and circulation by flow cytometry analysis. 
We conducted immunohistological studies to detect CD34 expressing fibrocytes 
localization, profibrotic TGF-β1 and S1P1 expression in myocardium after long term 
diabetes. We studied heart histology and measured fibrosis area in heart sections at the 
end of experimental period. We, further, evaluated the cardiac function of the mouse 
heart using ex vivo Langendorff’s heart perfusion system. 
2.2. Materials and Methods  
2.2.1. Animals 
This investigation was carried out in accordance with the Guide for the Care and 
Use of Laboratory Animals set forth by U.S. National Research Council (Eighth Edition, 
2011). All experimental procedures involving research animals were approved by the 
Institutional Animal Care and Use Committee (IACUC) at South Dakota State University 
(SDSU). Eight-week old male wild-type (WT) C57BL/6 mice weighing 22-25 g were 
purchased from the Charles River Laboratories (Wilmington, MA, USA) and two 
breeding pairs of Rag1 knockout (KO) mice weighing ~20 g lacking mature lymphocytes 
were obtained from The Jackson Laboratory (Bar Harbor, ME, USA). Rag1 KO mice 
were bred in the Animal Research Wing (ARW) at SDSU. All the mice were housed in 
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the ARW facility at SDSU and given ad libitum standard rodent chow food (5001; 
LabDiet, St. Louis, MO, USA) and water. Rag1 KO mice were kept in a specific 
pathogen free room and had free access to autoclaved food (5010; LabDiet) and water. 
2.2.2. Type 1 diabetes induction and physiological assessment 
Streptozotocin (STZ) is a glucosamine-nitrosourea antibiotic that destroys insulin 
secreting pancreatic beta cells rendering recipient animal diabetic.125 In present study, we 
used multiple low doses of STZ to induce type 1 diabetes in mice. Briefly, streptozotocin 
(STZ) (S0103; Sigma-Aldrich, MO, USA) was administered through intraperitoneal (i.p.) 
injection at a dose of 50 mg/kg body weight in 0.1 M sodium citrate buffer (pH 4.5) for 5 
consecutive day to induce Type 1 diabetes while the control group received only buffer 
(i.p). Body weights (g) were measured by an electric balance twice each week (OHAUS® 
Scout-Pro™, OHAUS, NJ, USA). Blood glucose levels (mg/dl) were measured in blood 
samples from tail veins at the beginning, 4- and 11-week post STZ injection by using a 
blood glucose meter (CONTOUR®, Bayer Healthcare LLC, IN, USA). STZ recipient 
mice with fasting blood glucose level over 200 mg/dl were considered as diabetic. 
2.2.3. Experimental protocol 
Age-matched WT and KO mice were divided into three groups: control, untreated 
diabetic (STZ), diabetic treated with FTY720 (FTY720+STZ). All mice went through 11-
week study period as described earlier.117 FTY720 (10006292; Cayman Chemical, MI, 
USA) was administered by i.p. injection at 0.3 mg/kg body weight every day for first four 
weeks. After that, there was an interim three week no treatment period, and then FTY720 
administration was resumed for another four week till the end of 11-weeks (Figure 2-1). 
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Serum insulin levels were measured after 11-week by using an ultrasensitive mouse 
insulin ELISA kit according to manufacturer’s instructions (90080; Crystal Chem Inc., 
IL, USA).  
 
 
 
 
 
 
 
Figure 2-1: Schematic diagram of 11-week long streptozotocin (STZ)-induced type 1 
diabetes mice model and treatment protocol. 
2.2.4. Flow cytometry analysis 
CD4+ and CD8+ T lymphocytes were measured in blood by two-color flow 
cytometry analysis at the end of 11-weeks. The blood samples were collected into 
heparinized blood collection tubes (367884, BD Biosciences, NJ) and mixed well to 
achieve anti-coagulation. The anti-mouse fluorescein isothiocyanate (FITC) conjugated 
CD4 (561828; IgG2b; BD Pharmingen, CA) and anti-mouse phycoerythrin (PE)-CD8a 
(561095; IgG2a; BD Pharmingen) antibodies were added into the freshly prepared 100 
µL of heparinized blood. Respective isotype controls for both FITC- (553988; IgG2b; BD 
Pharmingen) and PE-conjugated antibodies (551799; IgG2a; BD Pharmingen) were used 
to set detector compensation at the instrument during analysis. The tubes were then 
incubated for 30 min(s) at room temperature in the dark for antibody staining. Red blood 
cells lysis and cell fixation were done by adding 2 mL of 1x 1-step fix/lyse solution (00-
FTY720 (0.3 mg/kg/day i.p.) 
for 4-week 
 3-week pause FTY720 (0.3 mg/kg/day i.p.) 
resumed for next 4-week 
5-day STZ (50 mg/kg i.p.) to STZ and FTY720+STZ mice 
or buffer only i.p. to control mice 
 Flow cytometry analysis 
 Heart contractile force 
development measurement 
in ex-vivo Langendorff Heart  
perfusion system 
 Histology study 
 Fibrosis area assessment 
 Immunohistochemistry 
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5333; eBioscience, San Diego, CA, USA) and incubated for 15 min(s) at room 
temperature in the dark. After incubation, cells were washed by centrifugation 
(Eppendorf 5810R, Hauppauge, NY) at 500 x g for 5 min(s) at room temperature with 2 
mL of flow cytometry staining  buffer (00-4222; eBioscience) twice. The supernatants 
were discarded. The remaining cell pellets were re-suspended with 200 µL of flow 
cytometry staining buffer and proceeded to flow cytometry analysis. Positively stained 
CD4+ and CD8+ cell populations were counted on a BD FACSCalibur flow cytometry 
system (BD Biosciences, San Jose, CA, USA). Data acquisition and analysis were done 
by BD CellQuest Pro Software (BD Biosciences). 
2.2.5. Hemodynamics Study 
At the end of 11-week experimental period, mice were weighed, heparin (500 U 
kg-1) was injected i.p. and then anesthetized with phenobarbital (120 mg kg-1, i.p.). 
Surgical anesthesia was assessed by the absence of toe pinch reflex in anesthetized mice 
before starting the operation. Hearts were then rapidly excised and washed in ice-cold 
arresting solution (NaCl 120 mmol L-1, KCl 30 mmol L-1), and cannulated via the aorta 
with a 20 gauge stainless steel blunt needle. Heart perfusions were carried out at 70 
mmHg pressure on a modified Langendorff apparatus using Krebs–Henseleit solution 
(NaCl 118.5 mmol L-1, NaHCO3 25.0 mmol L
-1, KCl 4.75 mmol L-1, KH2PO4 1.18 mmol 
L-1, MgSO4 1.19 mmol L
-1, D-glucose 11.0 mmol L-1, CaCl2 1.41 mmol L
-1) 
supplemented with 95% O2 and 5% CO2 at 37°C.
118 Cardiac contractility was measured 
by a force displacement transducer (Model T03; Grass, Warwick, RI, USA) attached to 
the apex of the heart with a thin thread and a metal hook. The cardiac contractility was 
recorded with Biopac MP 100 data system (Goleta, CA, USA). 
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2.2.6. Hematoxylin and eosin (H&E) and Masson’s trichrome staining of heart 
sections 
After cardiac contractile force measurement, hearts were perfused and fixed with 
freshly prepared 4% paraformaldehyde in 0.1 M phosphate buffered saline, pH 7.4 for 10 
minutes. Hearts were removed after perfusion and placed in 4% paraformaldehyde 
overnight at 4⁰C. Paraffin-embedded (5 µm) heart sections were prepared. Hematoxylin 
& Eosin and Masson’s trichrome staining were done according to standard procedures. 
Heart histology was examined in H&E stained slides using Zeiss Axio Imager A1 upright 
microscope. Each heart section was graded based on the presence of eosinophilic 
interstitial collagen fibers, interstitial cellular infiltration, myocardial cell necrosis and 
myofiber striation and organization on a five-point scale for each characteristic from 0 to 
4.120,121 The composite scores were expressed from 0 to 16 for each group. Trichrome 
stained whole heart sections images were taken using Leica EZ4 HD stereomicroscope 
(Leica Microsystems, Buffalo Grove, IL, USA). The percent of fibrosis area in whole 
heart sections was quantified by using NIH Image J software (Bethesda, MA, USA).117 
2.2.7. Immunohistochemistry of heart sections 
Immunohistochemical detection of CD3, S1P1, TGF-β1 and CD34 expression was 
conducted with CD3 (10 µg/mL, sc-20047; Santa Cruz Biotechnology, Inc., CA), S1P1 
(15 µg/mL, MAB7089; R&D Systems, Inc., Minneapolis, MN), TGF-β1 (15 µg/mL, 
MAB240; R&D Systems, Inc.) and CD34 (10 µg/mL, MA5-17825; Pierce 
Biotechnology, Rockford, IL, USA) primary antibodies in 5 µm thick paraffin-embedded 
heart tissue sections. We used R&D systems mouse/rat cell and tissue staining HRP-DAB 
kit (CTS002/CTS017; R&D Systems) according to primary antibodies host species to 
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amplify and visualize primary antibody staining localization in heart tissue sections.  
Briefly, heart sections were first deparaffinized and hydrated through consecutive washes 
with xylene and graded alcohol series. Antigen unmasking was done through heat-
induced epitope retrieval (HIER) procedure by heating the slides at 95 ºC with 10 mM 
sodium citrate buffer (pH 6.0) for 40 minutes. Slides were cooled to room temperature 
and were washed with 1x Tris-buffered saline containing 0.01% v/v Tween 20 (1x TBST, 
pH 7.4). Endogenous peroxidase activity was quenched by incubating with peroxidase 
blocking reagent (R&D Systems) for 5 minutes. Sections were washed and blocked with 
blocking solution composed of 1% w/v bovine serum albumin, 1% v/v normal goat 
serum, 1% v/v donkey serum, 0.3% v/v Triton X-100 and 0.05% v/v Tween 20 in 1x 
phosphate buffered saline for 1 hour at room temperature. Avidin and biotin were 
blocked according to the manufacturer’s instructions (R&D Systems). Sections were then 
incubated with respective primary antibodies diluted in blocking solution overnight at 4 
ºC in sealed humid boxes. After overnight incubation, sections were washed with 1x 
TBST and incubated with secondary biotinylated antibody for 30 minutes at room 
temperature. Sections were then washed with 1x TBST and incubated with high 
sensitivity streptavidin conjugated to horseradish peroxidase (HSS-HRP) (Part 865006; 
R&D systems) for 30 minutes at room temperature. After incubation, sections were 
washed and incubated with 3, 3´ diaminobenzidine (DAB) for 2 minutes. DAB is a 
chromogenic substrate for HRP, and enzymatic conversion of DAB by peroxidase 
enzyme yields brown color precipitation at antigen localization site. Sections were gently 
washed under running tap water for 5 minutes and counterstained with Mayer’s 
hematoxylin (MHS16; Sigma-Aldrich, St. Louis, MO, USA) for nuclear staining. Finally, 
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sections were mounted with histological mounting medium Permount® (SP15; Fisher 
Scientific, Fair Lawn, NJ, USA). All experiments were done in triplicate. In all 
experiments, the slides incubated only with blocking solution was used as negative 
control to ensure specificity of IHC detection.  To count immunopositive CD3+ cells, 3o 
fields for each stained slide were pictured at bright-field under high magnification (400x) 
in Zeiss Axio Imager.A1 upright microscope equipped with Zeiss Achroplan objective 
lens (Carl Zeiss). Myocardium infiltrating cells number was calculated by counting the 
cells in imaged 400x fields and was expressed as cells/field.75 TGF-β1, S1P1 and CD34 
positive staining percent area were quantified in ten images and averaged.122 Stained 
sections were examined under Zeiss Axio microscope and imaged with Axiocam MRc 5 
digital camera. Images were used to quantify positively stained regions in heart section. 
2.2.8. Plasma S1P quantification by LC/MS/MS 
At the end of 11-weeks, blood samples were collected from mice in EDTA blood 
collection tubes (367856, BD Biosciences, NJ) and mixed well to achieve anti-
coagulation. The tubes were centrifuged immediately at 1300 x g at room temperature 
and plasma samples were collected from the top. The mice plasma samples were stored at 
-80 ºC until further analysis. Sphingosine 1-phosphate (S1P) levels in plasma were 
measured using liquid chromatography-tandem mass spectrometry method 
(LC/MS/MS).123,124 Briefly, S1P was extracted from 10 µL of plasma by methanol 
extraction. After dilution with methanol, final concentration was 10% plasma, 90% 
methanol, and 30 ng/ml of internal standard D-erhythro-sphingosine-1-phosphate (C17 
base) (860641; Avanti Polar Lipids, Alabaster, AL, USA). Sample tubes were then 
vortexed and centrifuged at 14,000 rpm for 10 minutes at 4 ºC. Supernatants were 
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collected and analyzed by LC/MS/MS. S1P and internal standard were eluted with 
isocratic mobile phase consisting of 70% acetonitrile/30% water/0.1% formic acid mobile 
phase at a flow rate of 0.25 ml/min through Waters XBridge™ Phenyl Column (150 cm 
length x 2 mm internal diameter; i.d., 5 µm particle size) with a C18 guard column (4 mm 
length x 2 mm i.d.) (Waters Corporation, Milford, MA, USA). The runtime for each 
injection was 4 min(s). The retention time for S1P and internal standard were about 1.87 
and 1.75, respectively. All the components of mobile phase were LC/MS grade reagents 
(Optima; Fisher Scientific, Fair Lawn, NJ, USA). Separation and LC/MS/MS analysis 
was carried out using Agilent 1100 series HPLC system (Agilent Technologies, 
Waldbronn, Germany) coupled with Finnigan TSQ Quantum Ultra triple quadrupole 
mass spectrometer (Thermo Electron Corporation, San Jose, CA, USA) operating in 
positive ion mode. S1P and internal standard were monitored by Multiple Reaction 
Monitoring (MRM) at 380.31 -> 264.31 m/z and 366.26 -> 250.27 m/z, respectively. S1P 
peak area was divided by the percent recovery of the internal standard in each sample to 
reconcile the loss. The concentration of S1P was calculated from loss-adjusted S1P peak 
area using a loss-adjusted standard curve of S1P (860492; Avanti Polar Lipids). The 
linearity of standard curve to calculate S1P concentration was determined by R2 value of 
0.99.  
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2.2.9. Data analyses  
Data was expressed as mean ± SEM. One-way ANOVA was used for statistical 
analysis followed by Tukey’s post hoc test for multiple comparisons of group means. 
Two-tailed unpaired student’s t-test was done, where applicable. Data were analyzed in 
GraphPad Prism Software (v5.01, 2007). A P value of less than 0.05 was considered 
statistically significant and indicated with an asterisk (*) or a number (#) sign. 
2.3. Results 
2.3.1. Assessment of metabolic and physiological parameters in diabetic mice 
In WT mice, both untreated (STZ, n=9) and FTY720 treated (FTY720+STZ, n=9) 
STZ recipient mice demonstrated lower body weight gain compared to only buffer 
recipient (Control, n=8) mice throughout the 11-week treatment period (Figure 2-2). 
There was no statistically significant difference in body weight between groups at the 
beginning. After 11-week, control mice gained 8.67 % higher body weight than STZ and 
14.63% higher body weight than FTY720+STZ mice (Table 2-1, Figure 2-2). 
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Figure 2-2: Body weight (g) changes in wild-type (WT) C57BL/6 mice during 11-week 
experimental period. Streptozotocin recipient both STZ and FTY720+STZ mouse groups 
exhibited less body weight gain during treatment period.  Sample size, n=8-9 mice in 
each group, *P < 0.05 as compared to control mice at the end of 11-weeks. The data is 
expressed as mean ± SEM.  
Blood glucose level was higher both in STZ (466.7±22.4 mg/dl vs. 159.3±8.21 
mg/dl, **P < 0.01, after 4-week) and FTY720+STZ (563.4±10.92 mg/dl vs. 159.3±8.21 
mg/dl, **P < 0.01, after 4-week) mice than control mice post STZ induction, although at 
the beginning there was no statistically significant difference in blood glucose levels 
between these groups (Table 2-1, Figure 2-3). After 11-week, STZ and FTY720+STZ 
mice remained hyperglycemic compared with control mice (Table 2-1, Figure 2-3). 
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Figure 2-3: Blood glucose levels (mg/dl) in WT C57BL/6 mice at the beginning, after 4- 
week and after 11-week of STZ induction. Sample size, n = 8-9 mice per each group, **P 
< 0.01 as compared to control mice after 4-weeks and after 11-weeks of post STZ-
induction. The data is expressed as mean ± SEM. 
 
Hyperglycemic STZ (0.41±0.02 ng/ml vs. 0.66±0.08 ng/ml, *P < 0.05) and 
FTY720+STZ (0.38±0.03 ng/ml vs. 0.66±0.08 ng/ml, *P < 0.05) mice had lower serum 
insulin level compared to control mice at the end of the treatment period (Figure 2-4). In 
sum, FTY720 treatment did not improve body weight, blood glucose and serum insulin 
levels in diabetic WT mice compared to untreated diabetic mice. 
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Figure 2-4: Serum insulin levels (ng/mL) in WT C57BL/6 mice after 11-week of STZ 
induction. Sample size, n = 8-9 mice per each group, *P < 0.05 between control and STZ 
& FTY720+STZ mice after 11-week of post STZ-induction. The data is expressed as 
mean ± SEM.
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Table 2-1: Summary of metabolic and physiological parameters in WT C57BL/6 mice after 11-week experimental period.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The data is expressed as mean ± SEM. Sample size, n = 8-9 mice in each group.  *P < 0.05 and **P < 0.01 as compared to control 
group. STZ, streptozotocin; FTY720, fingolimod.
 Control STZ FTY720+STZ 
At the beginning 
(before STZ induction) 
   
Body wt. (g) 22.1±0.53 22.2±0.47 20.86±0.23  
Blood glucose level (mg/dl) 162.38±3.59 152.33±9.05 131.67±8.68 
After 4-week of STZ induction    
Body wt. (g) 23.33±0.60 22.4±0.75 19.50±0.15 
Blood glucose level (mg/dl) 159.29±8.21 466.67±22.41** 563.44±10.92** 
After 11-week of STZ 
induction 
   
Body wt. (g) 26.83±0.51 24.5±0.65* 22.9±0.34* 
Blood glucose level (mg/dl) 151.29±15.39 504.00±20.29** 466.56±17.38** 
Serum insulin level (ng/ml) 0.66±0.08 0.41±0.02* 0.38±0.03* 
42 
 
 
 
 
In Rag1 KO mice, both untreated (STZ) and FTY720 treated diabetic 
(FTY720+STZ) mice showed lower body weight gain during study period similar to WT 
C57BL/6 mice. Rag1 STZ and FT720+STZ mice had 13.90% and 10.20% lower body 
weight than age-matched non-diabetic control mice, respectively, at the end of 11-week 
after STZ administration (23.97±1.09 g vs. 27.84±0.62 g and 25±0.51 g vs. 27.84±0.62 g, 
#P < 0.05; n=4-6 mice in each group) (Figure 2-5).  
 
 
 
 
 
 
 
 
 
 
 
Figure 2-5: Body weight (g) changes in Rag1 KO mice throughout 11-week 
experimental period. Sample size n =4-6 mice in each group, #P < 0.05 as compared to 
control mice. The data is expressed as mean ± SEM. 
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There was no significant difference in blood glucose levels between Rag1 KO 
mouse groups at the beginning (Figure 2-6, Table 2-2). After STZ induction, STZ 
(374.8±37.05 mg/dl vs. 155.7±6.06 mg/dl, ##P < 0.01) and FTY720+STZ (443.75±72.42 
mg/dl vs. 155.7±6.06 mg/dl, ##P < 0.01) mice exhibited higher blood glucose level as 
measured after 4-weeks. Both STZ and FTY720+STZ groups remained hyperglycemic at 
the end of 11-week compared to control group (Figure 2-6, Table 2-2). 
 
Figure 2-6: Blood glucose levels (mg/dl) at the beginning, after 4-week and after 11-
week of STZ administration in Rag1 KO mouse groups. Sample size, n =4-6 mice in each 
group, ##P < 0.01 as compared to control mice. The data is expressed as mean ± SEM. 
Along with hyperglycemia, diabetic KO mice had lower serum insulin level than 
control mice (0.78±0.12 ng/ml vs. 0.43±0.02 ng/ml, #P < 0.05) (Figure 2-7, Table 2-2). In 
summary, FTY720 treatment in Rag1 KO diabetic mice, did not exhibit significant 
improvement in body weight, and remained hyperglycemic as compared to control mice. 
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Figure 2-7: Serum insulin levels (ng/ml) after 11-week of post STZ induction in Rag1 
KO mouse groups. Sample size, n =5 mice in each group, #P < 0.05 as compared to 
control mice. The data is expressed as mean ± SEM.
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Table 2-2: Summary of metabolic and physiological parameters in Rag1 KO mice after 11-week of experimental period.  
 
 
 
 
 
 
 
 
 
 
 
 
The data is expressed as mean ± SEM. Sample size, n = 4-6 mice in each group. #P<0.05 and ##P < 0.01 as compared to control group. 
STZ, streptozotocin; FTY720, fingolimod.
 Control STZ FTY720+STZ 
At the beginning 
(before STZ induction) 
   
Body wt. (g) 24.95±0.58 22.23±1.02 25.43±0.40 
Blood glucose level (mg/dl) 162.50±10.00 153.29±4.48 129.75±6.05 
After 4-week of STZ induction    
Body wt. (g) 26.06±0.47 22.82±1.19 24.73±0.52 
Blood glucose level (mg/dl) 155.67±6.06 374.83±37.05## 443.75±72.42## 
After 11-week of STZ 
induction 
   
Body wt. (g) 27.84±0.61 23.97±1.09# 25.00±0.51# 
Blood glucose level (mg/dl) 150.80±10.27 394.00±47.86## 379.00±74.88## 
Serum insulin level (ng/ml) 0.66±0.08 0.41±0.02#  
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2.3.2. Effects of FTY720 treatment in CD4+ and CD8+ T cells number in the blood 
Sphingosine 1-phosphate (S1P) is an endogenous-bioactive lipid molecule that 
acts on five G-protein coupled receptors, S1P1-5. The concentration of S1P in plasma and 
lymph is 200 to 900 nM. Due to metabolic degradation of S1P in tissues, its 
concentration is 5 to 20 nM in tissues. This difference in concentrations of S1P between 
systemic circulation and tissues creates a concentration gradient of S1P.85,88 Single 
positive CD4+ and CD8+ T lymphocytes upregulate S1P1 receptor expression on their cell 
membrane upon maturation in lymphoid organs.114 The upregulation of S1P1 enables T 
lymphocytes to egress from lymphoid organs to blood and lymph through chemotactic 
response towards higher concentration of S1P present in systemic circulation. FTY720 
(Fingolimod) acts as ‘functional antagonist’ to S1P1 (EC50 0.2 nM).
88 Fingolimod binds 
to S1P1 and causes its internalization following subsequent degradation of the receptor in 
T lymphocytes.92 Thus, T lymphocytes chemotactic movement to blood is inhibited by 
FTY720 that causes sequestration of T cells in lymphoid organs. In our present study, we 
counted both CD4+ helper T cells and CD8+ cytotoxic T cells in blood by flow cytometry 
(Table 2-3, Figure 2-8 and Figure 2-9). FTY720 treatment in WT diabetic mice, 
significantly reduced both CD4+ (control, n=3, 12.02±1.06 %, STZ, n=4, 12.79±1.42 %, 
FTY720+STZ, n=4, 0.19±0.03 %; **P < 0.01 when FTY720+STZ compared with 
control and STZ group, data after 4-week) and CD8+  T cells in blood (control, n=3, 
7.97±0.68 %, STZ, n=4, 7.89±1.07 %, FTY720+STZ, n=4, 0.32±0.04 %; **P < 0.01 
when FTY720+STZ compared with control and STZ group, data after 4-week). The 
observed lymphopenia in FTY720 treated group sustained after 11-week (CD4 T cells: 
control, n=6, 9.10±1.44 %, STZ, n=8, 8.87±0.81%, FTY720+STZ, n=7, 0.24±0.07%; 
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**P < 0.01 when FTY720+STZ compared with control and STZ group, data after 11-
week; CD8+  T cells: control, n=6, 6.89±1.40 %, STZ, n=8, 5.80±0.78 %, FTY720+STZ, 
n=7, 0.75±0.21 %; **P < 0.01 when FTY720+STZ compared with control and STZ 
group, data after 11-week) (Table 2-3, Figure 2-8 and Figure 2-9). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-8: Flow cytometry analysis of CD4+ and CD8+ T lymphocytes in peripheral 
blood of WT C57BL/6 mice after 11-week experimental period. Representative dot plot 
(upper panel) and histogram plot (lower two panel) of flow cytometry analysis of CD4+ 
and CD8+ T lymphocytes in WT C57BL/6 mice blood. FTY720 treatment noticeably 
depleted both CD4+ and CD8+ T cells in peripheral blood compartment as observed in 
lower right (CD4+ stained cells) and upper left (CD8+ stained cells) quadrants in dot plot 
and in M1 gate in histogram.   
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Control STZ FTY720+STZ 
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Figure 2-9: Quantification of CD4+ and CD8+ T cells percent numbers in WT C57BL/6 
mice blood after 11-week of experimental period. **P < 0.01 as compared to control and 
STZ groups, n = 6-8 mice per group. The data is expressed as mean ± SEM.
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Table 2-3: Summary of CD4+ and CD8+ T cells percent numbers in peripheral blood of WT C57BL/6 mice after 11-weeks. 
 
 
 
 
 
 
 
 
 
 
 
The data is expressed as mean ± SEM. The value of ‘n’ represents number of mice in each group. **P<0.01 as compared with control 
and STZ mice. STZ, streptozotocin; FTY720, fingolimod. 
 
 Control STZ FTY720+STZ 
After 4-week of  
STZ induction 
   
CD4+ (relative % of total cell 
populations) 
12.02±1.06 (n=3) 12.79±1.42 (n=4) 0.19±0.03** (n=4) 
CD8+ (relative % of total cell 
populations) 
7.97±0.68 (n=3) 7.89±1.07 (n=4) 0.32±0.04** (n=4) 
After 11-week of  
STZ induction 
   
CD4+ (relative % of total cell 
populations) 
9.1±1.44 (n=6) 8.87±0.81 (n=8) 0.24±0.07** (n=7) 
CD8+ (relative % of total cell 
populations) 
6.89±1.40 (n=6) 5.80±0.78 (n=8) 0.75±0.21** (n=7) 
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Recombination activating gene 1 (Rag1) encodes recombinase enzyme Rag1 
which along with Rag2 mediate recombination in development process of both B and T 
cells receptor repertoire. In Rag1 deficient mice, recombination does not occur which 
thwart lymphocytes development at early stage. Thus, Rag1 deficient mice does not have 
any mature B or T lymphocytes.113 In our present study, flow cytometry analysis of Rag1 
KO mice blood did not yield any detectable CD4+ and CD8+ T cells (Figure 2-10). 
 
 
 
 
 
 
 
  
Figure 2-10: Representative flow cytometry analysis dot plot and histogram plot of CD4+ 
and CD8+ T cells in Rag1 KO mice peripheral blood. There was no detectable CD4+ and 
CD8+ T cells in Rag1 KO mice blood. Experiments are representative of triplicate 
samples. 
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2.3.3. Effects of FTY720 treatment on heart histology  
 
After 11-week diabetic period, heart sections from all the groups were prepared 
and H&E staining was done to evaluate heart histology. H&E stained sections were 
observed under microscope and graded on histological parameters. WT diabetic mice 
heart exhibited noticeable cardiomyocyte loss, large interstitial space indicating edema, 
focal and diffuse increased cellularity and myofiber disorganization in myocardium in 
comparison to control group. In contrast, FTY720 treatment in WT diabetic mice 
protected heart histology with improved myocytes organization and structure (Figure 2-
11). FTY720 treated WT diabetic mice heart had reduced cumulative histology score 
compared to WT STZ mice (control [n=5] 2.2±0.80; STZ [n=6], 9.67±0.49; 
FTY720+STZ [n=5], 3.4±0.75, #P < 0.05 when FTY720+STZ compared with STZ) 
(Figure 2-13). 
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Figure 2-11: Representative images of Hematoxylin and Eosin (H&E) stained heart 
tissue sections of WT C57BL/6 mice after 11-week of experimental period. Untreated 
WT diabetic mice heart sections exhibited altered cardiac architecture and 
disorganization of myocytes as compared to control group. FTY720 treatment preserved 
cardiac histology under diabetes. Upper panel magnification is 100x, lower panel 
magnification is 400x. Images are representative of n=5-6 mice heart tissue sections in 
each group. 
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Diabetic Rag1 KO mice (STZ, n=5) heart exhibited protected heart histology 
under hyperglycemic conditions. KO STZ mice heart histology score had no significant 
difference compared with control group (n=6) (control, 3.33±0.42; STZ, 3.00±0.45; P > 
0.05) (Figure 2-12). Notably, treatment with FTY720 exacerbated heart histology with 
marked myocytes breakage and disorganization in KO diabetic mice (FTY720+STZ, 
n=3; 10.33±0.33) (Figure 2-12 and Figure 2-13). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-12: Representative images of Hematoxylin and Eosin (H&E) stained heart 
tissue sections of Rag1 KO mice after 11-week of experimental period. Rag1 KO diabetic 
mice heart showed no significant difference in heart histology than control mice. 
Noticeably, FTY720 treatment in diabetic Rag1 KO mice exhibited altered cardiac 
histology with marked myocytes disarray.  Upper panel magnification is 100x, lower 
panel magnification is 400x. Images are representative of n=3-6 mice heart tissue 
sections in each group. 
Control STZ FTY720+STZ 
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Figure 2-13: Quantification of heart histology scores in WT C57BL/6 and Rag1 KO 
mice heart tissue sections. In WT mice, Control vs. STZ, *P < 0.05 and FTY720+STZ vs. 
STZ, #P < 0.05. In KO mice, control vs. STZ (P = ns) and STZ vs. FTY720+STZ, *P < 
0.05. Sample size, n = 3-6 mice in each group. The data is expressed as mean ± SEM. 
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2.3.4. Effects of FTY720 treatment on myocardial fibrosis  
 
Fibrosis area was measured in paraffin-embedded whole heart sections stained 
with Masson’s Trichrome staining. Blue color represents collagen deposition in heart 
sections (Figure 2-14 and 2-15). After 11-weeks, WT diabetic mice had increased 
collagen deposition in myocardium and perivascular area compared to control group 
(38.09±4.35 % vs. 7.40±1.23 %, *P < 0.05) (Figure 2-14 and 2-16). FTY720 treatment in 
WT diabetic mice significantly reduced interstitial and perivascular fibrosis compared to 
untreated diabetic mice (9.40±2.23 % vs. 38.09±4.35%, #P < 0.05) (Figure 2-14 and 2-
16). 
 
Rag1 KO control and STZ mice do not have any significant difference in total 
fibrosis percent area (7.20±1.72 % vs. 10.60±0.91 %, P= ns) (Figure 2-15 and 2-16). 
FTY720 treatment in Rag1 KO diabetic mice markedly increased interstitial fibrosis area 
compared to untreated KO diabetic mice (42.16±4.30 % vs. 10.60±0.91 %, *P < 0.05). 
(Figure 2-15 and 2-16). 
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Figure 2-14: Representative images of Masson’s Trichrome stained heart tissue sections 
of WT C57BL/6 mice after 11-week experimental period. Arrows indicate collagen 
staining as blue color. Diabetic WT mice myocardium exhibited increased interstitial and 
perivascular fibrosis. FTY720 treatment reduced markedly fibrosis development in 
diabetic WT mice heart sections. Upper panel magnification is 16x, lower panel 
magnification is 400x. Images are representative of n=5-7 mice heart tissue sections in 
each group. 
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Figure 2-15: Representative images of Masson’s Trichrome stained heart tissue sections 
of Rag1 KO mice after 11-week experimental period. Untreated Rag1 KO diabetic mice 
heart did not exhibit increased fibrosis compared with control mice, while FTY720 
treatment in this mice strain developed increased fibrosis. Arrow indicates collagen 
deposition. Upper panel magnification is 16x, lower panel magnification is 400x. Images 
are representative of n=3-6 mice heart tissue sections in each group. 
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Figure 2-16: Quantification of percent fibrosis area in WT C57BL/6 and Rag1 KO mice 
heart after 11-weeks. In WT mice, control (n=6) vs. STZ (n=7), *P < 0.05; control (n=6) 
vs. FTY720+STZ (n=5), #P < 0.05. In Rag1 KO mice, control (n=6) vs. STZ (n=5), P = ns, 
STZ vs. FTY720+STZ (n=3), *P < 0.05. The data is reported as mean ± SEM. 
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2.3.5. Effects of FTY720 treatment on cardiac contractility  
 
We determined the force of contraction development in an ex-vivo Langendorff’s 
heart perfusion system after 11-weeks. The data is expressed as fold change in contractile 
force development compared to control. Cardiac dysfunction was observed in STZ-
induced diabetic WT C57BL/6 mice. There was no alternation in myocardial contractility 
between STZ-induced diabetic Rag1 KO mice and control Rag1 KO mice (Figure 2-
17B). Chronic treatment with FTY720 improved cardiac contractile force in diabetic WT 
C57BL/6 mice but reduced contractile force in diabetic Rag1 KO mice (Figure 2-17A 
and 2-17B). 
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Figure 2-17: Effect of FTY720 on cardiac contractile force in diabetic WT C57BL/6 and 
(A) and Rag1 knockout mice (B) hearts. Chronic Treatment with FTY720 preserved the 
cardiac function of diabetic WT hearts but attenuated contractile force of diabetic Rag1 
KO mice. The contractile force was expressed as fold change relative to control. Sample 
size, n = 4-9 mice in each group. The data is expressed as mean ± SEM. *P < 0.05, control 
vs. STZ; #P < 0.05, STZ vs. FTY720+STZ. 
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2.3.6. FTY720 reduces CD3+ T cells infiltration into the myocardium 
 
Although normal heart does not exhibit appreciable amount of CD3+ T 
lymphocytes, under pathological conditions T cells can infiltrate the heart.76 To detect 
CD3+ T lymphocytes in diabetic myocardium, we carried out immunostaining with 
mouse monoclonal CD3 IgG antibody. CD3+ T cells were barely detected in WT control 
hearts. On the other hand, we observed increased CD3+ T cells presence in interstitial 
space with close proximity to cardiomyocytes in diabetic WT mice, indicating T cells 
direct involvement in cardiac injury under diabetes (Figure 2-18A). FTY720 treatment 
reduced detectable CD3+ T cells in WT diabetic mice myocardium (STZ, 0.97±0.03 
cells/field vs. FTY720+STZ, 0.28±0.05 cells/field; #P<0.05) (Figure 2-18B). Rag1 KO 
heart sections exhibited no CD3+ T cell staining. 
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Figure 2-18: Immunohistochemical detection of CD3+ T cells in heart tissue section of 
WT C57BL/6 mice after 11-week experimental period. (A) Increased infiltration of CD3+ 
T cells in diabetic WT C57BL/6 mice myocardium were observed. FTY720 treatment 
reduced CD3+ T cells number in diabetic WT mice myocardium. Black arrows indicate 
detected CD3+ T cells in mice myocardium. Images are representative of three 
independent experiments. The magnification is 400x. (B) Results are from three 
independent experiments. The data is expressed as mean ± SEM. Control vs. STZ; *P < 
0.05; STZ vs. FTY720+STZ; #P < 0.05.  
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2.3.7. FTY720 reduces TGF-β1 expression in diabetic WT myocardium   
 
Transforming growth factor beta 1 (TGF-β1) is a profibrotic cytokine that can 
activate fibrotic pathway in heart that induces fibrosis.126 To measure total TGF-β1 
expression in cardiac tissue, we conducted immunohistochemistry and quantified the 
intensity and staining area. TGF-β1 expression was increased in diabetic WT mice 
myocardium after 11-week diabetic period compared to control mice (8.09±0.19 % 
staining area vs. 3.69±0.17 % staining area, *P<0.05) (Figure 2-19A and 2-20). FTY720 
treatment significantly reduces TGF-β1 expression in diabetic heart compared to 
untreated diabetic mice (3.80±0.12 % staining area vs. 8.09±0.19 % staining area, 
#P<0.05) (Figure 2-19A and 2-20). 
 
In contrast, diabetic Rag1 KO mice heart sections exhibited statistically no 
significant difference in TGF-β1 expression than control mice (3.48±0.26 % staining area 
vs. 3.35±0.38 % staining area, P=ns). FTY720 treatment in Rag1 KO hyperglycemic 
mice increased TGF-β1 expression in myocardium compared to untreated diabetic mice 
(6.61±0.51% vs. 3.35±0.38%, *P<0.05) (Figure 2-19B and 2-20). 
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Figure 2-19: FTY720 treatment effect in TGF-β1 expression in heart tissue sections of 
WT C57BL/6 and Rag1 KO mice after 11-week treatment period. (A) Representative 
immunohistochemical images show reduced TGF-β1 expression in WT FTY720 treated 
diabetic mice compared to untreated diabetic mice. (B) TGF-β1 expression was reduced in 
diabetic Rag1 KO mice, while FTY720 treatment increased TGF-β1 expression in Rag1 
KO mice heart sections. Black arrows indicate TGF-β1 expression localization in 
myocardium. Images are representative of three independent experiments. The 
magnification is 400x. 
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Figure 2-20: Quantification of TGF-β1 percent staining area in WT C57BL/6 and Rag1 
KO mice myocardium. Results are from three independent experiments. The data is 
expressed as mean ± SEM. In WT mice, Control vs. STZ, *P < 0.05, STZ vs. 
FTY720+STZ, #P < 0.05. In Rag1 KO mice, control vs. STZ, P = ns, Control, STZ vs 
FTY720+STZ, *P < 0.05. 
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2.3.8. Effects of FTY720 treatment on CD34 fibrocyte expression in the myocardium 
 
Fibrocytes are circulatory, sphindle shaped, monocyte-derived profibrotic cells 
that augment fibrotic conditions. Chronic injury invokes fibrocytes recruitment at the site 
of inflammation.62 CD34 surface expression can be considered as a biomarker for 
fibrocytes.62,63 We detected CD34 expression pattern and quantified expression level by 
immunostaining in mice heart sections. In WT control mice, CD34 expressing cells 
predominantly appeared in perivascular region, while in diabetic WT mice, CD34 
expressing cells appeared in interstitial space of myocardium and closely adherent to 
myocytes (Figure 2-21A). The total expression of CD34 in myocardium was increased in 
untreated diabetic mice heart tissue compared with control mice (6.59±0.20% vs. 
2.97±0.44%, *P<0.05) (Figure 2-22). Fingolimod treatment markedly reduced CD34 
expressing cells presence in diabetic myocardium compared to untreated diabetic mice 
(3.11±0.21% vs. 6.59±0.20%, #P<0.05) (Figure 2-21A and 2-22).  
 
Rag1 KO control and diabetic mice heart sections exhibited minimal expression 
of CD34 cells in myocardium (2.35±0.05% vs. 2.27±0.20%, P=ns) (Figure 2-21B and 2-
22). FTY720 treatment increased CD34 cells expression in interstitial space of diabetic 
Rag1 KO mice heart compared to untreated KO diabetic mice (4.45±0.12% vs. 
2.27±0.20%, *P<0.05) (Figure 2-21B and 2-22). 
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Figure 2-21: Representative immunostaining images of CD34 bearing fibrocytes in heart 
tissue sections of WT C57BL/6 and Rag1 KO mice after 11-weeks. (A) In WT control 
mice, CD34 fibrocytes are localized in perivascular area, while in WT diabetic mice heart 
CD34 cells are found increasingly adjacent to myocardium. FTY720 treatment reduced 
CD34 cells in myocardium of WT diabetic mice. (B) Rag1 KO control and diabetic mice 
myocardium have minimal CD34 expressing cells. FTY720 treatment in Rag1 KO 
diabetic mice significantly increased CD34 cells expression in the mouse heart sections. 
Black arrows indicate CD34 cells detected by immunostaining. Images are from three 
independent experiments. The magnification is 400x. 
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Figure 2-22: Quantification of percent area staining of CD34 expression in heart tissue 
sections of WT C57BL/6 and Rag1 KO mice after 11-weeks. Results are from three 
independent experiments. The data is expressed as mean ± SEM. Control vs. STZ; *P < 
0.05 and STZ vs. FTY720+STZ; #P < 0.05 in WT mice. Control vs. STZ, P = ns, STZ vs. 
FTY720+STZ; *P < 0.05 in Rag1 KO mice. 
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2.3.9. Increased plasma S1P levels and S1P1 expression in myocardium in diabetic 
mice 
 
Chronic inflammatory conditions in mice, such as colitis-associated cancer and 
myocardial infarction, lead to increased S1P synthesis at the site of tissue 
injury/inflammation.116,130 In addition, S1P1 receptor expression has been detected to 
increase at the site of tissue injury/inflammation. This phenomenon indicates presence of 
a positive feedback loop of S1P-S1P1 signaling in inflamed tissue.
116,130 To this end, it is 
noteworthy that long term diabetes is associated with chronic systemic and local 
inflammation. Thus, in the present study we measured mice plasma S1P level by using 
LC/MS/MS technique and also detected S1P1 expression in the myocardium.  
 
Hyperglycemia increased plasma S1P level in both WT and KO mice (Figure 2-
23A, 2-23B and 2-24A, 2-24B, *P<0.05, as compared with control mice). In WT mice, 
plasma S1P level was increased in diabetic mice compared to control mice (0.61±0.02 µM 
vs. 0.42±0.05 µM, *P < 0.05) (Figure 2-24A). FTY720 treatment reduced plasma S1P level 
about 1.20 –fold, but yielded no statistical significant difference with diabetic mice S1P 
level (0.51±0.05 µM vs. 0.61±0.02 µM, P > 0.05) (Figure 2-24A). Similarly, Rag1 KO 
diabetic mice have increased S1P levels compared to control mice (0.70±0.02 µM vs. 
0.50±0.04 µM, *P < 0.05) (Figure 2-24B). 
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Figure 2-23: Measurement of sphingosine 1-phosphate (S1P) level in the plasma samples 
of WT C57BL/6 and Rag1 KO mice by LC/MS/MS. (A) Representative full-scan product 
ion mass spectra of [M+H]+ for S1P (upper panel) and internal standard (IS) C17-S1P 
(lower panel). (B) Representative SRM chromatograms of S1P (upper panel) and IS 
(lower panel).  
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Figure 2-24: Quantification of plasma S1P level in the plasma samples of WT C57BL/6 
and Rag1 KO mice after 11-week experimental period. (A) In WT mice, Control (n=7) 
vs. STZ (n=9), *P < 0.05, STZ (n=9) vs. FTY720+STZ (n=8), P > 0.05. (B) In Rag1 KO 
mice, control (n=3) vs. STZ (n=4), *P < 0.05. The data is expressed as mean ± SEM. 
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We further detected sphingosine 1-phosphate receptor 1 (S1P1) expression in 
heart tissue sections by immunohistochemistry and quantified the expression level. S1P1 
expression was detected in cardiomyocytes, cells in interstitial spaces and in endothelial 
cells in control mouse heart tissue (Figure 2-25A). Hyperglycemia increased S1P1 
expression in cardiomyocytes in WT STZ mice compared to control mice (6.13±0.27% 
vs. 3.13±0.18%, *P<0.05) (Figure 2-25A and 2-26). Fingolimod treatment markedly 
reduced S1P1 expression in cardiomyocytes and limits the expression mainly on the 
endothelial cells compared to untreated diabetic mice (3.15±0.08% vs. 6.13±0.27%, 
#P<0.05) (Figure 2-25A and 2-26).  
 
Similar S1P1 expression profile was observed in Rag1 KO heart sections. 
Untreated Rag1 KO diabetic mice heart sections exhibited increased S1P1 expression 
(5.30±0.18 % [STZ] vs. 3.29±0.25 % [control], *P < 0.05), while FTY720 treatment 
reduces S1P1 expression (3.10±0.36 % [FTY720+STZ] vs. 5.30±0.18 % [STZ], 
#P < 
0.05) (Figure 2-25B and 2-26). 
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Figure 2-25: Representative immunohistochemistry images of S1P1 expression in WT 
C57BL/6 and Rag1 KO mice myocardium after 11-weeks. Both WT C57BL/6 (A) and 
Rag1 KO (B) diabetic mice heart sections exhibited increased S1P1 expression. FTY720 
treatment limits cardiomyocyte expression of S1P1 in both WT (A) and KO (B) mice 
myocardium. Images are representative of triplicate experiments for each group. The 
magnification is 400x. 
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Figure 2-26: Quantification of S1P1 expression in WT C57BL/6 and Rag1 KO mice 
heart tissue sections after 11-weeks. Results are from three independent experiments. The 
data is expressed as mean ± SEM. Control vs. STZ, *P < 0.05, STZ vs. FTY720+STZ, #P 
< 0.05 in WT and KO mice. 
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2.4. Discussion 
Recent studies have reported that the T lymphocytes infiltration is an important 
component in myocardial fibrogenesis in murine myocardial infarction model and 
pressure overload transverse aortic constriction models.74,76 In the present study, we for 
the first time report the chronic administration of FTY720 treatment reduced cardiac 
fibrosis area and improved contractility under chronic hyperglycemic condition compared 
to untreated diabetic mice in wild-type (WT) C57BL/6 mice. FTY720 treatment induced 
sustained reduction of CD4+ and CD8+ T lymphocytes in the blood and was associated 
with reduced CD3+ T cells infiltration into heart tissue of diabetic WT mice compared to 
untreated WT diabetic mice. Cardiac protection and anti-fibrosis were also observed in 
diabetic Rag1 knock-out (KO) mice without any mature lymphocytes. Remarkably, 
FTY720 caused heart injury in diabetic Rag1 KO mice.  
FTY720, also known as fingolimod, is an orally active immunomodulator drug 
approved by FDA for relapsing multiple sclerosis.92 FTY720 is a synthetic structural 
analogue of endogenous sphingosine, becomes activated in vivo upon phosphorylation by 
sphingosine kinase 2 and then acts on all five S1P receptors (S1P1-5).
92,93,128 FTY720 
binds with S1P1 receptor with high affinity (0.3 nM); causes ligand induced 
internalization and degradation of the receptor (functional antagonism).88,89 Mature T 
cells express higher S1P1 receptor on their cell surface that enables these cells to sense 
the increased concentration gradient of endogenous ligand sphingosine 1-phosphate 
(S1P) in blood and lymph than in lymphoid tissues.85,89 Thus, S1P-S1P1 driven 
chemotaxis enables T cells exit from lymphoid organs to periphery. Fingolimod 
downmodulates mature T lymphocytes cell surface S1P1 receptor and sequesters the T 
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cells in lymphoid organs. Thus, FTY720 inhibits the recirculation of T cells between 
lymphoid organs and blood.95 In experimental autoimmune encephalomyelitis, FTY720 
alters lymphocytes trafficking directed towards central nervous system and thus provides 
protection from immune assault mediated by T lymphocytes.92,95 Similarly, we found that 
FTY720 causes both CD4+ and CD8+ T cells sustained depletion in blood as shown in 
this study, and maintained the pronounced lymphopenia at the end of 11-week study 
period. To correlate circulatory T cells deficiency effect with heart T cells infiltration, we 
conducted immunostaining to detect myocardium infiltrating CD3+ T cells. WT diabetic 
mice myocardium increased CD3+ T cells presence in interstitial space that was reduced 
in FTY720 treatment WT diabetic mice. FTY720 protected diabetic WT mouse hearts 
against hyperglycemia-induced injury. Trichrome staining showed less fibrosis area in 
heart sections of FTY720 treatment diabetic WT mice compared to untreated diabetic 
mice. These cardiac protective effects are consistent with the study in diabetic Rag1 KO 
mice that lacks mature lymphocytes.  
After 11-weeks, diabetic Rag1 KO mouse hearts showed integrated cardiac 
structure with less fibrosis and preserved contractile force. Fibrosis development involves 
complex network of cellular and molecular milieu. We further investigated CD34 bearing 
fibrocytes localization in cardiac tissue. Diabetic mice myocardium exhibited increased 
myocytes adherent CD34 fibrocytes with increased expression of profibrotic mediator 
TGF-β1. Diabetic WT mice under FTY720 treatment as well as Rag1 KO diabetic mice 
showed significantly less fibrocytes presence in interstitial space of myocytes with 
reduced TGF-β1 expression. Elevated sphingosine 1-phosphate receptor 1 (S1P1) 
signaling has been implicated in potentiating inflammation in murine myocardium after 
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left anterior coronary artery ligation induced myocardial infarction within 4-weeks.116 
Similarly, both WT and KO mice under long term hyperglycemia in present study 
exhibited increased S1P1 expression in heart tissue after 11-weeks. This increment is 
reversed in both mice strain under FTY720 treatment. Paradoxically, FTY720 
administration in KO diabetic mice attenuates cardioprotection as observed in untreated 
diabetic KO mice: FTY720 treatment increases fibrotic area, worsens cardiac histology 
and reduces contractile force in KO diabetic mice. Increased CD34 infiltration with 
increased TGF-β1 expression has been observed in these mouse hearts. These findings 
indicate that FTY720 can modulate myocardial fibrosis through different mechanisms 
depending on the presence of T lymphocytes discussed later. 
Diabetic heart generates increased reactive oxygen species (ROS) due to 
metabolic perturbations in presence of hyperglycemia.3,26 Increased ROS induces 
proinflammatory signaling that activates endothelial cells.3 Activated endothelial cells as 
well as inflamed myocardium express increased adhesion molecules expression (e.g. 
vascular cell adhesion molecule 1; intercellular adhesion molecule 1) as observed in STZ-
induced diabetic rodent myocardium.129 Increased adhesion molecules expression recruits 
inflammatory mononuclear cells in heart that participate in inflammation potentiation and 
fibrosis generation.  Increased infiltration of CD3+ T cells into heart tissue, as early as 2-
week, has been reported in a STZ-induced diabetic rodent model that is associated with 
increased collagen deposition into myocardium with declined left ventricular 
contractility.111 Increased endothelial cell adhesion molecule ICAM-1 and increased T 
cells recruitment into heart tissue were detected in pressure overload TAC heart.76 T cells 
as an adaptive immune system cell continually recirculate between secondary lymphoid 
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organs e.g. spleen and lymph nodes as well as periphery that maximizes their interaction 
with antigen bearing antigen-presenting cells e.g. macrophages, B cells, dendritic cells. 
The continuous recirculation of T cells is necessary for activation, proliferation and 
subsequent generation of immune response in target organ. This concept has been 
implicated in recent report where T cells proliferation have been detected in heart 
draining lymph nodes of mice underwent MI and TAC surgery induced injury after 
activation through heart derived neoantigens e.g. myocytes debris encountering.77 In 
these models, increased T cells recruitment into heart was associated with increased 
fibrosis. From our lab, we have also reported earlier that the inhibition of PKC-θ, a 
selectively T cell expressed protein kinase C family protein necessary for T cell 
activation, by a cell permeable peptide inhibitor in STZ-induced diabetic cardiomyopathy 
model reduces T cells presence into cardiac tissue associated with antifibrotic effect.117 
Despite these findings, the effect of T cells trafficking modulation in long term diabetes 
associated fibrogenesis is still not known. In our present chapter work, we for the first 
time report that FTY720 induced T cells reduction in blood is associated with reduced 
myocardial fibrosis under long term 11-week diabetic period.  
Fibrocytes are circulating monocyte-derived CD34 expressing cells that appear in 
injured tissue and can secrete extracellular matrix (ECM) protein as well as under chronic 
profibrotic milieu e.g. TGF-β1, apoptotic debris etc. and can differentiate in to ECM 
protein synthesizing fibroblasts.62 To determine fibrocytes localization in diabetic heart 
tissue, we used CD34 as a biomarker for immunostaining of fibrocytes. One of the unique 
findings of our current work is that FTY720 treatment reduced interstitial appearance of 
CD34 expressing fibrocytes in diabetic myocardium. Similarly, diabetic KO mice without 
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FTY720 treatment exhibited minimal expression of CD34 cells in their heart tissue. In 
addition, profibrotic mediator TGF-β1 expression is markedly reduced in FTY720 
treatment diabetic WT mice heart. Rag1 KO diabetic mice heart sections showed similar 
expression profile of TGF-β1. Altogether, our findings for the first time demonstrate that 
simultaneous high magnitude presence of T cells and fibrocytes in diabetic myocardium 
results in profibrotic microenvironment as manifested by increased TGF-β1 expression 
and increased myocardial fibrosis. Fingolimod causes reduction of T lymphocytes in 
circulation and heart tissue that is associated with attenuation in TGF-β1 expression and 
CD34 fibrocytes in diabetic cardiac tissue. 
S1P-S1P1 signaling has been reported as a proinflammatory mediator in colitis-
associated cancer127 and more recently, in the long term myocardial infarction murine 
model.116 In this paradigm, increased S1P level under inflammatory condition increases 
S1P1 expression that causes persistent activation of transcription factor STAT3 which 
further potentiates proinflammatory molecules gene expression. Thus, we measured S1P 
level by LC/MS/MS in plasma and quantified S1P1 expression in heart tissue by 
immunohistochemistry. Increased plasma S1P levels were observed in both diabetic WT 
and KO mice. Although FTY720 treatment reduced about 1.20-fold S1P level in diabetic 
mice, the statistical test did not show any significant difference between untreated and 
treated diabetic mice blood. This result is consistent with earlier reports as in heart injury 
model FTY720 treatment did not reduce serum S1P level.116,127 Further, diabetic 
myocardium showed increased expression of S1P1 receptor suggesting activation of S1P-
S1P1 inflammatory loop in present long term diabetic model. Here, we for the first time 
demonstrate increased S1P1 expression in diabetic myocardium. Notably, FTY720 
81 
 
 
 
reduces increased S1P1 expression in cardiomyocytes in both WT and KO mice. 
Recently, Zhang et al. reported FTY720 reduces S1P1 expression in mouse heart tissue 
after myocardial infarction and protects the heart from inflammation, dysfunction and 
cardiac remodeling.116  
Surprisingly, FTY720 treatment in diabetic Rag1 KO mice exacerbated fibrosis, 
worsened cardiac histology and decreased cardiac force of contraction with discernible 
disarray and loss of myofibers compared with untreated diabetic KO mice. There could 
be two possible explanations to describe this paradoxical result. First, fate of cell 
membrane S1P1 receptor in presence of sustained FTY720 in extracellular space, and 
second, FTY720 actions on other S1P receptors. S1P1 receptor is widely distributed in 
different tissues/cells and involved in many important physiological functions including 
maintenance of vascular tone and maturation and endothelial cell barrier regulation.85 
Cell surface residing receptor internalization and re-insertion to cell membrane is a way 
of G protein-coupled receptors regulation that maintains receptor responsiveness in case 
of sustained ligand presence in extracellular space. FTY720 binds to S1P1 and 
internalizes the receptor and causes ubiquitinylation and proteasomal degradation unlike 
natural ligand S1P induced S1P1 internalization, in which case receptor surface 
expression recycled back shortly.84,94 FTY720 induced downregulation and degradation 
of S1P1 receptor can be a possible cause of contradicting results in reported studies. In 
lipopolysaccharide-induced murine inflammatory lung injury model, treatment with 
single dose of FTY720 (0.1 mg kg-1 body weight, i.p.) after 1 hour of lipopolysaccharide 
administration, prevented pulmonary vascular leakage by endothelial barrier 
enhancement as examined after 24 hours.130 In another study, FTY720 (0.5 mg kg-1 body 
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weight, i.p.) administration before and after 24 hour lipopolysaccharide induction; at 48 
hour examination of bronchoalveolar lavage showed increased total protein 
concentration, suggesting increased pulmonary vascular leak.131 In the same study, 
authors reported in bleomycin induced lung injury model (fibrosis independent of T 
cells), FTY720 (0.5 mg kg-1 body weight, i.p.) three times for 2 weeks increased collagen 
deposition and fibrosis compared with control mice. Notably, in later investigation higher 
dose and chronic administration of FTY720 opposes pulmonary vascular protection as 
seen in single dose FTY720. As lungs are more susceptible to endothelial barrier 
disruption due to presence of extensive microvascular network associated with alveolar 
air spaces might be the reason for observed effect. In contrast, cardiac microvascular 
endothelial cells in STZ-induced diabetic rats have reduced S1P1 expression and 
increased membrane translocation of S1P3.
132 The opposing roles of S1P1 and S1P3 in 
endothelial cells have been reported in STZ-induced rodent model.132 Activation of S1P1 
has been implicated in promoting angiogenesis whereas S1P3 stimulation leads to 
impaired barrier function.132 We have observed similar S1P1 expression pattern in 
diabetic mouse heart section in present work. Although FTY720 reduces total S1P1 
expression in diabetic myocardium, but maintained its expression on endothelial cells in 
WT diabetic mice (Figure 2-25). This discrepancy in FTY720 effects on S1P1 receptor on 
T cells and cardiac microvascular endothelial cells might be due to the differential 
association of the receptor with specific molecules in lipid rafts, cellular niche where G 
protein-coupled receptor specific signaling and internalization/recycling tasks occur, in 
different cell types.84 In another paradigm, FTY720 (1 mg kg-1 body weight, immediately 
before) protects WT mice brain in transient middle cerebral artery occlusion, but 
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abolishes protection in Rag1 KO mice.133 This implies that FTY720- mediated protection 
in acute transient cerebral ischemia and reperfusion results from not by direct 
neuroprotection rather its effect on neurovasculature and its interaction with immune 
cells. In our present study, although Rag1 KO mice heart does not have any T cells but 
FTY720 treatment causes increased TGF-β1, CD34 expression with increased collagen 
deposition in heart. These results indicate FTY720 in absence of T cells may activate 
different fibrotic pathway, while in presence of T cells by inhibiting T cells infiltration 
and profibrotic milieu into the heart it exerts cardioprotection in diabetes. In this regard, 
both pharmacokinetic and pharmacodynamic characteristics of FTY720 should be taken 
into consideration. FTY720 is a lipophilic drug molecule with large volume of 
distribution (VD is 1116-1737 L) and long elimination half-life (t1/2 is 4.5 days).
134,135 
Thus, in our present study continuous systemic administration of FTY720 might create a 
sustained drug pool in the blood to act on its target receptors. Keller et al. reported that 
FTY720 in dose dependent manner (0.1-1 µM) can activate S1P3 receptor on fibroblasts 
that causes differentiation into collagen producing myofibroblasts.136 In summary, 
FTY720 treatment induced increased fibrosis area in Rag1 KO diabetic mice indicates 
that the drug might activate other fibrotic pathways in absence of lymphocytes either by 
affecting S1P1 receptor functions in heart or by acting on other S1P receptors.  
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2.5. Conclusions 
In summary, the important findings of the present study are: (1) diabetic 
myocardium exhibited profibrotic milieu manifested by increased T cells infiltration with 
increased TGF-β1 and CD34 expressing fibrocytes into myocardium, (2) fingolimod 
(FTY720) reduced T lymphocytes infiltration into the myocardium, inhibited profibrotic 
milieu in myocardium and attenuated fibrotic remodeling with improved cardiac 
contractility in WT diabetic mice, (3) FTY720 induced cardiac fibrosis in Rag1 KO mice 
indicates the potential role of FTY720 in activating fibrotic remodeling in absence of 
lymphocytes under diabetes. 
Nonetheless, FTY720 is a non-specific S1P1 receptor agonist, and S1P1 receptor 
expression not exclusive to T lymphocytes only. Therefore, for the next set of 
experiments, we utilized conditional T cell specific S1P1 receptor knock out (TS1P1KO) 
mice through Cre-loxP approach. These studies are discussed in the next chapter. 
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CHAPTER 3: EFFECTS OF GENTIC DEPLETION OF T CELL S1P1 RECEPTOR ON 
CARDIAC FIBROSIS IN DIABETIC CARDIOMYOPATHY 
3.1. Introduction 
In chapter 2, we discussed that chronic administration of sphingosine 1-phosphate 
receptor 1 (S1P1) modulator, FTY720, profoundly reduced circulatory CD4
+ and CD8+ T 
cells number in wild-type (WT) C57BL/6 diabetic mice. FTY720 treatment reduced 
CD3+ T cells infiltration in diabetic WT mice myocardium compared to untreated 
diabetic mice. Further, FTY720 treated diabetic WT mice myocardium showed 
attenuated profibrotic TGF-β1 and CD34 expressing cells expression compared to 
untreated diabetic mice heart. Rag1 knock out mice, lacking mature B and T 
lymphocytes, exhibited less fibrosis and preserved contractility under diabetic conditions. 
Interestingly, FTY720 treatment in Rag1 KO diabetic mice increased fibrosis area and 
attenuated contractility. These contrary results indicate that FTY720 may target different 
mechanistic pathways in the absence of lymphocytes to induce cardiac fibrosis. Notably, 
FTY720 is not only selective to S1P1 receptor among five S1P receptors, but can also act 
on other S1P receptors (S1P2,3,4,5).
88,92,128,136 FTY720 can induce transdifferentiation of 
fibroblasts to myofibroblasts similar to TGF-β at concentrations of 0.1 to 1 µM by acting 
through S1P3 receptor.
136 In another recent report, FTY720 was shown to cause 
contraction of fibroblasts by targeting S1P2 receptor.
128 Thus, FTY720 may induce 
fibrosis by activating other fibrotic pathways that override lymphocytes depletion 
associated cardioprotection in Rag1 knock out mice under diabetes. 
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In this chapter of the dissertation, we have reported the use of Cre-loxP mediated 
genetic recombination approach to generate conditional T cell specific S1P1 receptor 
knock out mice (TS1P1KO). Use of this genetic tool enables us to deplete S1P1 receptor 
gene specifically on T lymphocytes. To this end, our goal is to demonstrate that the 
modulation of S1P1 mediated T lymphocytes trafficking protects heart under diabetic 
conditions. Littermate and TS1P1KO mice undergone chronic STZ-induced type 1 
diabetic cardiomyopathy model. At the end point of experimental period (11-weeks), we 
studied heart histology, assessed fibrosis area, and measured cardiac contractility in ex-
vivo Langendorff perfusion system. CD3+ T cells number, profibrotic molecular and 
cellular milieu were assessed through evaluation of TGF-β1 and CD34 expression by 
immunohistochemistry in heart tissue. 
3.2. Materials and Methods  
3.2.1. T cell specific S1P receptor 1 knock out mice generation 
To achieve conditional T cell specific sphingosine 1-phosphate receptor 1 (S1P1) 
depletion we used reported Cre-LoxP approach.83,137 Specific depletion of S1P1 on T cell 
was achieved by crossing S1P1
loxP/loxP mice (The Jackson Laboratory, Bar Harbor, ME), 
carrying modified S1P1 gene with two loxP sequences flanking exon 2 (coding region of 
S1P1), with lymphocyte tyrosine kinase (Lck) promoter bearing Cre mice (Taconic, 
Hudson, NY).83 The offspring mice were genotyped to detect TS1P1KO mice bearing 
S1P1
loxp/loxP allele with the Lck-Cre gene and littermate control mice with S1P1
WT allele 
with Cre by genotyping polymerase chain reaction. Briefly, genomic DNA was extracted 
from ear punch tissues by using sodium hydroxide and Tris-HCl buffer.138 Presence of 
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Cre transgene and S1P1 alleles in extracted genomic DNA from offspring mice, primers 
and PCR conditions were used as described in table 3-1. 
 Table 3-1: Genotyping PCR primers and reaction conditions for Cre and S1P1 genes.   
 
In both cases, primer sequences and PCR conditions were followed according to 
the manufacturers’ instruction (S1P1: The Jackson Laboratory; Cre: Taconic). All primer 
pairs were acquired from Eurofins MWG Operon (Huntsville, AL). PCR reactions were 
carried out by using KAPA LongRange HotStart kit (KK3501, Kapa Biosystems Inc. 
Wilmington, MA) in a thermal cycler (MasterCycler Personal, Eppendorf).  After PCR 
amplification, DNA bands were detected in 3% w/v agarose gel electrophoresis 
containing 0.02 % v/v ethidium bromide and imaged at ChemiDoc™ XRS+ system 
coupled with Image Lab software (Bio-Rad, Hercules, CA). Mutant S1P1
loxP allele 
Genes Primers PCR Reaction Conditions 
Cre Forward (5’-->3’):   CCTGGAAAATGCTTCTGTCCGTTTG 
Reverse (5’-->3’):   ACGAACCTGGTCGAAATCAGTGCG 
Initial denaturation: 95 ºC for 5 minutes 
30 cycles of  
Denaturation:  95 ºC for 1 minute 
Annealing: 56 ºC for 1 minute 30 seconds 
Extension: 72 ºC for 2 minutes; followed by 
Final extension: 72 ºC for 8 minutes 
 
S1P1 Forward (5’-->3’):  GAGCGGAGGAAGTTAAAAGTG 
Reverse (5’-->3’):   CCTCCTAAGAGATTGCAGCAA 
Initial denaturation: 94 ºC for 3 minutes 
35 cycles of  
Denaturation:  94 ºC for 30 seconds 
Annealing: 55 ºC for 30 seconds 
Extension: 72 ºC for 30 seconds; followed by 
Final extension: 72 ºC for 2 minutes 
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amplified at 250-bp and wild-type S1P1 allele at 200-bp (The Jackson Laboratory). Mice 
carrying mutant S1P1
loxP allele with Cre transgene were TS1P1KO mice. Blood samples 
from all the mouse used in the present study were analyzed by flow cytometry to confirm 
appropriate use of mouse type. All mice were housed in specific pathogen free room in 
Animal Research Wing (ARW) facility at South Dakota State University (SDSU) and 
given free access to autoclaved food (5010, LabDiet) and water. Mice used in the present 
investigation were handled and cared for according to the Guide for the Care and Use of 
Laboratory Animals by U.S. National Research Council (Eighth Edition, 2011). All the 
experimental procedures were approved by Institutional Animal Care and Use Committee 
at SDSU. 
3.2.2. Induction of Type 1 diabetes 
We used repeated low doses of streptozotocin (STZ) to induce type 1 diabetes in 
mice as described in chapter 2. Briefly, streptozotocin (S0103, Sigma-Aldrich, MO) at a 
dose of 50 mg/kg body weight in 0.1 M sodium citrate buffer (pH 4.5) was administered 
intraperitoneally for five day at the beginning. Both littermate control and TS1P1KO mice 
were divided into vehicle and STZ treated (diabetic) groups. Vehicle group received 0.1 
M sodium citrate buffer (pH 4.5) only. All mice then underwent 11-week long study 
period. Body weights (g) were measured twice each week in an electric balance machine 
(OHAUS® Scout-Pro™, OHAUS, NJ, USA). Blood glucose levels (mg/dl) were 
measured in the blood samples from tail vein of mice in a glucose meter (CONTOUR®, 
Bayer Healthcare LLC, IN) at three time points: at the beginning, 4- and 11-week post 
STZ induction. STZ recipient mice with blood glucose levels above 200 mg/dl were 
considered hyperglycemic. 
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3.2.3. Flow cytometry analysis of CD4+ and CD8+ T cells 
We measured helper CD4+ and cytotoxic CD8+ T cells proportions in peripheral 
blood of all mice by two color flow cytometry analysis as described in chapter 2 in a BD 
FACSCalibur flow cytometer (BD Biosciences, San Jose, CA). Data was acquired and 
analyzed by BD CellQuest Pro software (BD Biosciences).  
3.2.4. Flow cytometry analysis of regulatory T cells 
We measured percentage of CD4+Foxp3+ regulatory T cells (Treg cells) in spleen 
and blood after 11-weeks. Single-cell suspension of spleen was prepared from freshly 
dissected spleen from anesthetized mice. Spleen was cut into 1 mm3 pieces and passed 
through 70 µm nylon cell strainer (352350, Corning Inc. NY) by gentle press with a 
rubber plunger. The dissociated cells were collected in isolation buffer containing 0.5% 
w/v bovine serum albumin (A2153, Sigma-Aldrich, MO) and 2 mM EDTA in 0.01 M 
PBS (P3813, Sigma-Aldrich). The cell suspension was centrifuged at 300 x g for 10 
minutes at RT. Supernatant was discarded and incubated at RT for 5 minutes with 5 mL 
of 1 x RBC lysis buffer (00-4333, eBioscience) per spleen. Cell suspension was washed 
twice in isolation buffer by centrifugation at 500 x g for 10 minutes at RT. The cell pellet 
was re-suspended in 10 mL isolation buffer and counted in Cellometer Auto T4 
(Nexcelom, MA). One million (1 x 106) cells were taken in 100 µL FCS buffer into each 
tube for staining. For staining in blood, 100 µL of heparinized blood was prepared as 
described above. Red blood cells were lysed with 2 mL of 1 x RBC lysis buffer by 
incubating for 5 minutes at RT.  Both splenocytes (1 x 106) and blood (100 µL) were dual 
stained with fluorescein isothiocyante (FITC)-conjugated anti-mouse CD4 (11-0041-82, 
eBioscience) and phycoerythrin (PE)-conjugated anti-mouse Foxp3 (12-5773, 
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eBioscience) antibodies. Respective isotype controls FITC-IgG2b (11-4732, eBioscience) 
and PE-IgG2a were used to set compensations at detectors of flow cytometer. We used 
anti-mouse/rat Foxp3 staining set (Catalog# 72-5775, eBioscience) for Foxp3 staining 
according to manufacturer’s instructions (eBioscience, CA). Briefly, first staining with 
CD4 antibody was carried out at RT for 30 minutes followed by washing with 2 mL of 
FCS buffer at 500 x g for 5 minutes twice. The cells were then prepared for intracellular 
staining by re-suspending in 1 mL of fixation/permeabilization buffer at 4 ºC   for 30 
minutes in dark. The cells were then washed with 2 mL of 1 x permeabilization buffer at 
500 x g for 5 minutes at RT twice. The cell pellets were re-suspended with 100 µL of 1 x 
permeabilization buffer and incubated with Foxp3 antibody for 30 minutes at 4 ºC in 
dark. The cells were washed with 2 mL of 1 x permeabilization buffer followed by 2 mL 
of FCS buffer at 500 x g at RT. The cell pellets were re-suspended in 200 µL of FCS 
buffer. Flow cytometry analysis was carried out in BD FACSCalibur flow cytometer 
coupled with CellQuest Pro software (BD Biosciences).  
3.2.5. Cardiac contractility measurement 
We assessed cardiac contractile force (g) in all mice after 11-week diabetic period 
in a modified Langendorrf heart perfusion system ex-vivo, as described in chapter 2. 
Developed cardiac contractile force (Fc) and the maximal rate of development of 
contractile force (±dFc/dtmax) were recorded and analyzed with Biopac MP 100 data 
system (Goleta, CA, USA). 
3.2.6. Evaluation of heart histology and fibrosis area 
Heart histology was studied in H&E stained, and fibrosis area was determined in 
Masson’s trichrome stained heart sections at the end of 11-weeks. H&E stained sections 
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were examined under bight field microscope (Carl Zeiss, Germany), and histological 
scores were given to each heart sections based on the observed characteristics, such as,  
(i) presence of eosinophilic interstitial collagen fibers, (ii) extent of cellularity in 
interstitial space of myocardium, (iii) myocardial cell necrosis/loss, (iv) myofiber 
striation and myocytes organization on a five-point scale for each characteristic from 0 to 
4.120,121 The cumulative scores were expressed from 0 to 16 for each group. Trichrome 
stained heart sections images were acquired through a Leica EZ4 HD stereomicroscope 
as a whole (Leica Microsystems, Buffalo Grove, IL, USA). The percentage of fibrosis 
area relative to whole heart area was quantified by using NIH Image J (Bethesda, MA) 
software as described by Zhao et al.117 
3.2.7. Immunohistochemical (IHC) analysis of heart sections 
CD3+ T cells, TGF-β1 and CD34 bearing cells expression were analyzed in 
myocardium by immunohistochemistry in paraffin-embedded 5 µm tissue sections with 
CD3 (10 µg/mL, sc-20047; Santa Cruz Biotechnology, Inc., CA), TGF-β1 (15 µg/mL, 
MAB240; R&D Systems, Inc., Minneapolis, MN) and CD34 (10 µg/mL, MA5-17825; 
Pierce Biotechnology, Rockford, IL, USA) primary antibodies. R&D systems mouse/rat 
cell and tissue staining HRP-DAB kit (CTS002/CTS017; R&D Systems) were used to 
amplify positive signals and visualize corresponding to mouse/rat primary antibodies. 
Detailed procedure was described in chapter 2.  To count immunopositive CD3+ cells, 30 
fields of stained heart sections were pictured at bright-field under 400x magnification in 
an upright microscope (Carl Zeiss, Germany). Myocardium infiltrating cells number 
(cells/field) was calculated by counting the cells number in imaged 400x fields.75 TGF-β1 
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and CD34 positive staining percent area were quantified and averaged in 10 fields of 
400x magnification images by using NIH ImageJ software (Bethesda, MD).119,139 
3.2.8. Data analyses 
Data was expressed as mean ± SEM. One-way ANOVA was used for statistical 
analysis of data followed by Tukey’s post hoc test of group means. Data was analyzed in 
GraphPad Prism Software (v5.01, 2007). A P value of less than 0.05 was considered 
statistically significant and is indicated with an asterisk (*) or a number (#) or a currency 
(¤) sign when comparing between different groups.  
 
3.3. Results 
3.3.1. T cell specific S1P receptor 1 knock-out mice showed lymphopenia  
All offspring mice from S1P1
loxP/loxP and Lck-Cre breeding pair were genotyped 
by PCR and immunophenotyped for CD3+ T cells in spleen, CD4+ and CD8+ T cells in 
blood by flow cytometry. Lymphocyte tyrosine kinase driven Cre recombinase deletes 
coding region of sphingosine 1-phsophate receptor 1 (S1P1) at exon 2 in offspring mutant 
mice specifically on T cells (Figure 3-1A). Figure 3-1B demonstrated PCR amplicons 
band for S1P1 gene and Cre gene in offspring mice after genomic DNA amplification by 
using specific primer sets for mentioned genes. Mice bearing S1P1 mutant allele 
amplified at 250-bp with Cre transgene presence were T cell specific S1P receptor 1 
knock out (TS1P1KO) mice (Figure 3-1B). Littermate control mice with S1P1 WT allele 
amplified at 217-bp with Cre transgene were used.   
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Figure 3-1: Generation and detection of conditional T cell specific S1P receptor 1 knock 
out mice. (A) Mice carrying flanked S1P1 gene at exon 2 (coding region of S1P1 gene) by 
loxP sites are cross-bred with mice carrying Lck promoter driven Cre recombinase, 
results in T cell specific S1P1 genetic depletion in progenies. Figure adapted and 
modified from Allende et al.83 (B) Left panel: PCR bands for S1P1 gene and right panel: 
PCR bands for Cre transgene amplification in genomic DNA extracted from offspring 
mice. Left panel: lane ‘a’ represents heterozygote, lane ‘b’ represents wild-type and lane 
‘c’ represents mutant band of S1P1 gene. In two panel combination, lane ‘b’ represents 
littermate control mice genotype and lane ‘c’ represents TS1P1KO mice genotype. In 
both panels, lane ‘d’ represents DNA ladder. 
 
Mature T lymphocytes express S1P1 on their cell surface to exit from thymus and 
secondary lymphoid organs to blood and lymph. As TS1P1KO mice T cells lack S1P1 due 
to Cre mediated recombination at genomic level, T cells mature in thymus but could not 
exit in periphery as reported earlier.83 In our present study, thus, we counted CD3+ T cells 
proportions in spleen of littermate control and TS1P1KO mice. TS1P1KO mice exhibited 
A B 
a b c d a b c d 
200 bp 
300 bp 
300 bp 
400 bp 
S1P1 Cre 
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near 2.73-fold decrease in CD3+ T cells percent in spleen as compared to littermate 
control mice (Figure 3-2A and 3-2B, Table 3-2). Similarly, TS1P1KO mice had about 
90% less CD4+ and CD8+ T cells in blood as compared with littermate control mice 
(Figure 3-3A and 3-3B, Table 3-2).    
 
 
 
 
 
 
 
 
 
 
 
Figure 3-2: Flow cytometry analysis of CD3+ T cells in spleen of littermate control and 
TS1P1KO mice. (A) Representative flow cytometry histogram plot exhibit depleted CD3
+ 
T cells in TS1P1KO mice spleen than littermate mice under M1 gate. (B) Quantification 
of CD3+ T cells number in littermate control and TS1P1KO mice spleen. Data are 
representative of three independent experiments. *P<0.05 between littermate control and 
TS1P1KO mice. The data is expressed as mean ± SEM. 
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Figure 3-3: Flow cytometry analysis of CD4+ and CD8+ T cells in littermate control and 
TS1P1KO mice blood. (A) Histogram plot show remarkable deficiency of both CD4
+ and 
CD8+ T cells in TS1P1KO mice blood compared to littermate mice under M1 gate. (B) 
Quantification of CD4+ and CD8+ T cells number in littermate and TS1P1KO mice blood. 
**P < 0.01 between littermate and TS1P1KO mice, n= 5-6 mice in each group. The data 
is expressed as mean ± SEM. 
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Table 3-2: Summary of CD3+ T cells in spleen, CD4+ and CD8+ T cells number in blood 
of littermate control and TS1P1KO mice. 
 
The data is expressed as mean ± SEM. The value of ‘n’ represents number of mice in 
each group. *P < 0.05 and **P < 0.01 as compared to littermate control mice. 
 
3.3.2. Physiological characteristics assessment 
Streptozotocin (STZ) is a nitrosourea compound that alkylates DNA and is 
pancreatic β-cells toxic due to its transport through glucose transporter 2 into these 
cells.96,125 Thus, STZ administration in mice destroys insulin producing β-cells rendering 
them hyperglycemic.96 STZ-induced type 1 diabetic model exhibits salient pathological 
changes in heart corresponding to clinical diabetic cardiomyopathy manifested by 
increased oxidative stress and inflammation and increased collagen deposition in cardiac 
interstitium with cardiac ventricular dysfunction. In the present work, both littermate 
control and TS1P1KO mice were divided into vehicle treated and STZ treated groups. 
There was no significant difference in body weight between littermate vehicle and 
 Littermate Control TS1P1KO 
CD3+ T cells in spleen 
(% of cell populations) 
30.80±1.75 (n=3) 11.27±3.25* (n=3) 
CD4+ T cells in blood  
(% of cell populations) 
20.94±0.47 (n = 5) 0.91±0.17** (n = 5) 
CD8+ T cells in blood  
(% of cell populations) 
11.86±0.21 (n = 6) 1.37±0.26** (n = 6) 
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littermate STZ mice, and TS1P1KO vehicle and TS1P1KO STZ mice at the beginning 
before STZ induction (Figure 3-4, Table 3-3). After STZ administration, through 11-
week both littermate and KO STZ recipient mice showed less body weight gain trend 
compared to only vehicle treated mice (Figure 3-4). After 11-weeks, littermate STZ mice 
had 15.29% reduced body weight compared with littermate vehicle mice, and TS1P1KO 
STZ mice have 17.75% reduced body weight compared to TS1P1KO vehicle mice 
(Figure 3-4, Table 3-3). There was no significant difference between littermate STZ and 
TS1P1KO STZ mice body weight at the end of 11-weeks (Figure 3-4, Table 3-3). 
 
 
 
 
 
 
 
 
 
Figure 3-4: Body weights (g) change in littermate and TS1P1KO mice during 11-week 
experimental period. Both littermate and TS1P1KO STZ-recipient mice exhibited lower 
body weight gain throughout 11-weeks. Both littermate and TS1P1KO STZ mice had 
significantly low body weights (g) at the end of 11-week compared to littermate and 
TS1P1KO vehicle mice, respectively. *P<0.05 between vehicle and STZ groups of 
littermate and TS1P1KO mice. Sample size n = 6-10 mice in each group. The data is 
expressed as mean ± SEM.
0 20 40 60 80
10
15
20
25
30
Littermate Vehicle
TS1P1KO Vehicle
Littermate STZ
TS1P1KO STZ
*
Days post STZ administration
B
o
d
y
 w
e
ig
h
t 
(g
)
 
 
98 
 
Table 3-3: Summary of physiological parameter in littermate and TS1P1KO mice during 11-week experimental period. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The data is expressed as mean ± SEM. *P < 0.05 between vehicle and STZ groups of littermate and TS1P1KO mice. The value of ‘n’ 
represents number of mice in each group.
 
 
Littermate Vehicle 
(n=6) 
TS1P1KO Vehicle 
(n=6) 
Littermate STZ 
(n=10) 
TS1P1KO STZ 
(n=8) 
At the beginning 
(before STZ 
induction) 
    
Body wt. (g) 20.45±0.78 20.73±0.53 21.58±0.52  21.93±0.35 
After 4-week of STZ 
induction 
    
Body wt. (g) 22.73±0.64 21.72±0.83 20.95±0.49 20.30±0.59 
After 11-week of 
STZ induction 
    
Body wt. (g) 25.30±0.73 23.54±1.15 21.97±0.40* 19.99±1.003* 
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There was no significant difference between littermate and TS1P1KO mice blood 
glucose levels (mg/dl) at the beginning (Figure 3-5, Table 3-4). STZ administration 
rendered both littermate and TS1P1KO mice hyperglycemic as measured in 4-weeks. 
Hyperglycemia was sustained in STZ recipient littermate and TS1P1KO mice at the end 
of 11-weeks (Figure 3-5, Table 3-4). There was no significant difference between 
littermate STZ and TS1P1KO STZ mice blood glucose levels at the end of 11-weeks 
(Figure 3-5, Table 3-4). 
 
 
 
 
 
 
 
 
Figure 3-5: Blood glucose levels (mg/dl) during 11-week study period in littermate and 
TS1P1KO mice. Bar graph shows blood glucose levels (mg/dl) at the beginning, after 4- 
week and after 11-week. Sample size, n = 6-10 mice in each group. **P < 0.01 between 
vehicle and STZ groups of littermate and TS1P1KO mice, respectively. The data is 
expressed as mean ± SEM.
0
200
400
600
Littermate Vehicle
TS1P1KO Vehicle
Littermate STZ
TS1P1KO STZ
**
At the
beginning
After
4-week
After
11-week
ns
B
lo
o
d
 g
lu
c
o
s
e
 l
e
v
e
l
(m
g
 d
l
-1
)
**
 
 
100 
 
Table 3-4: Summary of metabolic parameter in littermate and TS1P1KO mice during 11-week experimental period. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The data is expressed as mean ± SEM. **P < 0.01 between vehicle and STZ groups of littermate and TS1P1KO mice. The value of ‘n’ 
represents number of mice in each group.
 Littermate Vehicle 
(n=6) 
TS1P1KO Vehicle 
(n=6) 
Littermate STZ 
(n=10) 
TS1P1KO STZ 
(n=8) 
At the beginning 
(before STZ 
induction) 
    
Blood glucose level 
(mg/dl) 
142.67±13.59 139.83±11.33 142.70±7.32 140.63±10.15 
After 4-week of STZ 
induction 
    
Blood glucose level 
(mg/dl) 
128.5±7.61 123.67±13.52 433.50±46.57** 391.63±44.30** 
After 11- week of 
STZ induction 
    
Blood glucose level 
(mg/dl) 
129.67±9.87 129.50±15.96 422.80±44.69** 350.00±32.98** 
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3.3.3. Flow cytometry analysis of T lymphocyte subsets 
Flow cytometry analysis was used to determine CD4+ and CD8+ T cells in the 
blood and CD4+Foxp3+ T cells in spleen and blood after 11-weeks (Figure 3-6 and 3-7). 
TS1P1KO vehicle and STZ mice had about 90% reduction of both CD4
+ (CD4+ T cells: 
littermate vehicle, 12.93±3.98 %, littermate STZ, 12.10±1.75 % vs. TS1P1KO vehicle, 
1.37±0.02 %, TS1P1KO STZ, 1.21±0.61 %, n=4-5 mice in each group, **P < 0.01) and 
CD8+ (CD8+ T cells: littermate vehicle, 7.73±1.43%, littermate STZ, 7.11±0.80 % vs. 
TS1P1KO vehicle, 1.61±0.13 %, TS1P1KO STZ, 1.29±0.44%, n=4-5 mice in each group, 
**P < 0.01) T cells in blood after 11-week experimental period (Figure 3-6A and 3-6B, 
Table 3-5). This data demonstrates sustained T lymphocytes deficiency in TS1P1KO mice 
circulation.  
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Figure 3-6: Flow cytometry analysis of CD4+ and CD8+ T cells in blood of littermate and 
TS1P1KO mice at the end of 11-weeks. (A) Representative flow cytometry dot plots 
showing CD4+ (in lower right quadrant) and CD8+ (in upper left quadrant) T cells in the 
blood of littermate and TS1P1KO mice. TS1P1KO mice exhibited noticeable less CD4
+ 
and CD8+ T cells in the blood. (B) Both vehicle and STZ groups of TS1P1KO mice had 
significantly reduced CD4+ and CD8+ T cells number than littermate vehicle and STZ 
mice, respectively. **P<0.01 between littermate and TS1P1KO mouse groups. Sample 
size, n = 3-5 mice in each group. The data is expressed as mean ± SEM. 
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Further, we counted CD4+FoxP3+ T cells proportion percent in spleen and blood 
by two-color flow cytometry. In littermate diabetic mice, CD4+FoxP3+ T cells were 
increased by 1.60-fold in spleen (3.15±0.22 % vs. 1.97±0.27 %, n=3, #P < 0.05) and 1.82-
fold in blood (1.58±0.19 % vs. 0.87±0.21 %, n=3, #P < 0.05) compared to littermate 
vehicle mice after 11-weeks (Figure 3-7A and 3-7B). In contrast, similar to reduced 
CD3+ T cells in spleen and CD4+ and CD8+ T cells in blood, TS1P1KO vehicle mice had 
2.94-fold (in spleen) and 4.58-fold (in blood) decreased (spleen: 0.67±0.12 % vs. 
1.97±0.27 %, n=3, *P < 0.05, blood: 0.19±0.03 % vs. 0.87±0.21 %, n=3, *P < 0.05) and 
TS1P1KO STZ mice had 2.28-fold (in spleen) and 3.76-fold (in blood) decreased (spleen: 
1.38±0.37 % vs. 3.15±0.22 %, n=3, *P < 0.05, blood: 0.42±0.18 % vs. 1.58±0.19 %, n=3, 
*P < 0.05) CD4+Foxp3+ T cells compared to littermate vehicle and STZ mice, 
respectively (Figure 3-7A and 3-7B, Table 3-5). There was no statistically significant 
difference between TS1P1KO vehicle and STZ mice (spleen: 1.38±0.37 % vs. 0.67±0.12 
%, n=3, P value = 0.1407, blood: 0.42±0.18 % vs. 0.19±0.03 %, n=3, P value = 0.2624) 
in CD4+Foxp3+ T cells percent in spleen and blood, although about 2-fold increase in 
average percent of cells was observed in TS1P1KO diabetic mice (Figure 3-7A and 3-7B, 
Table 3-5). 
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Figure 3-7: Flow cytometry analysis of CD4+Foxp3+ regulatory T cells in spleen and 
blood of littermate and TS1P1KO mice at the end of 11-weeks. (A) Representative flow 
cytometry dot plots showing CD4+Foxp3+ T cells staining (in upper right quadrant) in 
littermate and TS1P1KO mice spleen after 11 weeks.  (B) Diabetic littermate mice had 
increased CD4+Foxp3+ T cells number in spleen and blood compared to littermate vehicle 
mice. Both vehicle and STZ mice of TS1P1KO had reduced CD4
+Foxp3+ T cells in 
spleen and blood than littermate vehicle and STZ mice, respectively, at the end of 11-
weeks. #P<0.05 littermate STZ vs. littermate vehicle, and *P<0.05 between TS1P1KO 
vehicle, STZ and littermate vehicle, STZ mice. The data is expressed as mean ± SEM. 
Sample size, n = 3 mice in each group.
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Table 3-5: Summary of CD4+, CD8+ T cells percent in blood, and CD4+Foxp3+ T cells percent in spleen and blood of littermate and 
TS1P1KO mice after 11-weeks. 
 
 
 
 
 
 
 
 
 
All values represent percent (%) of cell population. The data is expressed as mean ± SEM. n = 3-5 mice in each group. *P < 0.05 and 
**P < 0.01 between vehicle and STZ groups of littermate and TS1P1KO mice. 
#P < 0.05 between vehicle and STZ groups of littermate 
mice. Percent of CD4+Foxp3+ T cells, spleen: P = 0.14 between TS1P1KO vehicle and TS1P1KO STZ mice, blood: P = 0.26 between 
TS1P1KO vehicle and TS1P1KO STZ mice. 
 Littermate Vehicle 
 
TS1P1KO Vehicle 
 
Littermate STZ 
 
TS1P1KO STZ 
 
CD4+ T cells in  
blood  
12.93±3.98 1.37±0.02** 12.10±1.75 1.21±0.61** 
CD8+ T cells in  
blood  
7.73±1.43 1.61±0.13** 7.11±0.80 1.29±0.44** 
CD4+Foxp3+ T cells 
in spleen  
1.97±0.27 0.67±0.12* 3.15±0.22# 1.38±0.37* 
CD4+Foxp3+ T cells 
in blood  
0.87±0.21 0.19±0.03* 1.58±0.19# 0.42±0.17* 
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3.3.4. Assessment of cardiac histology and fibrosis area  
Hematoxylin and Eosin (H&E) stained heart sections were prepared after 11-
weeks. H&E stained sections were examined microscopically at magnification of 400x 
and graded based on morphology, organization, presence of cellularity in myocardium, 
myocytes loss presence of collagen fiber. Littermate STZ (diabetic) mice exhibited 
deteriorated myocardium structure manifested by myocytes loss and increased interstitial 
space with presence of increased cellularity compared with littermate vehicle mice 
(cumulative histology score; littermate STZ (n=9): 9.56±0.58 vs. littermate vehicle (n=4): 
3±0.41, *P < 0.05) (Figure 3-8 and 3-9). TS1P1KO STZ mice (diabetic) heart exhibited 
preserved myocardial structural phenotype as compared with littermate diabetic mice 
(TS1P1KO STZ (n=7): 3±0.58 vs. littermate STZ (n=9): 3±0.41, 
#P < 0.05) (Figure 3-8 
and 3-9). Notably, TS1P1KO vehicle mice showed altered heart phenotype demonstrated 
by loss of interstitial space between myocytes with thickening of vascular smooth muscle 
cells and perivascular edema compared with littermate vehicle mice (TS1P1KO vehicle 
(n=4): 9.5±0.87 vs. littermate vehicle (n=4): 3±0.41, 
¤
P < 0.05) (Figure 3-8 and 3-9). 
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Figure 3-8: Representative images of Hematoxylin and Eosin (H&E) stained heart tissue 
sections of littermate and TS1P1KO mice after 11-weeks. Littermate STZ mice heart 
section showed discernible myocytes loss with increased cellularity and disorganization 
in myocardium after 11-week experimental period. TS1P1KO mice heart sections 
exhibited preserved heart histology under diabetes. Interestingly, TS1P1KO vehicle mice 
exhibited altered cardiac phenotype with congested myocytes and thickening of 
perivascular smooth muscles. Images are representative of heart sections of 4-9 mice in 
each group. The magnification is 200x. 
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Figure 3-9: Quantification of heart histological scores in littermate and TS1P1KO mice 
after 11-weeks. *P < 0.05 between littermate vehicle and littermate STZ mice, #P < 0.05 
between TS1P1KO STZ and littermate STZ mice, 
¤
P < 0.05 between littermate vehicle 
and TS1P1KO vehicle mice. The data is expressed as mean ± SEM, n = 4-9 mice in each 
group. 
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Collagen deposition was quantified semi-quantitatively in Masson’s Trichrome 
stained heart sections of all mice after 11-week experimental period. Diabetic littermate 
mice (n=9) showed increased fibrosis area relative to whole heart area compared to 
littermate vehicle mice (n=4) (46.48±8.06 % vs. 7.65±0.86 %, *P < 0.05) (Figure 3-10 
and 3-11). Diabetes induced increase of collagen deposition in interstitial and 
perivascular area in littermate diabetic mice. TS1P1KO vehicle mice (n=4) heart showed 
increased fibrosis area as compared with littermate vehicle mice (n=4) (46.03±7.16 % vs. 
7.65±0.86 %, 
¤
P < 0.05) (Figure 3-10 and 3-11). Notably, TS1P1KO diabetic mice (n=7) 
heart showed less fibrosis area compared to littermate diabetic mice (6.15±0.62 % vs. 
46.48±8.06 %, #P < 0.05) (Figure 3-10 and 3-11).  
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Figure 3-10: Representative images of Masson’s Trichrome stained heart tissue sections 
in littermate and TS1P1KO mice after 11-weeks. Upper panel shows whole heart sections 
(magnification is 16x) and lower panel shows magnified section images (magnification is 
200x). Littermate STZ mice had increased perivascular and interstitial fibrosis area 
compared with littermate vehicle mice. TS1P1KO STZ mice had noticeable less fibrosis 
than littermate STZ. Interestingly, TS1P1KO vehicle mice heart sections exhibited 
increased fibrosis than littermate vehicle mice. 
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Figure 3-11: Quantification of percent fibrosis area in heart sections of littermate and 
TS1P1KO mice after 11-weeks. *P<0.05 in littermate STZ vs. littermate vehicle mice, 
#P<0.05 in TS1P1KO STZ vs. littermate STZ mice and 
¤
P<0.05 in TS1P1KO vehicle vs. 
littermate vehicle mice. Sample size, n = 4-9 mice in each group. The data is expressed as 
mean ± SEM. 
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3.3.5. TS1P1KO mice exhibits improved cardiac contractility under hyperglycemia 
 
We determined the cardiac force of contraction in an ex-vivo Langendorff’s heart 
perfusion system. The data is expressed as a fold change in contractile force development 
compared to littermate control mice. Littermate diabetic mice showed 29.37% reduction 
in contractility as compared with littermate vehicle mice (P = 0.19) (Figure 3-12). 
TS1P1KO mice exhibited 33.07% increase in force of contraction development than 
littermate diabetic mice (P=0.06) (Figure 3-12). Interestingly, TS1P1KO vehicle mice 
have attenuated contractility compared to littermate vehicle mice (*P < 0.05) (Figure 3-
12). 
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Figure 3-12: Cardiac contractility in littermate and TS1P1KO mice after 11-week study 
period. Littermate STZ mice (n=8) showed reduction in contractile force compared to 
littermate vehicle mice (n=5) (P value is 0.19 between these two groups). TS1P1KO STZ 
mice (n=5) showed improved contractile force compared to littermate STZ mice (n=8) (P 
= 0.06 between these two groups). TS1P1KO vehicle mice (n=6) have significantly 
attenuated force of contraction than littermate vehicle mice (*P < 0.05). The contractile 
force is expressed as fold change relative to control. The data is expressed as mean ± 
SEM. 
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3.3.6. Reduced CD3+ T cells infiltration in diabetic TS1P1KO mice myocardium 
We detected CD3+ T cells in myocardium by immunostaining with anti-mouse 
CD3 antibody. Increased CD3+ T cells infiltration has been observed in myocardium of 
littermate STZ mice (1.75±0.15 cells/field vs. 0.86±0.04 cells/field, n=3 independent 
experiments, *P < 0.05) than littermate control mice (Figure 3-13 and 3-14). TS1P1KO 
STZ mice myocardium exhibited significantly less CD3+ T cells (0.84±0.09 cells/field vs. 
1.75±0.15 cells/field, n=3 independent experiments, #P < 0.05) than littermate STZ mice 
(Figure 3-13 and 3-14). 
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Figure 3-13: Immunohistochemical detection of CD3+ T cells in littermate and TS1P1KO 
mice heart tissue section at the end of 11-weeks. Littermate STZ mice heart section show 
increased infiltration of CD3+ T cells into cardiac tissue compared to littermate vehicle 
mice. TS1P1KO STZ mice myocardium do not have noticeable CD3
+ T cells infiltration 
compared to littermate STZ mice. Images are representative of three independent 
experiments. 
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Figure 3-14: Quantification of infiltrated CD3+ T cells in heart tissue sections of 
littermate and TS1P1KO mice after 11-week experimental period. CD3
+ T cells number 
(cells per 400x magnification field) was significantly higher in littermate STZ mice heart 
section than littermate vehicle mice. *P < 0.05 between littermate STZ and littermate 
vehicle mice. TS1P1KO STZ mice heart tissue have reduced CD3
+ T cells infiltration as 
compared to littermate STZ mice. *P < 0.05 between TS1P1KO STZ and littermate STZ 
mice. Results are from three independent experiments. The data is presented as mean ± 
SEM. 
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3.3.7. Reduced TGF-β1 expression in TS1P1KO diabetic mice myocardium  
 
We determined profibrotic cytokine transforming growth factor beta 1 (TGF-β1) 
expression in myocardium of all mice group after 11-week diabetic period. TGF-β1 
expression was increased in littermate diabetic mice cardiac tissue compared to littermate 
vehicle mice (6.79±0.59 % staining area vs. 2.64±0.23 % staining area, *P < 0.05) 
(Figure 3-15 and 3-16). TS1P1KO diabetic mice exhibited reduced TGF-β1 expression in 
myocardium after 11 weeks as compared with littermate diabetic mice (3.54±0.10 % 
staining area vs. 6.79±0.59 % staining area, #P < 0.05) (Figure 3-15 and 3-16). In 
contrast, TS1P1KO vehicle mice myocardium exhibited increment of TGF-β1 expression 
as compared with littermate vehicle mice (6.78±0.71 % staining area vs. 2.64±0.23 % 
staining area, 
¤
P < 0.05) (Figure 3-15 and 3-16).  
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Figure 3-15:  Immunohistochemical detection of TGF-β1 expression in littermate and 
TS1P1KO mice heart tissue sections after 11-weeks. Representative images of TGF-β1 
immuno-staining. Littermate STZ mice myocardium show increased TGF-β1 expression 
compared to littermate vehicle mice. TS1P1KO STZ mice myocardium exhibit reduced 
TGF-β1 expression than littermate STZ mice. Notably, TS1P1KO vehicle mice 
myocardium exhibit increased TGF-β1 expression than littermate vehicle mice. The 
magnification for all images is 400x.  
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Figure 3-16: Quantification of TGF-β1 expression in heart tissue sections of littermate 
and TS1P1KO mice after 11-week experimental period. Results are from three 
independent experiments. The data is expressed as mean ± SEM. *P < 0.05 between 
littermate vehicle and littermate STZ, #P < 0.05 between littermate STZ and TS1P1KO 
STZ and 
¤
P < 0.05 between littermate vehicle and TS1P1KO vehicle. 
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3.3.8. TS1P1KO mice myocardium have less CD34 cells in diabetes 
 
Fibrocytes under chronic inflammation are recruited through chemokine 
interactions to the site of injury. Recruited fibrocytes can synthesize extracellular matrix 
protein and transdifferentiate into collagen producing myofibroblasts. CD34 is a surface 
antigen that is expressed by fibrocytes and can be used as a biomarker to detect these 
cells from other cell types. In our present work, we detected CD34 expressing cells in 
mice myocardium after 11-week of experimental period. Littermate STZ mice 
myocardium exhibited higher CD34 expressing cells than littermate vehicle mice 
(6.25±0.28 % staining area vs. 2.74±0.12 % staining area, *P < 0.05) (Figure 3-17 and 3-
18). Notably, diabetic TS1P1KO mice myocardium exhibited less CD34 expressing cells 
than littermate diabetic mice (2.97±0.17 % staining area vs. 6.25±0.28 % staining area, #P 
< 0.05) (Figure 3-17 and 3-18). In contrast, TS1P1KO vehicle mice myocardium have 
increased CD34 expressing cells compared to littermate vehicle mice (6.52±0.47 % 
staining area vs. 2.74±0.12 % staining area, 
¤
P < 0.05) (Figure 3-17 and 3-18). 
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Figure 3-17: Immunohistochemical detection of CD34 fibrocytes expression in littermate 
and TS1P1KO mice heart tissue sections after 11-weeks. Representative images of CD34 
fibrocytes immunostaining. Littermate STZ mice myocardium show increased CD34 
expressing cells than littermate vehicle mice. Notably, diabetic TS1P1KO mice 
myocardium exhibit reduction of CD34 expression than littermate diabetic mice. In 
contrast, TS1P1KO vehicle mice myocardium exhibit increased CD34 expression 
compared to littermate vehicle mice. The magnification for all images is 400x.  
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Figure 3-18: Quantification of CD34 fibrocytes expression in heart tissue sections of 
littermate and TS1P1KO mice after 11-week experimental period. Results are from three 
independent experiments. The data is expressed as mean ± SEM. *P < 0.05 between 
littermate vehicle and littermate STZ, #P < 0.05 between littermate STZ and TS1P1KO 
STZ and 
¤
P < 0.05 between littermate vehicle and TS1P1KO vehicle. 
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3.4. Discussion 
In the present study, we for the first time demonstrated that conditional T cell 
specific sphingosine 1-phosphate receptor 1 genetic depletion associated T lymphocytes 
deficiency in circulation exerts cardioprotection with reduced myocardial fibrosis under 
chronic hyperglycemia compared to littermate diabetic mice. 
Several lines of investigation demonstrated T lymphocytes involvement in cardiac 
injury and cardiac remodeling in experimental cardiac injury settings.77 In chronic 
pressure overload murine transverse aortic constriction model, increased 
activated/effector CD4+CD44high T cells have been detected in heart tissue with increased 
cardiac collagen content and cardiac dysfunction after 6-week of this model.75 In murine 
myocardial infarction (MI) model, increased CD4+Ki67+ T cells have been detected in 
heart draining mediastinal lymph nodes after 7-day of MI injury.74 Increased CD4+IFN-γ+ 
T cells have been detected in 7-day post-MI heart tissues. In this report, the authors 
demonstrated that presence of CD4+ T cells increases collagen deposition in heart as CD4 
knock out mice showed reduction of collagen density after MI injury.74 Becher et al. 
demonstrated that diabetic rodent myocardium have augmented infiltration of CD3+ T 
lymphocytes within 6-week of diabetes induction by STZ that positively correlated with 
increased ventricular stiffness and decreased systolic and diastolic left ventricular 
function.111 Increased proinflammatory T cell subsets, such as CD4+IFN-γ+, 
CD4+CD28null, in peripheral blood of human diabetic patients associated with adverse 
cardiac events.78,79,110 Thus, modulation of T cell function and abundance can be a 
potential therapeutic strategy to protect heart under chronic diabetic conditions. To this 
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end, the effects of T cells trafficking modulation by means of molecular mechanism to 
heart in diabetes has not been precisely determined yet. 
In chapter 2, we demonstrated that fingolimod (FTY720), a novel 
immunomodulator drug, causes sustained CD4+ and CD8+ T cells deficiency in the blood 
of C57BL/6 mice that is associated with reduced fibrosis area and improved cardiac 
contractility. FTY720 acts as a functional antagonist on mature T lymphocytic cell 
membrane G protein coupled receptor, sphingosine 1-phosphate receptor 1 (S1P1).
88,89,92 
Binding of phosphorylated FTY720 to S1P1 receptor causes internalization of the 
receptor from cell membrane to cytosol and promotes proteasomal degradation there. The 
absence of S1P1 receptor on cell membrane disables T lymphocytes to sense the 
increased chemotactic gradient of sphingosine 1-phosphate (S1P) present in blood and 
lymph that results in sequestration of mature lymphocytes in primary (thymus) and 
secondary lymphoid organs, such as spleen, and lymph nodes. Thereby, FTY720 creates 
substantial T lymphocytes deficiency in systemic circulation. For this immunomodulatory 
function, fingolimod (FTY720) is approved for treatment of relapsing-remitting multiple 
sclerosis. FTY720 treatment reduces autoimmune TH17 cells in circulation and reduces 
infiltrating autoreactive T lymphocytes in central nervous system. Therefore, 
administration of FTY720 protects the central nervous system from autoimmune T cell 
mediated destruction in these patients and in experimental autoimmune 
encephalomyelitis rodents.91,92 To this point, it is noteworthy that S1P1 receptor is widely 
expressed in different type of cells, other than T lymphocytes, including vascular 
endothelial cells, cardiomyocytes and both innate and adaptive immune cells.85,140 
Although FTY720 reduced myocardial fibrosis in C57BL/6 mice, administration of 
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FTY720 exacerbated cardiac histology and increased fibrosis area in Rag1 knockout mice 
(lacking mature B and T lymphocytes) under diabetic conditions. FTY720 can act on 
other four S1P receptors (S1P2,3,4,5) besides S1P1 (EC50 value is 0.2 nM) in varying 
affinity (EC50 value for S1P2 is >10000 nM and for S1P3 is 5 nM).
88 Opposite results 
between C57BL/6 and Rag1 KO mice of FTY720 treatment indicate that the drug targets 
different fibrotic pathway in complete absence of lymphocytes under chronic 
hyperglycemia. Notably, FTY720 at higher concentrations (0.1-1 µM) can activate S1P3 
receptor in fibroblasts that causes them to differentiate into collagen producing 
myofibroblasts.136 In isolated murine S1P3 knock out fibroblasts, FTY720 did not 
increase myofibroblast differentiation marker alpha smooth muscle actin (α-SMA), 
whereas FTY720 was able to increase α-SMA expression in wild-type mice fibroblasts. 
Primary human fibroblasts express mRNAs for different S1P receptors in the following 
order: S1P3 >> S1P1 > S1P2 > S1P5 > S1P4. Treatment with S1P1-, S1P3-, S1P4- and 
S1P5- antisense oligonucleotide to isolated primary human fibroblasts resulted in 
substantial reduction of respective protein levels. Notably, FTY720 mediated 
myofibroblast differentiation only abrogated in S1P3 ASO treated fibroblasts. Further, it 
has been found that FTY720 activates Smad3 pathway in fibroblasts acting through S1P3 
receptor in fibroblasts leading to myofibroblast differentiation.136 In a more recent report, 
FTY720 has been shown to activate S1P2 receptor to induce myofibroblast contraction in 
vitro.128 Thus, nonselective functions of FTY720 on S1P receptor subtypes make it 
obscure to dissect the mechanism through which it increases fibrosis area in Rag1 knock 
out mice, devoid of mature B and T lymphocytes. These circumstances set the premise 
126 
 
 
for our current study objective to dissect the effects of genetic S1P1 receptor deficiency in 
T lymphocytes in murine diabetic cardiomyopathy model. 
In the present study through genetic loss-of-function approach we generated T 
cell specific S1P1 knockout (TS1P1KO) mice. TS1P1KO mice showed profound 
deficiency of CD3+ T cells in spleen and reduced CD4+ and CD8+ T cells in blood than 
littermate control mice. Immunohistochemical analysis in cardiac tissue revealed the 
presence of fibrotic milieu in littermate mice myocardium under 11-week diabetic period. 
Littermate diabetic mice myocardium showed increased presence of CD3+ T cells with 
concomitant increase of profibrotic cytokine TGF-β1 expression and fibroblast progenitor 
CD34 expressing fibrocytes presence after 11-week of chronic hyperglycemia. 
Comparatively, TS1P1KO mice myocardium showed less CD3
+ T cells infiltration with 
reduced TGF-β1 and CD34 expression in myocardium with improved cardiac contractile 
force than littermate diabetic mice after the same length of diabetic period. Additionally, 
CD4+Foxp3+ T cells number were increased in spleen and blood of diabetic littermate 
mice. CD4+Foxp3+ T cells are considered as regulatory T cells (Treg cells) that maintain 
immune tolerance by suppressing excessive immune reaction at periphery. S1P1 mediated 
signaling has been shown to negatively regulate Treg cells development in thymus and 
periphery through Akt-mTOR pathway activation, whereas it promotes TH1 helper T cells 
differentiation.141,142 It is beyond the scope of our present study objectives to elucidate 
S1P1 mediated T cells differentiation effect on cardiac fibrosis in diabetes. However, it is 
important to note that, Zhen et al. reported increased Treg cells in STZ-induced diabetic 
mice spleen and blood with activated/memory phenotype. Notably, Treg cells from STZ 
treated mice showed reduced immunosuppressive ability than buffer recipient control 
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mice after 4-month diabetic period.143 The authors observations indicate that under 
chronic hyperglycemia T cells phenotype changed towards more effector phenotype. 
Several epidemiological studies reported increased proinflammatory T cells in periphery 
in diabetic patients that correlate with the adverse cardiac outcomes.78,79 To this end, 
based on the results of the present study, our conclusion is deficiency of T lymphocytes 
in TS1P1KO mice under chronic hyperglycemia ameliorates fibrosis and preserves heart 
histology as compared with littermate diabetic mice. 
Mature T lymphocytes continually recirculate between secondary lymphoid 
organs and systemic circulation. This movement increases the probability of interaction 
of T cells with antigen presenting cells (APCs), such as macrophages and dendritic 
cells.90 T lymphocytes encounter with antigen bearing APCs activates T cells that results 
in proliferation of activated T cells in respective lymph nodes. Effector T cells then can 
migrate to inflamed tissue and participate in potentiating the immune response by 
secreting cytokines, growth factors, and through direct cell-cell contact. T lymphocytes 
trafficking has been found to be involved in murine myocardial injury models.77,144 After 
left coronary artery ligation in mouse heart, heart draining lymph nodes have increased 
CD4+ T cells proliferation and infiltration into the myocardium.74 Another report 
demonstrated that in murine chronic transverse aortic constriction model, increased CD3+ 
T cells infiltration was associated with increased fibrosis area and cardiac 
dysfunction.75,76 In our present study, TS1P1KO mice have reduced CD4
+ and CD8+ T 
cells in circulation, as T cells in these mice have decreased S1P1 mRNA expression due 
to Lck driven Cre-mediated recombination of S1P1 gene at the coding region.
83 CD4+ and 
CD8+ T cells in these mice sequester in thymus and have reduced in secondary lymphoid 
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organs as shown consistent with the literature.
83
 We observed less CD3
+ T lymphocytes 
infiltration in diabetic TS1P1KO mice myocardium than littermate diabetic mice. 
Altogether, altered T lymphocytes trafficking in TS1P1KO mice is a contributing factor 
for the observed cardioprotection under long term hyperglycemia. 
Surprisingly, TS1P1KO vehicle mice myocardium exhibited increased collagen 
deposition in myocardium with altered heart histology and attenuated cardiac force of 
contraction. Although TS1P1KO vehicle mice myocardium did not exhibit increased 
presence of T cells compared with littermate vehicle mice, TGF-β1 and CD34 bearing 
cells expression were increased in these mouse myocardium. These contrasting results 
indicate the complexity of cardiac fibrotic remodeling and important contributions of 
different types of immune cells to maintain the collagen homeostasis in heart under both 
physiological and pathological conditions. To this point, it is noteworthy that TS1P1KO 
mice have increased circulatory B lymphocytes (B220+ lymphocytes) in their blood as 
immune compensatory mechanism of reduced circulating T cells.83 Lack of programmed 
cell death protein-1 (PD-1-/-) in mice resulted in severe form of dilated cardiomyopathy 
with increased interstitial fibrosis, disarrayed and disrupted myofilaments.145 PD-1 acts as 
negative regulator of lymphocytes proliferation. Increased IgG autoantibodies against 
cardiac proteins were deposited in PD-1-/- murine myocardium. Strikingly, PD1-/- mice 
generated in Rag2-/- background (mice lacking mature B and T lymphocytes) did not 
develop dilated cardiomyopathy.145 Interestingly, B lymphocytes have been also 
implicated in heart failure development by secreting autoantibodies against 
cardiomyocytes.146 Similarly, our results presented in chapter 2 and earlier117 demonstrate 
that Rag1 knock-out mice lacking mature B and T lymphocytes exhibit resistance against 
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diabetes induced fibrosis and cardiac dysfunction as compared to C57BL/6 mice with 
normal B and T cells compartment. TS1P1KO mice had significantly lower T cells in 
circulation and lymphoid organs due to the lack of S1P1 in T cells that increases B cells 
number in circulation.83 Altered B and T cells number in the circulation might contribute 
to develop fibrosis in TS1P1KO vehicle mice, as B lymphocytes secreted antibodies have 
shown detrimental effects on cardiomyocytes.146  
Proinflammatory cytokines, such as TNF-α, IL-1β and IL-6, can cause cardiac 
dysfunction by negatively affecting cardiac contractility and cardiac extracellular matrix 
compartment remodeling. To this end, the inhibition of proinflammatory cytokine TNF-α 
is not proven efficacious in a human clinical trial.147 Thus, a more comprehensive 
understanding of molecular and cellular basis of heart failure development should be 
investigated in different models of cardiac dysfunction to devise better and effective 
therapeutic interventions. In our present study, T cell trafficking modulation by genetic 
depletion of T cell S1P receptor 1 protects heart in chronic diabetes. To this end, T cells 
S1P1 receptor is a potential therapeutic target to modulate T cells trafficking in chronic 
inflammatory conditions, such as diabetes and hypertension, to ameliorate cardiac 
fibrosis. In this regard, several newer, more specific S1P1 receptor modulator drug 
molecules have shown promising results. For instance, unlike S1P1 receptor non-specific 
agonist FTY720, ponesimod (Actelion, Switzerland), a selective S1P1 agonist (EC50 
value is 5.7 nM), is now under Phase III clinical trial for depleting T lymphocytes in 
circulation.149 Ponesimod has been shown efficacious in preventing T cell mediated tissue 
damage in rodent delayed-type hypersensitivity of the skin and adjuvant-induced rodent 
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arthritis model.148,149 Thus, specific S1P1 receptor modulator drugs can be used more 
effectively to modulate T lymphocytes trafficking in clinical practices. 
3.5. Conclusions 
In summary, key findings of our present investigation are: (1) presence of T 
lymphocytes normal trafficking between lymphoid organs and circulation is an important 
determinant of cardiac fibrotic remodeling both under physiological and pathological 
conditions; (2) T cell specific genetic S1P receptor 1 deficiency reduces circulatory T 
lymphocytes in TS1P1KO mice; (3) TS1P1KO mice myocardium exhibits less CD3
+ T 
cells with reduced fibrosis area, preserved cardiac histology and improved cardiac 
contractility under chronic diabetes. 
However, our present study did not assess the role of specific subset of T 
lymphocytes in diabetic myocardial fibrogenesis. In the next study, we isolated CD4+ T 
cells from wild-type littermate mice, and intravenously transfer the isolated CD4+ T cells 
to TS1P1KO mice. We evaluated cardiac fibrotic response in TS1P1KO mice after CD4
+ 
T cells transfer in chronic diabetes. These studies are discussed in the next chapter. 
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CHAPTER 4: EFFECTS OF CD4 T CELL TRANSFER TO TS1P1KO MICE ON 
CARDIAC FIBROSIS IN DIABETIC CARDIOMYOPATHY 
 
4.1. Background  
 In chapter 3, we demonstrated that conditional T cell specific sphingosine 1-
phosphate receptor 1 (S1P1) genetic depletion results in marked reduction of both single 
positive CD4+ and CD8+ T lymphocytes in systemic circulation. T-cell specific S1P1 
knock-out mice (TS1P1KO) in long term streptozotocin (STZ)-induced type 1 diabetic 
cardiomyopathy model exerted less fibrosis and improved cardiac contractility compared 
to diabetic littermate mice. We found less CD3+ T cells invasion into diabetic TS1P1KO 
mice heart sections compared to diabetic littermate mice. The expression of profibrotic 
cytokine TGF-β1 and CD34 fibrocytes were also reduced in diabetic TS1P1KO mice 
heart sections compared to diabetic littermate mice. However, our studies did not 
elucidate specific subset of T lymphocytes role in myocardial fibrogenesis in long term 
diabetes. Among the helper CD4+ and cytotoxic CD8+ T lymphocytes, CD4+ T 
lymphocytes have been found to be responsible for cardiac fibrosis generation in various 
cardiovascular diseases including hypertension, myocardial infarction and myocarditis.36 
To date, four distinct CD4+ T lymphocyte subsets have been reported including TH1, TH2, 
TH17 and regulatory T cells.
68 All the CD4+ T cell subsets have been reported to be 
involved in cardiac fibrosis.36 The expression of T helper type 1 (TH1) CD4
+ T cells 
increases collagen content and have been shown to increase procollagen synthesis in 
cardiac fibroblasts.69 T helper type 2 (TH2) CD4
+ T cells cytokines IL-4 and IL-13 have 
been reported to be pro-fibrotic stimulators leading to synthesis of collagen in 
fibroblasts.36,150 T helper type 17 (TH17) cells have been implicated in cardiac fibrosis in 
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autoimmune inflammatory myocarditis.151 On the other hand, regulatory T cells attenuate 
cardiac fibrosis in experimental models of hypertension, angiotensin-induced 
cardiomyopathy and myocardial infarction.152,153,154 The attenuation of inflammation by 
regulatory T cells has been implicated as a mechanism to reduce myocardial fibrosis 
under pathological conditions.36 CD4+ T lymphocytes have also been reported to 
facilitate fibrocytes development from blood derived monocytes and increase the 
collagen deposition in murine kidney.155  
Several epidemiological studies have reported the expansion of pro-inflammatory 
CD4+ T lymphocytes in diabetic patients with increased systemic inflammation and 
adverse cardiovascular outcomes including acute coronary events.78,79,110 The time course 
analysis in rodent STZ-induced diabetic cardiomyopathy model has shown increased 
CD3+ T lymphocytes into myocardium as early as 2-week after STZ induction.111 As both 
mature CD4+ and CD8+ T lymphocytes express CD3+ on their cell surface,156 ambiguity 
exists to precisely determine the cellular origin of infiltrating CD3+ T cells in the 
myocardium under chronic diabetes. 
TS1P1KO mice, due to genetic depletion of T cell specific S1P receptor 1, have 
substantially reduced CD4+ and CD8+ T cells in blood and cardioprotection with less 
myocardial fibrosis in long term diabetic cardiomyopathy model (Chapter 3). Because 
CD4+ T cells have been shown to participate in cardiac fibrosis, we hypothesized that 
adoptive transfer of CD4+ T cells from littermate mice to TS1P1KO mice reverses the 
cardioprotective and antifibrotic effect in chronic diabetes. Evaluating the effects of 
adoptive transfer of CD4+ T lymphocytes on myocardial fibrosis in chronic diabetes will 
help to elucidate the role of CD4+ T cells more precisely, which in turn will facilitate 
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future therapeutic strategy to ameliorate cardiac fibrosis in diabetes. In this study, we 
isolated splenic CD4+ T cells from littermate mice and reconstituted purified CD4+ T 
cells into TS1P1KO mice intravenously. CD4
+ T cells recipient mice underwent long 
term STZ-induced diabetes. At the end point of experimental period, we evaluated 
cardiac contractility in an ex-vivo Langendorff’s heart perfusion system, we also studied 
heart histology and fibrosis area. In addition, we assessed myocardium infiltrating CD3+ 
T cells number, profibrotic TGF-β1 and CD34 expressing fibrocyte expression in cardiac 
tissue by immuohistological studies. 
4.2. Materials and Methods  
4.2.1. T cell specific S1P receptor 1 knock out mice 
T cell specific S1P receptor 1 knock out (TS1P1KO) mice from S1P1
loxP/loxP mice 
and Lck-Cre mice breeding colony were genotyped and immunophenotyped as described 
in chapter 3. We housed all mice in specific pathogen free room in Animal Research 
Wing (ARW) facility at SDSU. Mice were given ad libitum rodent autoclaved food 
(5010, LabDiet) and water. The animals were handled and cared in accordance with the 
Guide for the Care and Use of Laboratory Animals by U.S. National Research Council 
(Eighth Edition, 2011). All experimental procedures were approved by Institutional 
Animal Care and Use Committee (IACUC) at SDSU. 
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4.2.2. Isolation of CD4+ T cells and adoptive transfer 
We isolated CD4+ T cells by positive selection from the littermate control mice 
spleen by using microbeads conjugated with CD4+ antibody from Miltenyi Biotech 
(Auburn, CA). Briefly, freshly excised spleen from anesthetized littermate control mice 
was cut into 1 mm3 pieces and passed through 70 µm nylon cell strainer (352350, 
Corning Inc. NY). The dissociated cells were collected in isolation buffer containing 
0.5% w/v bovine serum albumin (A2153, Sigma-Aldrich, MO) and 2 mM EDTA in 0.01 
M PBS (P3813, Sigma-Aldrich). The single-cell suspensions were centrifuged at 300 x g 
for 10 minutes at room temperature (RT). Supernatants were discarded and red blood 
cells were lysed by incubating at RT for 5 minutes with 5 mL of 1 x RBC lysis buffer 
(00-4333, eBioscience) for each spleen. After incubation, the single-cell suspensions 
were washed twice in isolation buffer by centrifugation at 500 x g for 10 minutes at RT. 
The cell pellets were re-suspended in 10 ml isolation buffer and cell numbers were 
counted in Cellometer Auto T4 (Nexcelom, MA) in prepared single-cell suspension of 
splenocytes (Figure 4-1).  
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Figure 4-1: Schematic diagram of preparation of single-cell suspensions from littermate 
mouse spleen. The images used in the figure were taken from multiple web based sources 
for schematic representation. 
The prepared single-cell suspension of splenocytes was then incubated with 10 µL 
of mouse CD4 antibody-microbeads (130-049-201, Miltenyi Biotech) per 107 cells at 4 
ºC for 15 minutes. Cells were washed by centrifugation with isolation buffer at 300 x g 
for 10 minutes at RT. The cell pellets were re-suspended with 500 µL of isolation buffer 
per 108 cells and proceeded to magnetic separation. The magnetically labeled cells were 
passed through MS column (130-042-201, Miltenyi Biotech) attached to a magnet (130-
042-102, Miltenyi Biotech) by washing with 500 µL isolation buffer for three times. 
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Specific CD4 microbeads labeled cells were then collected by removing the MS column 
from the magnet followed by immediate flushing of the column with a rubber plunger. 
The collected CD4 positive T cells were counted, and viability was measured by trypan 
blue exclusion assay. We also assessed the isolated CD4+ T cells purity by flow 
cytometry using anti-mouse CD4 antibody (11-0041-82, eBioscience). The isolated CD4+ 
T cell viability and purity were ~90-95% in each case (Figure 4-2).  
 
Figure 4-2: Schematic diagram of experimental procedure to isolate CD4+ T cells from 
single-cell suspensions of splenocyte of littermate control mice. The images used in the 
figure were taken from multiple web based sources for schematic presentation. 
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One million (106) CD4+ T cells prepared by the above mentioned procedure in 
0.01 M PBS was intravenously transferred through tail vein to littermate and TS1P1KO 
mice. After CD4+ T cells transfer, littermate and TS1P1KO mice were observed for one 
week. After one week, both strains were divided into vehicle and streptozotocin treated 
group. The groups is represented as ‘CD4+mouse type & treatment name’. All mice 
underwent similar 11-week long experimental protocol as described in chapter 3. The 
experimental protocol is shown below (Figure 4-3). 
   
 
 
 
 
 
 
 
Figure 4-3: Schematic diagram of experimental protocol of adoptive transfer of CD4+ T 
cells in littermate and TS1P1KO mice followed by 11-week long streptozotocin (STZ)-
induced type 1 diabetes. 
4.2.3. Flow cytometry analysis of CD4+ and CD8+ T cells in peripheral blood 
We measured helper CD4+ and cytotoxic CD8+ T cells proportions in peripheral 
blood of mice by two color flow cytometry analysis as described in chapter 2 in a BD 
FACSCalibur flow cytometer (BD Biosciences, CA). Date was acquired and analyzed by 
BD CellQuest Pro software (BD Biosciences, CA).  
One (01) week 
observation 
Five (05) 
consecutive day 
STZ or buffer only 
intraperitoneal 
injection  
Eleven (11) week long experimental period 
Day 1: One million of CD4+ T cells transfer 
intravenously to littermate and TS1P1KO mice 
Following salient experiments were 
done at the end of 11 weeks: 
 Flow cytometry analysis 
 Heart contractile force 
measurement in ex-vivo 
Langendorff Heart  
perfusion system 
 Histology study 
 Fibrosis area assessment 
 Immunohistochemistry 
studies 
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4.2.4. Flow cytometry analysis of regulatory T cells 
We measured relative percentage of CD4+Foxp3+ regulatory T cells (Treg cells) in 
spleen and blood after 11-week study period in mice according to the procedures 
described in chapter 3. Flow cytometry analysis was carried out in BD FACSCalibur flow 
cytometer coupled to CellQuest Pro software (BD Biosciences).  
4.2.5. Cardiac contractility assessment  
We assessed cardiac contractile force (g) in the mice after 11-week experimental 
period in a modified Langendorrf’s heart perfusion system ex-vivo, as described in 
chapter 2. Cardiac contractile force was recorded and analyzed with Biopac MP 100 data 
system (Goleta, CA, USA). The fold change in cardiac contractile force relative to 
littermate vehicle mice was measured. 
4.2.6. Heart histology and analysis of cardiac fibrosis 
Paraffin-embedded 5 µm thick heart sections of littermate and TS1P1KO mouse 
groups were prepared at the end of 11-weeks. Heart histology in Hematoxylin & Eosin 
stained, and fibrosis area in Masson’s trichrome stained heart sections were studied at the 
end of 11-weeks. H&E stained sections were examined under bright field illumination in 
a upright microscope (Carl Zeiss, Germany), and score was given for each heart section 
for (i) the presence of eosinophilic interstitial collagen fibers, (ii) extent of cellularity in 
interstitial space of myocardium, (iii) myocardial cell necrosis/loss, (iv) myofiber 
striation and myocytes organization on a five-point scale for each characteristics from 0 
to 4.120,121 The cumulative scores were expressed from 0 to 16 for each group. Trichrome 
stained whole heart sections image was acquired using a Leica EZ4 HD stereomicroscope 
(Leica Microsystems, Buffalo Grove, IL, USA). The percentage of fibrosis area relative 
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to the whole heart area was quantified by using NIH Image J (Bethesda, MA) software as 
described by Zhao et al.117 
4.2.7. Immunohistochemical analysis on littermate and TS1P1KO mice heart 
sections 
CD3+ T cells, TGF-β1 and CD34 bearing cell expression were analyzed in 
myocardium by immunohistochemistry in paraffin embedded 5 µm tissue sections with 
CD3 (10 µg/mL, sc-20047; Santa Cruz Biotechnology, Inc., CA), TGF-β1 (15 µg/mL, 
MAB240; R&D Systems, Inc., Minneapolis, MN) and CD34 (10 µg/mL, MA5-17825; 
Pierce Biotechnology, Rockford, IL, USA) primary antibodies. R&D systems mouse/rat 
cell and tissue staining HRP-DAB kit (CTS002/CTS017; R&D Systems) were used to 
amplify positive signals and visualize by using corresponding mouse/rat primary 
antibodies. The detailed procedure is described in chapter 2.  To count immunopositive 
CD3+ cells, 30 fields of stained heart sections were pictured at bright-field under 400x 
magnification in an upright microscope (Carl Zeiss, Germany). Myocardium infiltrating 
cells number was calculated by counting the cells number in imaged 400x fields 
(cells/field).75 TGF-β1 and CD34 positive staining percent area were quantified in 10 
fields of 400x magnification images by using NIH ImageJ software (Bethesda, MD) and 
the averaged percent of staining area is presented.119,139 
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4.2.8. Data analyses 
 All the data was expressed as mean ± SEM. One-way ANOVA was used for 
statistical analysis followed by Student-Newman-Keuls post hoc test for multiple 
comparisons of group means to evaluate statistical significance. Two-tailed unpaired 
Student’s t-test was done, where applicable. Data was analyzed in GraphPad Prism 
software (v5.01, 2007). A P value of less than 0.05 was considered statistically 
significant, and indicated with an asterisk (*) or a number (#) sign.  
 
4.3. Results 
4.3.1. Isolated CD4+ T cell number and purity by flow cytometry analysis 
 Total cell number was 7.03±0.45 million cells per milliliter (n=14) in single-cell 
suspensions of splenocytes from littermate control mice. Isolated CD4+ T cell numbers 
were 5.09±0.46 million cells per milliliter (n=14) from single-cell suspensions. The 
purity of isolated CD4+ T cells was about 90-95% as analyzed by CD4+ antigen 
expression in cells of CD4 positive and CD4 negative fraction from MS column effluent 
by flow cytometry analysis (Figure 4-4). 
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Figure 4-4: Representative flow cytometry histogram represents CD4+ T cells staining 
and number in total isolated splenocytes of littermate control mice (panel A). CD4+ T 
cells staining in positive fraction after separation through MACS positive selection 
method exhibited only CD4+ staining in positive fraction (panel B). CD4+ T cells staining 
in negative fraction after separation, yielded negligible CD4+ staining (panel C). 
4.3.2. Assessment of physiological parameters in chronic diabetes 
We measured body weight (g) twice each week and blood glucose level (mg/dl) at 
the beginning, after 4-week and after 11-week during experimental period. In our present 
study, both littermate control and TS1P1KO mice were divided into vehicle treated and 
streptozotocin (STZ) treated groups where all mice received one million CD4+ T cells 
isolated from littermate mice spleen. Both littermate and TS1P1KO mice recipient of 
streptozotocin (STZ) exhibited less body weight gain compared to vehicle treated mice 
during 11-week study period. CD4+ T cells recipient littermate and TS1P1KO groups had 
no significant difference in body weight at the beginning (Figure 4-5, Table 4-1). But 
after STZ injection, CD4+ T cells recipient littermate STZ mice showed 39.68% reduced 
body weight compared to littermate vehicle mice and TS1P1KO STZ mice had 35.83% 
 17.07% in M1 gate 95.99% in M1 gate  0.10% in M1 gate 
CD4+ T cells in total 
splenocytes 
 
CD4+ T cells in positive 
fraction 
 
CD4+ Staining  
in negative fraction 
 
M1 
M1 
M1 
A B C 
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reduced body weight compared to TS1P1KO vehicle mice at the end of 11-weeks (Figure 
4-5, Table 4-1). This reduction was 2.59-fold less (39.68 % vs. 15.29 %) in body weight 
for littermate STZ and 2.01-fold less (35.83 % vs. 17.75 %) in body weight for KO STZ 
mice compared to respective STZ mice of both strain without CD4+ T cells transfer 
(Figure 4-5, Table 4-1). 
 
 
 
 
 
 
 
 
Figure 4-5: Body weight (g) change in CD4+ T cells recipient littermate and TS1P1KO 
mice during 11-week study period. Both CD4+ T cells recipient littermate and TS1P1KO 
STZ mice exhibited lower body weight gain trend throughout 11-week, and showed 
significantly lower body weight (g) at the end of 11-week compared to littermate and 
TS1P1KO vehicle mice. *P<0.05 vs. CD4+littermate vehicle and CD4+TS1P1KO vehicle 
mice, respectively. Sample size n = 4-5 mice per each group. All data are expressed as 
means ± SEM at each time point.
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Table 4-1: Summary of physiological parameter in CD4+ T cells recipient littermate and TS1P1KO mice during 11-week experimental 
period. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The data is expressed as mean ± SEM. *P < 0.05 between vehicle and STZ groups of CD4+ T cells recipient littermate and TS1P1KO 
mice. The values of ‘n’ represent number of mice in each group.
 
 
CD4+Littermate Vehicle 
(n=5) 
CD4+TS1P1KO Vehicle 
(n=5) 
CD4+Littermate STZ 
(n=4) 
CD4+TS1P1KO STZ 
(n=4) 
At beginning 
(before STZ 
induction) 
    
Body wt. (g) 25.24±1.27 24.62±0.33 26.78±0.82  25.68±0.31 
After 4-week of STZ 
induction 
    
Body wt. (g) 27.86±0.82 26.72±0.52 22.38±0.63* 21.75±1.14 
After 11-week of 
STZ induction 
    
Body wt. (g) 32.1±1.45 30.4±1.07 22.98±0.82* 22.38±1.53* 
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At the beginning of the study, there was no significant difference in blood glucose 
level (mg/dl) among CD4+ T cells recipient littermate and TS1P1KO mice (Figure 4-6, 
Table 4-2). However, STZ induction exhibited significantly higher blood glucose level in 
both littermate and TS1P1KO mice compared to respective vehicle only treated mice of 
two strains after 4-weeks (Figure 4-6, Table 4-2). Hyperglycemia persisted significantly 
after 11-week in both littermate and TS1P1KO STZ mice compared to vehicle treated 
mice (Figure 4-6, Table 4-2). Notably, TS1P1KO STZ mice recipient of CD4
+ T cells 
showed 1.50-fold increased high blood glucose level compared to without CD4+ T cells 
recipient TS1P1KO STZ mice (CD4+TS1P1KO STZ, [n=4], 527.75±41.16 mg/dl vs. 
TS1P1KO STZ, [n=7], 350±32.98 mg/dl, 
#P<0.05) (Figure 4-7).
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Figure 4-6: Blood glucose level (mg/dl) during 11-week study period in CD4+ T cells 
recipient littermate and TS1P1KO mice. Bar graphs show blood glucose level (mg/dl) at 
the beginning, after 4-week and after 11-week of streptozotocin (STZ) administration in 
all mice. Sample size, n = 5-4 mice per each group. **P < 0.01 between vehicle and STZ 
groups of CD4+ T cells recipient littermate and TS1P1KO mice blood glucose level after 
4-week and after 11-week of STZ induction. The data is expressed as mean ± SEM.
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Figure 4-7: Blood glucose level (mg/dl) at end of 11-week in diabetic TS1P1KO mice 
without- and with- CD4+ T cells adoptive transfer. CD4+ T cells recipient TS1P1KO STZ 
mice (n=4)  exhibited significantly higher blood glucose level compared to TS1P1KO 
STZ mice without CD4+ T cells transfer (n=4) at the end of 11 weeks, *P < 0.05. The 
data is expressed as mean ± SEM. 
 
 
 
 
 
 
 
 
TS1P1KO STZ CD4+TS1P1KO STZ
0
200
400
600
TS1P1KO STZ
CD4+TS1P1KO STZ
*
B
lo
o
d
 g
lu
c
o
s
e
 l
e
v
e
l
(m
g
 d
l
-1
)
 
 
147 
 
 
Table 4-2: Summary of metabolic parameter in CD4+ T cells recipient littermate and TS1P1KO mice during 11-week experimental 
period. 
 
 
 
 
 
 
 
 
 
 
 
 
The data is expressed as mean ± SEM. **P < 0.01 between vehicle and STZ groups of CD4+ T cells recipient littermate and TS1P1KO mice.
 CD4+Littermate Vehicle 
(n=5) 
CD4+TS1P1KO Vehicle 
(n=5) 
CD4+Littermate STZ 
(n=4) 
CD4+TS1P1KO  STZ 
(n=4) 
At the beginning 
(before STZ 
induction) 
    
Blood glucose level 
(mg/dl) 
146±12.03 126.80±8.35 138.50±12.84 133.75±6.70 
After 4-week of STZ 
induction 
    
Blood glucose level 
(mg/dl) 
135.40±8.27 137.40±12.63 403±27.97** 466.75±56.76** 
After 11-week of 
STZ induction 
    
Blood glucose level 
(mg/dl) 
145.20±5.83 142.60±11.14 432.50±42.52** 527.75±41.16** 
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4.3.3. Flow cytometry analysis of T lymphocyte subsets 
 We measured dissected spleen wet weight (mg) and calculated spleen weight 
(mg) to body weight (g) ratio in both without- and with- CD4+ T cells recipient mice to 
detect gross splenic structural remodeling in long term diabetes. One-way ANOVA 
followed by Tukey’s post hoc test yielded no significant difference between spleen 
weight (mg) to body weight (g) ratio between littermate and TS1P1KO mice without- and 
with-CD4+ T cells transfer (Table 4-3). Notably, splenocytes number (x106 cells/mL) was 
significantly increased, as analyzed by student’s two-tailed t-test, in littermate and 
TS1P1KO vehicle mice after CD4
+ T cells transfer compared to littermate and TS1P1KO 
vehicle mice without CD4+ T cells transfer. Although, littermate STZ mice had 12.84% 
and TS1P1KO STZ mice had 21.34% increased splenocytes number (x10
6 cells/mL) after 
CD4+ T cells transfer compared to littermate vehicle and TS1P1KO vehicle mice without 
CD4+ T cells transfer, two-tailed t-test did not yield significant differences between these 
two groups (Figure 4-8, Table 4-4).    
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Table 4-3: Summary of spleen weight (mg) to body weight (g) ratio in littermate                          
and TS1P1KO mice without- and with- CD4
+ T cells transfer. 
 
 
 
 
 
 
 
 
 
 
 
The data is expressed as mean ± SEM. ‘n’ value represents number of mice in each 
group. 
 
 
 
 
 
 
 
 
 
 
Groups Spleen wt. (mg)/body wt. (g) 
Littermate Vehicle (n=4) 2.97±0.37  
TS1P1KO Vehicle (n=5) 2.61±0.24 
Littermate STZ (n=8) 2.82±0.23 
TS1P1KO STZ (n=6) 2.72±0.27 
CD4+Littermate Vehicle (n=5) 2.43±1.69 
CD4+TS1P1KO Vehicle (n=5) 2.48±0.32 
CD4+Littermate STZ (n=4) 2.79±0.29 
CD4+TS1P1KO STZ (n=4) 2.15±0.23 
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Figure 4-8: Effects in total splenocytes number (x106 cells/ml) in littermate and 
TS1P1KO mice after CD4
+ T cells transfer compared to littermate and TS1P1KO mice 
without CD4+ T cells transfer. Both littermate and TS1P1KO vehicle mice had 
significantly increased splenocytes number after CD4+ T cells transfer compared to 
littermate and TS1P1KO vehicle mice, respectively, without CD4
+ T cells transfer, 
*P<0.05. Diabetic littermate (P = 0.72) and TS1P1KO mice (P = 0.47) had increased 
splenocytes number after CD4+ T cells transfer  compared to littermate and TS1P1KO 
STZ mice, respectively, without CD4+ T cells transfer. The data is expressed as mean ± 
SEM. ‘n’ value represents number of mice in each group. 
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Table 4-4: Summary of splenocytes number (x106 cells/ml) in littermate and TS1P1KO 
mice without- and with- CD4+ T cells transfer. 
 
 
 
 
 
 
 
 
 
 
The data is expressed as mean ± SEM. *P < 0.05 compared to littermate vehicle and 
TS1P1KO vehicle without CD4
+ T cells transfer. ‘n’ value represents number of mice in 
each group. 
 
 
 
 
 
 
 
 
 
 
Groups Splenocytes number  
(x106 cells/ml) 
Littermate Vehicle (n=3) 44.5±3.32 
TS1P1KO Vehicle (n=4) 34.73±6.74 
Littermate STZ (n=3) 50.1±10.89 
TS1P1KO STZ (n=3) 33.73±9.65 
CD4+Littermate Vehicle (n=5) 79.64±5.68* 
CD4+TS1P1KO Vehicle (n=5) 65.35±5.80* 
CD4+Littermate STZ (n=4) 57.48±14.69 
CD4+TS1P1KO STZ (n=4) 42.88±6.83 
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 After CD4+ T cells adoptive transfer, although CD4+ and CD8+ T cell 
numbers in TS1P1KO mouse groups blood remained significantly lower than littermate 
mouse groups, CD4+ T cells number in TS1P1KO mice was increased by 1.58-fold in 
vehicle and 1.95-fold in STZ mice compared to TS1P1KO vehicle and STZ groups, 
respectively, without CD4+ T cells transfer at the end of 11-weeks (Figure 4-9A, 4-9B, 4-
10 and Table 4-5). CD8+ T cell numbers did not show any significant difference between 
these two categories of mouse. Similarly, CD4+Foxp3+ T cells number had increased in 
spleen of both CD4+ T cells recipient TS1P1KO vehicle and STZ groups than TS1P1KO 
mice without CD4+ T cells transfer (Figure 4-11A, 4-11B and Table 4-6). CD4+littermate 
STZ mice had increased CD4+Foxp3+ T cells than CD4+littermate vehicle mice after 11-
weeks (Figure 4-11B). Both CD4+TS1P1KO vehicle and CD4+TS1P1KO STZ mice had 
reduced CD4+Foxp3+ T cells than CD4+littermate vehicle and CD4+littermate STZ mice, 
respectively, at the end of 11-weeks (Figure 4-11B). In blood, there was no significant 
difference between CD4+Foxp3+ T cells numbers between groups after CD4+ T cells 
transfer (Figure 4-11B). Although in CD4+TS1P1KO vehicle mice had 2.63-fold 
increased CD4+Foxp3+ T cells in blood than TS1P1KO vehicle mice without CD4
+ T cells 
transfer (Table 4-6).
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Figure 4-9: Quantification data of CD4+ and CD8+ T cells number in blood of littermate 
and TS1P1KO mice after CD4
+ T cells transfer at the end of 11-weeks. (A) 
Representative flow cytometry dot plot show increased CD4+ T cells in lower right 
quadrant of TS1P1KO vehicle and STZ mice blood after CD4
+ T cells transfer compared 
to TS1P1KO vehicle and STZ mice, respectively, without CD4
+ T cells transfer at the end 
of 11-weeks. (B) Quantification of flow cytometry data of CD4+ and CD8+ T cells in 
CD4+ T cells recipient mice blood after 11-weeks. *P<0.05 between CD4+littermate 
vehicle and CD4+TS1P1KO vehicle mice, and CD4+littermate STZ and CD4+TS1P1KO 
STZ mice, n = 3-4 mice per group. The data is expressed as mean ± SEM. 
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Figure 4-10: Comparison of CD4+ T cells number in blood between CD4+ T cells 
recipient TS1P1KO mouse groups and TS1P1KO mouse groups without CD4
+ T cells 
transfer at the end of 11-weeks. After CD4+ T cells transfer both TS1P1KO vehicle and 
TS1P1KO STZ mice exhibited increased number of CD4
+ T cells in blood at the end of 
11 weeks compared to TS1P1KO vehicle and TS1P1KO STZ mice without CD4
+ T cells 
transfer. The data is expressed as mean ± SEM. P = 0.1894 between TS1P1KO vehicle 
and CD4+TS1P1KO vehicle mice, and P = 0.098 between TS1P1KO STZ and 
CD4+TS1P1KO STZ mice, n = 3-4 mice per group. 
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Table 4-5: Summary of CD4+ T cells number in blood of TS1P1KO mouse groups 
without- and with- CD4+ T cells transfer after 11-weeks. 
 
 
 
 
 
 
 
The data is expressed as mean ± SEM. ‘n’ value represents number of mice in each 
group. P = 0.1894 between TS1P1KO vehicle and CD4+TS1P1KO vehicle mice, and P = 
0.098 between TS1P1KO STZ and CD4+TS1P1KO STZ mice, n = 3-4 mice per group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Groups CD4+ T cells in blood  
(% of cell populations) 
TS1P1KO Vehicle (n=3) 1.37±0.02 
CD4+TS1P1KO Vehicle (n=3) 2.16±0.50 (36.57% increase, P =0.1894) 
TS1P1KO STZ (n=3) 1.21±0.61 
CD4+TS1P1KO STZ (n=4) 2.37±0.23 (48.95% increase, P =0.098) 
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Figure 4-11: Quantification data of CD4+Foxp3+ T cells number in spleen and blood of 
littermate and TS1P1KO mice after CD4
+ T cells transfer at the end of 11-week 
experimental period. (A) Representative flow cytometry dot plot show noticeable 
increase in CD4+ T cells (lower right quadrant) and CD4+Foxp3+ T cells (upper right 
quadrant) presence in TS1P1KO vehicle and STZ mice spleen after CD4
+ T cells transfer 
compared to TS1P1KO vehicle and STZ mice, respectively, without CD4
+ T cells transfer 
at the end of 11-weeks. (B) Quantification of flow cytometry data of CD4+Foxp3+ T cells 
in CD4+ T cells recipient mice spleen and blood after 11-weeks. *P<0.05 between 
CD4+littermate vehicle and CD4+littermate STZ mice, and #P < 0.05 between 
CD4+liitermate vehicle and CD4+TS1P1KO vehicle, and CD4+littermate STZ and CD4+ 
TS1P1KO STZ mice , n = 4-5 mice per group. The data is expressed as mean ± SEM. 
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Table 4-6: Summary of CD4+Foxp3+ T cells number in spleen and blood of TS1P1KO 
mouse groups without- and with- CD4+ T cells transfer after 11-weeks. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD4+ T cells recipient TS1P1KO vehicle and TS1P1KO STZ mice showed increased 
CD4+Foxp3+ T cells in spleen compared to TS1P1KO vehicle and TS1P1KO STZ mice, 
respectively, without CD4+ T cells transfer. CD4+ T cells recipient TS1P1KO vehicle 
mice showed increased CD4+Foxp3+ T cells in blood compared to TS1P1KO vehicle 
without CD4+ T cells transfer. P values calculated through two-tailed student’s t-test. The 
data is expressed as mean ± SEM. The value of ‘n’ represents number of mice in each 
group. 
 
 
 
Groups CD4+Foxp3+ T cells 
(% of cell populations) 
Spleen 
TS1P1KO Vehicle (n=3) 0.67±0.12 
CD4+TS1P1KO Vehicle (n=5) 1.12±0.20 (40.18% increase, P=0.16) 
TS1P1KO STZ (n=3) 1.38±0.37 
CD4+TS1P1KO STZ (n=4) 1.68±0.08 (17.86% increase, P=0.40) 
Blood 
TS1P1KO Vehicle (n=3) 0.19±0.03 
CD4+TS1P1KO Vehicle (n=4) 0.50±0.06 (62% increase, *P<0.05) 
TS1P1KO STZ (n=3) 0.42±0.18 
CD4+TS1P1KO STZ (n=4) 0.30±0.06 
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4.3.4. CD4+ T cells transfer exacerbates cardiac disorganization in TS1P1KO mice 
under diabetes 
 
We prepared Hematoxylin and Eosin (H&E) stained heart sections after 11-week 
experimental period. H&E stained sections were examined microscopically and graded 
based on cardiomyocyte morphology, organization, degree of cellularity in interstitial 
space, myocyte loss, and presence of collagen fibers in interstitial space. CD4+ T cells 
recipient TS1P1KO STZ mice (CD4+TS1P1KO STZ, n=4) hearts showed exacerbated 
myocytes organization with discernible disarray compared to TS1P1KO STZ mice without 
CD4+ T cells transfer (cumulative heart histology score: 9.25±0.95 vs. 3±0.58, *P < 0.05) 
(Figure 4-12A, 4-12B and 4-13A, 4-13B). Noticeably, CD4+ T cells recipient TS1P1KO 
vehicle mice (n=5) showed improved heart histology compared to TS1P1KO vehicle mice 
without CD4+ T cells transfer (n=4) (3±0.76 vs. 9.5±0.87, *P < 0.05) (Figure 4-12A, 4-
12B and 4-13A, 4-13B). 
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Figure 4-12: Heart histology study in H&E stained sections of CD4+ T cells recipient 
littermate and TS1P1KO mice after 11-week experimental period. (A) Diabetic 
CD4+littermate STZ and CD4+TS1P1KO STZ mice heart sections showed discernible 
disorganization of myocytes in myocardium after 11-week diabetes period. TS1P1KO 
mice vehicle heart sections exhibited improved heart histology under diabetes after CD4+ 
T cells transfer. The magnification is 200x. (B) Bar graphs represents cumulative heart 
histology score of littermate and TS1P1KO mice heart sections after CD4
+ T cells transfer 
at the end of 11-weeks. *P<0.05 between CD4+littermate vehicle and CD4+littermate 
STZ mice, and between CD4+TS1P1KO vehicle and CD4+TS1P1KO STZ mice. The data 
is expressed as mean ± SEM, n = 4-5 mice in each group. 
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Figure 4-13: Comparison between TS1P1KO mouse groups heart histology in H&E 
stained sections without- and with CD4+ T cells transfer. (A) Representative H&E stained 
heart sections images (magnification is 200x). Diabetic CD4+ TS1P1KO STZ mice heart 
sections showed discernible disorganization of myocytes in myocardium after 11-week 
diabetes period compared to TS1P1KO STZ mice without CD4
+ T cells transfer. In 
contrast, TS1P1KO vehicle mice heart sections exhibited improved heart histology under 
diabetes after CD4+ T cells transfer compared to TS1P1KO vehicle mice without CD4
+ T 
cells transfer. (B) Quantification of cumulative heart histology score of TS1P1KO mice 
heart sections at the end of 11-weeks. *P<0.05 between CD4+ TS1P1KO vehicle and 
TS1P1KO vehicle mice, and between CD4+TS1P1KO STZ and TS1P1KO STZ mice. The 
data is expressed as mean ± SEM, n = 4-7 mice in each group. 
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4.3.5. CD4+ T cells transfer increases fibrosis area in TS1P1KO diabetic mice 
We assessed fibrosis area in Tri-chrome stained heart sections after 11-week 
diabetic period. CD4+ T cells transfer to TS1P1KO mice exacerbated fibrotic area in 
diabetic TS1P1KO STZ mice (n=4) compared to TS1P1KO STZ mice (n=7) without CD4
+ 
T cells transfer (37.11±3.22 % vs. 11.86±4.34 %, *P < 0.05) (Figure 4-14A, 4-14B, 4-15A 
and 4-15B). Notably, CD4+ T cell recipient TS1P1KO vehicle mice (n=4) heart sections 
showed less fibrotic area compared to TS1P1KO vehicle mice (n=4) without CD4
+ T cells 
transfer (12.74±2.22 % vs. 46.03±7.60 %, *P < 0.05) (Figure 4-14A, 4-14B, 4-15A and 4-
15B). 
 
4.3.6. CD4+ T cells transfer attenuates cardiac contractility in TS1P1KO diabetic 
mice 
We determined cardiac contractility in ex-vivo Langendorff heart perfusion 
system at the end of 11-weeks. The contractile force was expressed as fold change 
compared to littermate control mice. After CD4+ T cells transfer, diabetic TS1P1KO mice 
had shown 22% lower contractile force compared to CD4+littermate control mice 
(P=0.57) (Figure 70). In contrast, TS1P1KO vehicle mice exhibited 47.09% higher 
contractile force after CD4+ T cells transfer compared to CD4+littermate vehicle mice 
(*P>0.05) (Figure 4-16). 
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Figure 4-14: Fibrosis extent assessment in Trichrome stained heart sections of CD4+ T 
cells recipient littermate and TS1P1KO mice after 11-weeks. (A) Upper panel represents 
whole heart sections (magnification 16x) and lower panel represents magnified section 
images (magnification 400x). CD4+ T cells transfer enhanced perivascular and interstitial 
fibrosis area in diabetic TS1P1KO mice. Notably, CD4
+ T cells transfer to TS1P1KO 
vehicle mice, attenuates fibrosis area. (B) Quantification of percent fibrosis area. *P<0.05 
in CD4+littermate STZ vs. CD4+littermate vehicle mice, *P<0.05 in CD4+TS1P1KO 
STZ vs. CD4+TS1P1KO vehicle mice. The data is expressed as mean ± SEM. n = 4 mice 
in each group.  
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Figure 4-15: Comparison between TS1P1KO mouse groups fibrosis extent in Masson’s 
Trichrome stained heart sections without- and with CD4+ T cells transfer. (A) Diabetic 
CD4+ TS1P1KO STZ mice heart sections exhibited enhanced fibrosis after 11-week 
diabetic period compared to TS1P1KO STZ mice without CD4
+ T cells transfer. In 
contrast, TS1P1KO vehicle mice heart sections exhibited attenuated fibrosis area after 
CD4+ T cells transfer compared to TS1P1KO vehicle mice without CD4
+ T cells transfer. 
(B) Quantification of fibrosis area in TS1P1KO mice heart sections. *P<0.05 in CD4+ 
TS1P1KO vehicle and TS1P1KO vehicle mice, and in CD4+TS1P1KO STZ and 
TS1P1KO STZ mice. The data is expressed as mean ± SEM, n = 4-7 mice in each group. 
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Figure 4-16: Cardiac contractile force in CD4+ T cells recipient littermate and TS1P1KO 
mice after 11-week study period. CD4+ T cells recipient TS1P1KO STZ mice showed 
reduced cardiac contractile force compared to CD4+littermate vehicle mice (P=0.57). In 
contrast, CD4+ T cells recipient TS1P1KO vehicle mice exhibited increased contractility 
compared to CD4+littermate vehicle mice. The data is expressed as mean ± SEM. 
Sample size, n=3 mice in each group. 
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4.3.7. Increased infiltration of CD3 T cells in TS1P1KO mouse hearts after 
reconstitution of CD4+ T cells 
  
We detected CD3+ T cells in heart tissue by immunostaining with mouse 
monoclonal CD3 antibody and counted the infiltrated CD3+ T cells in 30 high 
magnification fields (400x) for each heart sections (Figure 4-17). After CD4+ T cells 
transfer, in both vehicle and STZ group of TS1P1KO mice showed increased CD3
+ T 
cells in myocardium (vehicle: 1.56±0.06 cells/field vs. 0.97±0.08 cells/field,*P < 0.05, 
and STZ: 1.84±0.05 cells/field vs. 0.84±0.09 cells/field, n=3 independent experiments, #P 
< 0.05) than TS1P1KO vehicle and TS1P1KO STZ group, respectively, without CD4
+ T 
cells transfer (Figure 4-17, 4-18A and 4-18B). 
 
4.3.8. CD4+ T cells recipient diabetic TS1P1KO mice heart show increased TGF beta 
1 expression 
 
Transforming growth factor beta 1 expression was assessed in immunostained 
heart sections by computer assisted morphometric analysis. After CD4+ T cell transfer, 
TS1P1KO STZ mice heart sections exhibited increased TGF-β1 expression (5.45±0.08 % 
staining area vs. 3.54±0.10 % staining area, #P < 0.05, n= 3 experiments as compared to 
TS1P1KO STZ without CD4
+ T cells transfer (Figure 4-19, 4-20A and 4-20B). In 
contrast, TGF-β1 expression was reduced in TS1P1KO vehicle mice after CD4
+ T cells 
transfer (2.78±0.15 % staining area vs. 6.78±0.71 % staining area, *P < 0.05, n= 3 
experiments compared to TS1P1KO vehicle mice without CD4
+ T cells transfer (Figure 4-
19, 4-20A and 4-20B). 
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Figure 4-17: Immunohistochemical detection of CD3+ T cells in CD4+ T cells recipient 
littermate and TS1P1KO mice heart sections at the end of 11-weeks. CD4
+ T cells 
recipient TS1P1KO vehicle and TS1P1KO STZ mice heart sections have increased 
infiltration of CD3+ T cells after 11-week of experimental period compared to littermate 
vehicle mice. Images are representative of three independent experiments. The 
magnification is 400x. 
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Figure 4-18: Quantification of infiltrated CD3+ T cells in myocardium of CD4+ T cells 
recipient littermate and TS1P1KO mice. (A) CD3
+ T cells number (cells per 400x 
magnification field) was significantly higher in TS1P1KO vehicle and TS1P1KO STZ 
mice heart section compared to CD4+littermate vehicle mice. *P < 0.05 compared to 
CD4+littermate vehicle mice. (B)  Comparison of CD3+ T cells number in cardiac tissue 
between TS1P1KO mice with CD4
+ T cells transfer and TS1P1KO without CD4
+ T cells 
transfer. *P<0.05 compared to TS1P1KO vehicle mice, #P<0.05 compared to TS1P1KO 
STZ mice. Results are from three independent experiments. The data is expressed as 
mean ± SEM.  
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Figure 4-19: Immunohistochemical assessment of TGF beta 1 (TGF-β1) expression in 
CD4+ T cells recipient littermate and TS1P1KO mice heart sections at the end of 11-
weeks. CD4+ T cells recipient TS1P1KO vehicle and TS1P1KO STZ mice heart sections 
have increased TGF-β1 expression after 11-week of experimental period as compared to 
littermate vehicle mice. Images are representative of three independent experiments. The 
magnification is 400x. 
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Figure 4-20: Quantification of TGF-β1 expression in myocardium of CD4+ T cells 
recipient littermate and TS1P1KO mice. (A) TGF-β1 expression was significantly higher 
in littermate STZ (*P<0.05) and TS1P1KO STZ (
#P<0.05) mice heart section compared 
to CD4+littermate vehicle mice. TS1P1KO vehicle mice heart sections exhibited reduced 
TGF-β1 expression after CD4+ T cell transfer. (B) Comparison of TGF-β1 expression in 
cardiac tissue between TS1P1KO mice with CD4
+ T cells transfer and TS1P1KO mice 
without CD4+ T cells transfer. *P<0.05 compared to TS1P1KO vehicle mice, 
#P<0.05 
compared to TS1P1KO STZ mice. Results are from three independent experiments. The 
data is expressed as mean ± SEM.  
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4.3.9. CD4+ T cells recipient diabetic TS1P1KO mice heart exhibited increased CD34 
expression 
 
We evaluated CD34 expression by immunostaining in heart sections through 
computer assisted morphometric analysis. After CD4+ T cells transfer TS1P1KO diabetic 
myocardium exhibited increased CD34 expression (5.53±0.33 % staining area vs. 
2.97±0.17 % staining area, #P < 0.05, n= 3 experiments) than diabetic TS1P1KO mice 
without CD4+ T cells transfer (Figure 4-21, 4-22A and 4-22B). Remarkably, CD4+ T cells 
transfer reduced CD34 expression in TS1P1KO vehicle mice (2.77±0.43 % staining area 
vs. 6.52±0.47 % staining area, #P < 0.05, n= 3 experiments) than TS1P1KO vehicle mice 
without CD4+ T cells transfer (Figure 4-21, 4-22A and 4-22B). 
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Figure 4-21: Immunohistochemical assessment of CD34 expression in CD4+ T cells 
recipient littermate and TS1P1KO mice heart sections at the end of 11-weeks. (A) CD4
+ 
T cells recipient TS1P1KO STZ mice heart sections have increased CD34 expression 
after 11-week of experimental period. In contrast, CD4+ T cells recipient TS1P1KO 
vehicle mice exhibited reduced CD34 expression in their myocardium. Images are 
representative of three independent experiments. The magnification is 400x. 
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Figure 4-22: Quantification of CD34 expression in myocardium of CD4+ T cells 
recipient littermate and TS1P1KO mice. (A) CD34 expression was significantly higher in 
littermate STZ (*P<0.05) and TS1P1KO STZ (
#P<0.05) mice heart section compared to 
CD4+littermate vehicle mice. TS1P1KO vehicle mice heart sections exhibited reduced 
CD34 expression after CD4+ T cells transfer. (B) Comparison of CD34 expression in 
cardiac tissue between TS1P1KO mice with CD4
+ T cells transfer and TS1P1KO mice 
without CD4+ T cells transfer. *P<0.05 compared to TS1P1KO vehicle mice, 
#P<0.05 
compared to TS1P1KO STZ mice. Results are from three independent experiments. The 
data is expressed as mean ± SEM.  
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4.4. Discussion 
In this part of dissertation, we demonstrated that adoptive transfer of CD4+ T cells 
from littermate mice to T cell specific S1P receptor 1 knockout (TS1P1KO) mice causes 
exacerbation in cardiac histology and augmentation of fibrosis area in TS1P1KO mice 
under long term diabetes. We found that CD4+ T cells transfer to TS1P1KO mice 
increases infiltrating CD3+ T cells number into myocardium that is associated with 
enhanced pro-fibrotic molecular (TGF-β1) and cellular (CD34) moieties expression in 
myocardium of TS1P1KO mice under chronic hyperglycemia. 
In chapter 3, we have shown that T cell specific S1P receptor 1 genetic depletion 
results in profound deficiency of CD4+ helper T cells and CD8+ cytotoxic T cells in blood 
of TS1P1KO mice compared to littermate mice. We have demonstrated that TS1P1KO 
mice heart under long term streptozotocin (STZ)-induced type 1 diabetes exhibits 
cardioprotection and shows attenuated collagen deposition in myocardium with improved 
cardiac contractility compared to littermate diabetic mice. T lymphocytes under cardiac 
injury and inflammation, such as, myocardial infarction, hypertension, myocarditis, 
infiltrate in to the myocardium and participate in cardiac fibrotic remodeling and heart 
failure.36,73 Thus, we evaluated the infiltrating CD3+ T cells number in myocardium of 
diabetic littermate and TS1P1KO mice after 11-week experimental period. We have 
found that TS1P1KO mice heart tissue exhibited significantly less CD3
+ T cells invasion 
under chronic diabetes compared to littermate diabetic mice. Cardiac fibrosis is a 
complex, multifactorial, dynamic process in which diverse cellular and molecular 
interactions are involved.49,157,158 We, therefore, evaluated the expression of transforming 
growth factor beta 1 (TGF-β1) and CD34 expressing fibrocytes infiltration into the 
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myocardium of littermate and TS1P1KO mice after 11-week experimental period. Our 
immunohistochemical studies showed that TGF-β1 and CD34 expressing cells expression 
were reduced markedly in diabetic TS1P1KO mice compared to diabetic littermate mice. 
Enhanced myocardial fibrosis causes ventricular wall stiffening, which underlies diastolic 
dysfunction with subsequent systolic dysfunction, if unresolved.46,159 Therefore, we also 
evaluated the cardiac force of contraction in ex-vivo Langendorff’s heart perfusion 
system in littermate and TS1P1KO mice after 11-weeks. We found that cardiac 
contractility was improved in diabetic TS1P1KO mice compared to diabetic littermate 
mice. Therefore, we demonstrated that genetic depletion of T cell S1P1 receptor in mice 
results in circulatory T lymphocytes deficiency that is associated with cardioprotection 
and improved cardiac function in chronic diabetes. To this end, in this part of dissertation 
we further extended our investigation to evaluate the effects of naïve CD4+ T cells 
transfer from littermate mice to TS1P1KO mice in context of cardioprotection and cardiac 
fibrosis under chronic hyperglycemia.  
Among the two main subsets of T lymphocytes, CD4+ helper T cells and CD8+ 
cytotoxic T cells, CD4+ helper T cells have been reported to be involved in fibrotic 
remodeling in different organs, including heart, lungs, kidney and liver.36,150,160,161,162 
CD4+ T cells participate in fibrosis generation through several distinct molecular 
pathways, such as secretion of inflammatory cytokines that can stimulate collagen 
producing fibroblasts, increasing collagen cross-linking enzymes activity, such as lysyl 
oxidase (LOX) in heart tissue.70,163,164 Enhancement of T helper subset 1 (TH1) cells 
increased total cardiac collagen content and cross-linked collagen in C57BL/6 mice heart, 
whereas in a hypertensive disease model TH2 cytokine predominant BALB/c mice 
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exhibited increased cardiac collagen content with augmented ventricular stiffness.69,70,72 
TH1 cytokine IFN-γ and TH2 cytokine IL-4 have been shown to increase collagen cross-
linking enzyme LOX activity in heart in normal physiological and inflammatory 
conditions, respectively.69,70,72,73 In pressure overload transverse aortic constriction 
(TAC) murine model, mature lymphocytes lacking Rag2 knock-out (KO) mice heart 
tissue exhibited less LOX expression with attenuated fibrosis area after 6-week of TAC 
induction.75 Splenic 2 X 107 CD3+ T cells from wild-type C57BL/6 mice to Rag2KO 
mice increases LOX enzyme expression and fibrotic area in heart sections substantially 
after TAC induction compared to only buffer recipient Rag2KO mice.75 In another recent 
report, antibody induced neutralization of CD3 T cells activity showed cardioprotection 
in TAC induced heart failure model of mice as manifested by reduced fibrosis area and 
improved left ventricular function compared to only isotype treated mice after 4-weeks.76 
In TAC induced cardiac injury model, recruitment of T lymphocytes has been implicated 
with increased expression of adhesion molecules, such as ICAM-1, in cardiac endothelial 
cells.76 Several approaches including T lymphocytes depletion and neutralization of T 
cells activation have been tested experimentally to protect heart from T cell invasion 
under chronic injury in order to reduce fibrosis.157 To this end, in chapter 3, we for the 
first time showed that genetic depletion of T cell specific S1P1 receptor induced altered T 
lymphocytes trafficking in systemic circulation associated with cardioprotection and 
reduction in fibrosis area under chronic hyperglycemia. However, the type of T 
lymphocytes important in cardiac fibrogenesis in diabetes associated hyperglycemia is 
not known decisively, and our studies in chapter 3 also did not elucidate the role of 
specific subset of T cells in diabetic myocardial fibrogenesis. To this end, in the present 
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study we showed that CD4+ T cells reconstitution in TS1P1KO mice reverses the 
observed cardioprotection and antifibrotic effect under chronic diabetes. 
In TS1P1KO mice, T lymphocytes have depleted S1P1 expression due to T cell 
specific lymphocyte tyrosine kinase (Lck) promoter driven Cre-mediated recombination 
in coding region of S1P1 gene.
83 S1P receptor 1 plays important role in T lymphocytes 
egress from primary and secondary lymphoid organs to circulation.85 Genetic deficiency 
of S1P1 in T cells inhibits T cells egress from lymphoid organs and sequesters them in 
primary lymphoid organ thymus.83 Accordingly in chapter 3, we have shown that marked 
reduction of CD3+ T cells in spleen and CD4+, CD8+ T cells in blood of TS1P1KO mice. 
In the present chapter, we isolated CD4+ T cells from littermate mice spleen and 
intravenously transferred to TS1P1KO mice. Our flow cytometry analysis showed 1.58-
fold and 1.95-fold increase of CD4+ T cells in blood of TS1P1KO vehicle and TS1P1KO 
STZ mice, respectively, compared to TS1P1KO vehicle and TS1P1KO STZ mice without 
CD4+ T cells transfer after 11-weeks. CD4+Foxp3+ T cells number also increased in 
spleen of both TS1P1KO vehicle and TS1P1KO STZ mice as measured after 11-week 
than without CD4+ T cells transfer TS1P1KO vehicle and TS1P1KO STZ mice. Together 
the data indicate successful reconstitution of littermate CD4+ T cells in to TS1P1KO mice 
in our present work. At the end of 11-week STZ-induced diabetic period, CD4+ T cells 
recipient diabetic TS1P1KO STZ mice heart exhibited marked myocyte disorganization 
with increased interstitial and perivascular fibrosis, and reduced cardiac contractility 
compared to diabetic TS1P1KO mice without CD4
+ T cells transfer. Notably, diabetic 
TS1P1KO mice heart sections showed increased number of invading CD3
+ T cells 
number into myocardium compared to diabetic TS1P1KO mice without CD4
+ T cells 
177 
 
 
 
transfer at the end of 11-week diabetic period. Our immunohistolgical studies further 
revealed enhanced profibrotic TGF-β1 and CD34 expressing cells expression in diabetic 
TS1P1KO mice myocardium compared to diabetic TS1P1KO mice without CD4
+ T cells 
transfer. To this end, our findings revealed that CD4+ T cells are an essential component 
in cardiac fibrogenesis under chronic hyperglycemia that provoke profibrotic molecular 
and cellular milieu in myocardium to increase fibrosis area leading to cardiac 
dysfunction. 
Interestingly, administration of one million CD4+ T cells into TS1P1KO vehicle 
mice increases CD4+ T cells in circulation with increased presence of CD3+ T cells in 
myocardium than TS1P1KO vehicle mice without CD4
+ T cells transfer. Strikingly, CD4+ 
T cells recipient TS1P1KO vehicle mice myocardium showed reduced expression of 
TGF-β1 and CD34 expression with improved heart histology, reduced fibrosis area and 
significant improvement in cardiac contractility. In chapter 3, normoglycemic TS1P1KO 
vehicle mice myocardium showed exacerbated heart histology, increased fibrosis area 
and attenuated cardiac contractility whereas hyperglycemic TS1P1KO STZ mice 
myocardium showed cardioprotection with reduced fibrosis area and improved 
contractility. In present chapter, adoptive transfer of CD4+ T cells to TS1P1KO mice 
reverses the cardioprotection in hyperglycemic TS1P1KO STZ mice and ameliorates 
fibrosis in normoglycmeic TS1P1KO vehicle mice. These contrary results imply T 
lymphocytes have dual role in maintaining cardiac collagen homeostasis depending on 
the physiological conditions.  TS1P1KO mice have reduced T lymphocytes in blood that 
increases circulatory B lymphocytes by two-fold as reported by Allende et al.83 Notably, 
B lymphocytes generated auto-antibodies against heart derived antigens have been 
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implicated in cardiac dysfunction and fibrosis.146 In this regard, it is noteworthy that in 
chapter 2 we found that diabetic Rag1 KO mice lacking both mature T and B 
lymphocytes exhibited reduced fibrosis area and improved cardiac contractility compared 
to diabetic wild-type C57BL/6 mice. Notably, normoglycemic Rag1 KO mice did not 
show enhanced fibrosis unlike in normoglycemic TS1P1KO vehicle mice heart. Hence, 
imbalance between T lymphocytes and B lymphocytes number in periphery could be a 
possible reason of increased fibrosis area in normoglycemic TS1P1KO vehicle mice 
heart. Increased presence of CD34 fibrocytes in normoglycemic TS1P1KO vehicle mice 
heart indicate the presence of inflammation as CD34 fibrocytes recruited at the site of 
tissue injury and inflammation. Notably, CD4+ T cells recipient TS1P1KO vehicle mice 
spleen and blood showed 40.18% and 62% increase of regulatory CD4+Foxp3+ T cells 
than TS1P1KO vehicle mice without CD4
+ T cells recipient at the end of 11-week 
experimental period.152 Adoptive transfer of regulatory T cells in aortic constriction 
induced murine hypertension model reduced cardiac fibrosis area with reduced TGF-β1 
expression in cardiac tissue.152 In our present work, after CD4+ T cells transfer to 
TS1P1KO mice, normoglycemic TS1P1KO vehicle mice have increased CD4
+Foxp3+ T 
cells in periphery that couples with reduced TGF-β1 and CD34 expression in 
myocardium with reduced fibrosis compared to TS1P1KO vehicle mice without CD4
+ T 
cells transfer. Regulatory CD4+Foxp3+ T cells maintain immune tolerance in periphery 
by secreting immunosuppressive cytokines.68 Hence, increased regulatory CD4+Foxp3+ T 
cells after CD4+ T cells transfer to TS1P1KO mice could be a possible reason for the 
reduced fibrosis in TS1P1KO vehicle mice. 
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Altogether, our findings indicate the dual role of CD4+ T lymphocytes depending 
on normoglycemia and hyperglycemia. In normoglycemia, CD4+ T cells presence in 
peripheral blood is necessary to maintain collagen homeostasis in heart, whereas in 
chronic hyperglycemia CD4+ T cells potentiate collagen deposition by activating 
profibrotic signaling and enhancing proinflammatory cells recruitment to cardiac tissue. 
Thus, we demonstrated that CD4+ T lymphocytes as an upstream provocative cellular 
component in myocardial fibrotic remodeling under chronic hyperglycemic conditions. 
Our CD4+ T cells adoptive transfer experiment between littermate and TS1P1KO mice 
further demonstrated the necessity of S1P1 mediated signaling in CD4
+ T cells trafficking 
in systemic circulation as well as in cardiac tissue to modulate cardiac fibrotic 
remodeling both in normal and pathological conditions.  
4.5. Conclusions 
The important findings of our present investigation are: (1) supplement of CD4+ T 
cells increases myocardial fibrosis in TS1P1KO mice under chronic hyperglycemia with 
enhanced profibrotic milieu; (2) under normoglycemia CD4+ T cells transfer to TS1P1KO 
mice protects cardiac histology and attenuates fibrosis area; (3) S1P receptor 1 is crucial 
for CD4+ T lymphocytes trafficking that can be pharmacologically targeted to alter T 
lymphocytes trafficking to protect heart under diabetes. 
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CHAPTER 5: SUMMARY 
 
T lymphocytes are reported to be involved in cardiac fibrogenesis under cardiac 
inflammation and injury.73,77 T cells participate in fibrosis generation by secreting 
cytokines, growth factors that facilitate profibrotic microenvironment development which 
stimulate collagen producing fibroblasts.36,163 Activated fibroblasts, in turn, secrete 
excessive collagen into myocardium that ensues in fibrosis.36,165,166 The activation and 
recruitment of T cells into the myocardium have been observed in hypertension, 
myocardial infarction, diabetes, pressure overload-induced cardiac injury.74,76,77,111,152 To 
this end, enhanced T lymphocytes invasion has been detected in end stage heart failure 
patient myocardium compared to non-heart failure cardiac tissues.76 Video microscopic 
studies revealed T lymphocytes from heart failure patients adhered in significantly higher 
numbers to activated vascular endothelial cells than T cells from non-heart failure 
volunteers, indicating subsequent T cells infiltration into the inflamed cardiac tissue.76 To 
this end, reduction of T cells infiltration into the myocardium is considered as a potential 
translational target to protect the heart and reduce fibrosis in cardiovascular diseases.  
To target T lymphocytes, the biology of these cells need to be taken in 
consideration. The activation, proliferation and migration of T lymphocytes to inflamed 
tissue are regulated through orchestrated innate immune cells i.e. antigen-presenting cells 
and T lymphocytes interaction in respective tissue draining secondary lymphoid organs 
i.e. lymph nodes.90 This paradigm of T cells trafficking has been observed in 
experimental rodent heart failure and myocardial infarction model.77,157 After induction 
of heart failure and myocardial infarction, increased numbers of antigen presenting cells 
i.e. dendritic cells and T lymphocytes have been detected in heart draining lymph 
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nodes.74,75,76 The increased T cells number in heart draining lymph nodes was coupled to 
increased infiltration of T cells into the myocardium and increased cardiac fibrosis area. 
In line with these observations, an increased number of recent investigations have 
demonstrated that inhibition of T lymphocyte function reduces cardiac fibrosis and 
improves cardiac performance in heart failure and ischemic-reperfusion injury.77,157 
Several approaches, such as, antibody induced neutralization of T cells activation, 
depletion of T cells in transgenic mice, have been shown to reduce myocardial fibrosis 
with improved cardiac function.77,157 To this end, experimental data is scarce to 
ameliorate cardiac fibrosis by modulating other aspects of T lymphocytes biology. 
T lymphocytes trafficking from lymphoid organs to systemic circulation, i.e. 
blood, is an important aspect in immune response mediation. Naïve T lymphocytes 
continually recirculate between secondary lymphoid organs and systemic circulation.90 
Activation and proliferation of T lymphocytes occur in secondary lymphoid organs under 
appropriate microenvironment in response to inflammation, infection and injury. Upon 
activation, T lymphocytes trafficking from secondary lymphoid organs to periphery and 
the tissue leads to immune reaction in inflamed tissue. Epidemiological studies have 
shown increased presence of pro-inflammatory T cells in periphery of diabetic 
patient.78,79,110 In experimental rodent diabetic model, enhanced T lymphocytes 
infiltration into the cardiac tissue has been observed with increased cardiac collagen 
content and ventricular stiffness.111 Notably, the effects of T lymphocytes trafficking 
modulation in diabetes-induced fibrosis is not yet established. In our studies, we aimed to 
test our hypothesis that inhibition of T lymphocytes trafficking might protect diabetic 
heart and reduce myocardial fibrosis in chronic diabetes as discussed below. 
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In this dissertation, we have demonstrated that depletion of T lymphocytes in 
systemic circulation through modulating sphingosine 1-phosphate receptor 1 (S1P1) 
associated with reduced cardiac fibrosis and improved cardiac contractility in chronic 
diabetes. The depletion of T cells was achieved with both pharmacological agent – 
fingolimod (FTY70) and genetic approach – conditional knockout of T cell S1P1 receptor. 
In chapter 2, we have shown that treatment with S1P1 receptor modulator drug FTY720 
substantially reduced CD4+ and CD8+ T cells number in peripheral blood of wild-type 
(WT) C57BL/6 mice compared to WT control and untreated diabetic mice. Chronic 
FTY720 treatment reduced invading CD3+ T cells number into WT diabetic mice 
myocardium at the end of 11-week experimental period than untreated WT diabetic mice. 
In addition, FTY720 treated WT diabetic mice myocardium exhibited reduced expression 
of profibrotic TGF-β1 and fibroblast progenitor CD34 cells compared to untreated WT 
diabetic mice. The histology and morphometric analysis revealed that FTY720 improved 
heart histology and reduced cardiac fibrosis area in diabetic WT mice myocardium 
compared to untreated WT diabetic mice in chronic diabetes. Further, FTY720 treatment 
increased cardiac contractility of diabetic WT mice heart compared to untreated WT 
diabetic mice heart at the end of 11 weeks. We used recombination activating gene 1 
knock-out (Rag1 KO) mice lacking mature B and T lymphocytes as a complementary 
genetic mouse strain of WT C57BL/6 mice. Diabetic Rag1 KO mice exhibited improved 
heart histology, less cardiac fibrosis and improved contractility compared to untreated 
WT diabetic mice. Our findings, thus, indicate that T lymphocytes play an important role
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in fibrogenesis under diabetes. Paradoxically, we found that FTY720 treatment in Rag1 
KO mice increased fibrosis area, deteriorated heart histology and attenuated cardiac 
contractility under diabetes. These contrary results between WT C57BL/6 and Rag1 KO 
mice after FTY720 treatment indicate that the drug might be enhancing other fibrotic 
pathways in absence of T lymphocytes under diabetes. Although FTY720 has high 
affinity towards binding with S1P1 receptor, it can also activate other S1P receptors. 
FTY720 has been reported to bind on S1P3 receptor on fibroblasts that causes 
transdifferentiation of these cells into collagen producing myofibroblasts. Therefore, the 
paradoxical results of FTY720 treatment in Rag1 KO mice set the premise to study S1P1 
mediated T cells trafficking effects in cardiac fibrogenesis by using a more precise 
genetic approach.  
To this end, in chapter 3, we utilized genetic approach to study specifically S1P1 
loss-of-function effect on T lymphocytes trafficking to systemic circulation, and its 
associated effects in myocardial fibrosis generation in chronic diabetes. We generated 
conditional T cell specific S1P receptor 1 knock-out (TS1P1KO) mice through Cre-loxP 
approach. TS1P1KO mice exhibited marked reduction of CD4
+ and CD8+ T cells in blood 
compared to littermate control mice. Under chronic diabetes, TS1P1KO mice heart 
sections exhibited significantly reduced invaded CD3+ T cells with less fibrosis area 
compared to littermate mice. We further investigated the effects of reduced CD3+ T cells 
into myocardium on profibrotic molecular and cellular milieu by immunohistochemistry. 
We demonstrated that diabetic TS1P1KO mice heart tissue had reduced expression of 
TGF-β1 and CD34 fibrocytes expression compared to diabetic littermate mice. These 
results indicate that T lymphocytes in diabetes is involved in myocardial fibrogenesis, 
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and inhibition of S1P1 receptor associated altered T cells trafficking exerts 
cardioprotection in chronic diabetes. Paradoxically, TS1P1KO vehicle treated mice at the 
end of 11-week showed increased cardiac fibrosis area with deteriorated cardiac 
contractility compared to littermate vehicle mice. Although TS1P1KO vehicle mice 
myocardium had reduced CD3+ T cells infiltration into myocardium, TGF-β1 and CD34 
expression were increased. Our observations is consistent with the literature notion that 
fibrosis is a complex, multifactorial disease in which both systemic and cardiac resident 
cells can affect cardiac collagen homeostasis. Notably, in TS1P1KO mice blood, two 
times higher B lymphocytes number have been reported compared to littermate mice. To 
this end, B lymphocytes have been implicated to secrete autoantibodies that can cause 
myocytes apoptosis leading to fibrosis generation.146 Programmed cell death-1 (PD-1) 
gene knock out mice developed severe form of cardiomyopathy with increased interstitial 
fibrosis.145 PD-1 receptor is a negative immune regulator of lymphocytes proliferation, 
thus, genetic depletion of PD-1 results in increased deposition of IgG antibodies in 
myocardium. Notably, PD-1 KO mice generated in Rag2 KO mice background did not 
develop fibrosis indicating important contributions of lymphocytes in maintaining cardiac 
collagen homeostasis. In line with this finding, in chapter 2 we showed that diabetic Rag1 
KO mice have reduced cardiac fibrosis area compared to diabetic WT mice. TS1P1KO 
mice have increased B lymphocytes in circulation, while have substantially reduced T 
lymphocytes in circulation compared to littermate mice. Imbalance between B and T 
lymphocytes number might be one of the possible reasons for increased cardiac fibrosis 
under normoglycemia in TS1P1KO mice. To this end, the results shown in chapter 4 
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demonstrated the effects of reconstitution of splenic CD4+ T cells from littermate mice to 
TS1P1KO mice on cardiac fibrogenesis and cardiac function. 
In chapter 4, we demonstrated that adoptive transfer of naïve CD4+ T cells from 
littermate mice spleen exacerbated cardiac fibrosis area and reduced cardiac contractility 
in TS1P1KO mice in chronic diabetes. Infiltrating CD3
+ T cells numbers increased in 
myocardium of TS1P1KO mice after CD4
+ T cells transfer. Further, the reconstitution of 
CD4+ T cells increased TGF-β1 and CD34 cell expression in diabetic TS1P1KO mice 
compared to diabetic TS1P1KO mice without CD4
+ T cells transfer. Notably, adoptive 
transfer of one million CD4+ T cells from littermate mice to TS1P1KO mice improved 
heart histology, reduced cardiac fibrosis area and increased cardiac contractility under 
normoglycemia compared to normoglycemic TS1P1KO mice without TS1P1KO mice. 
We found that CD4+ T cells transfer increased CD4+ T cells number in blood and 
CD4+Foxp3+ T cells number in spleen and blood of TS1P1KO vehicle mice compared to 
TS1P1KO vehicle mice without CD4
+ T cells transfer. TS1P1KO vehicle mice 
myocardium exhibited increased CD3+ T cells presence in their myocardium compared to 
TS1P1KO vehicle mice without CD4
+ T cells transfer. Our immunohistochemistry studies 
showed that TGF-β1 and CD34 cells expression were reduced in TS1P1KO vehicle mice 
after CD4+ T cells transfer indicating attenuated profibrotic microenvironment compared 
to TS1P1KO vehicle mice without CD4
+ T cells transfer. Our results, thus, indicate that 
CD4+ T cells can play dual role in cardiac fibrosis depending normoglycemic and 
hyperglycemic conditions. Under normal physiological conditions CD4+ T cells presence 
in periphery, i.e., blood, is necessary to maintain collagen homeostasis in cardiac tissue, 
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while in chronic diabetes CD4+ T cells facilitate cardiac fibrosis generation by 
potentiating profibrotic signaling in myocardium. 
Overall, following are the key findings in this dissertation: 
(1) T lymphocytes trafficking modulatory drug FTY720-induced CD4+ and CD8+ T 
cells reduction in systemic circulation is associated with cardioprotection and 
attenuated fibrosis area under chronic diabetes in WT C57BL/6 mice. Lack of T 
lymphocytes associated cardioprotection in diabetes was confirmed in Rag1 KO 
mice lacking mature lymphocytes. Contradictory results of FTY720 treatment in 
Rag1 KO diabetic mice indicate FTY720 can target other fibrotic signaling 
pathways in absence of T lymphocytes. (Chapter 2) 
(2) Conditional T cell specific S1P receptor 1 (S1P1) genetic ablation ensued in 
marked reduction of CD4+ and CD8+ T cells in blood and reduced infiltration of 
CD3+ T cells in cardiac tissue under diabetes. Nonetheless, the presence of T 
lymphocytes in periphery is necessary to maintain collagen homeostasis in 
TS1P1KO mice as TS1P1KO mice under normoglycemic condition exhibited 
exacerbation of fibrosis. (Chapter 3) 
(3) Adoptive transfer of CD4+ T cells reversed cardioprotection and increased fibrosis 
area in TS1P1KO mice under diabetes, while attenuated fibrosis and improved 
contractility in TS1P1KO normoglycemic mice. Thus, CD4
+ T cells might play 
dual role depending on peripheral immune compartment composition and 
pathological conditions in maintaining cardiac fibrosis. (Chapter 4) 
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In summary, we have demonstrated through pharmacological and genetic approaches 
that S1P1 receptor mediated T cells trafficking to periphery is directly responsible for 
cardiac fibrosis development under chronic hyperglycemic conditions. 
Alteration/depletion of T lymphocytes trafficking in periphery by modulating S1P1 
receptor is a novel, promising translational approach to ameliorate myocardial fibrosis, to 
protect the cardiac histology and improve cardiac contractility in chronic diabetes.  
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CHAPTER 6: FUTURE PROSPECTS 
Recent studies have shown T lymphocytes involvement in myocardial 
fibrogenesis in different cardiovascular diseases. To this end, the present study provides 
evidence that alteration/depletion of T lymphocytes trafficking to systemic circulation 
through modulation of S1P1 receptor function is cardioprotective and attenuates cardiac 
fibrosis under chronic diabetes. Our findings give rise to exciting new research directions 
to ameliorate diabetic myocardial fibrogenesis as outlined below: 
(1) Although FTY720 treatment has reduced cardiac fibrosis in diabetic WT 
C57BL/6 mice, but increases fibrosis area in diabetic Rag1 KO mice (chapter 2). 
Rag1 KO mice lacks mature lymphocytes due to genetic deficiency of Rag1 gene 
necessary for mature lymphocytes development. FTY720 treatment increased 
fibrosis area in diabetic Rag1 KO mice. These results indicate FTY720 targets 
other fibrotic mechanisms which overrides cardioprotective effects of FTY720 in 
the absence of lymphocytes. Thus, mechanisms of FTY720 induced cardiac 
fibrosis in Rag1 KO mice under diabetes need to be studied further. 
(2) Genetic depletion of T lymphocytic S1P receptor 1 (S1P1) reduces T lymphocytes 
number substantially and exerts antifibrotic effect under chronic diabetes (chapter 
3). The fate of T lymphocytic S1P1 under high glucose level has not been 
investigated yet. The implications of S1P1 mediated signaling in T lymphocytes 
infiltration to diabetic myocardium should be investigated further.  
(3) We have shown that adoptive transfer of CD4+ T cells to TS1P1KO mice reverses 
the observed cardioprotection and increases fibrosis in diabetes (chapter 4). 
Notably, CD4+ T cells can further differentiate into TH1, TH2, Tregs and TH17 
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cells.68 Thus, further studies on CD4+ T cells differentiation in chronic diabetic 
mice and their effects in context of myocardial fibrosis is warranted. 
(4) In our present study, we primarily focused on the extent of CD3+ T lymphocytes 
infiltration to myocardium and levels of expression of TGF-β1 and fibrocytes 
(CD34) invasion. We found that increased fibrosis area was coupled to increased 
CD34 cells in interstitial space of myocardium. This indicates a direct correlation 
between CD34 cells and the extent of myocardial fibrosis. Although our 
immunohistochemical studies detected localization of CD34 cells in myocardium, 
we did not elucidate the recruitment mechanism of these cells in diabetic 
myocardium. CD34 cells recruitment to the site of inflammation/injury from the 
blood occurs through chemokine-chemokine receptor interactions.61,62,63 Thus, 
further studies are warranted to understand the chemokine receptor types 
expressed by diabetic myocardium that facilitates CD34 cells recruitment under 
inflammatory and profibrotic conditions, and how T lymphocytes modulate the 
chemokine receptors expression in myocardium, if any.  
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